<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns:m="http://schemas.microsoft.com/office/2004/12/omml"
xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 15">
<meta name=Originator content="Microsoft Word 15">
<link rel=File-List href="index_files/filelist.xml">
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>admin</o:Author>
  <o:LastAuthor>Admin</o:LastAuthor>
  <o:Revision>2</o:Revision>
  <o:TotalTime>1059</o:TotalTime>
  <o:Created>2018-06-27T06:17:00Z</o:Created>
  <o:LastSaved>2018-06-27T06:17:00Z</o:LastSaved>
  <o:Pages>122</o:Pages>
  <o:Words>40883</o:Words>
  <o:Characters>233038</o:Characters>
  <o:Lines>1941</o:Lines>
  <o:Paragraphs>546</o:Paragraphs>
  <o:CharactersWithSpaces>273375</o:CharactersWithSpaces>
  <o:Version>16.00</o:Version>
 </o:DocumentProperties>
 <o:OfficeDocumentSettings>
  <o:RelyOnVML/>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]-->
<link rel=themeData href="index_files/themedata.thmx">
<link rel=colorSchemeMapping href="index_files/colorschememapping.xml">
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:GrammarState>Clean</w:GrammarState>
  <w:TrackMoves>false</w:TrackMoves>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="false"
  DefSemiHidden="false" DefQFormat="false" DefPriority="99"
  LatentStyleCount="371">
  <w:LsdException Locked="false" Priority="0" QFormat="true" Name="Normal"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 1"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 2"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 3"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 4"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 5"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 6"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 7"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 8"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 9"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 9"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 1"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 2"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 3"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 4"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 5"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 6"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 7"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 8"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 9"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal Indent"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="footnote text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="annotation text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="header"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="footer"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index heading"/>
  <w:LsdException Locked="false" Priority="35" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="caption"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="table of figures"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="envelope address"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="envelope return"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="footnote reference"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="annotation reference"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="line number"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="page number"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="endnote reference"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="endnote text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="table of authorities"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="macro"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="toa heading"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 5"/>
  <w:LsdException Locked="false" Priority="10" QFormat="true" Name="Title"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Closing"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Signature"/>
  <w:LsdException Locked="false" Priority="1" SemiHidden="true"
   UnhideWhenUsed="true" Name="Default Paragraph Font"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text Indent"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Message Header"/>
  <w:LsdException Locked="false" Priority="11" QFormat="true" Name="Subtitle"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Salutation"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Date"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text First Indent"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text First Indent 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Note Heading"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text Indent 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text Indent 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Block Text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Hyperlink"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="FollowedHyperlink"/>
  <w:LsdException Locked="false" Priority="22" QFormat="true" Name="Strong"/>
  <w:LsdException Locked="false" Priority="20" QFormat="true" Name="Emphasis"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Document Map"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Plain Text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="E-mail Signature"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Top of Form"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Bottom of Form"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal (Web)"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Acronym"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Address"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Cite"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Code"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Definition"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Keyboard"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Preformatted"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Sample"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Typewriter"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Variable"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal Table"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="annotation subject"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="No List"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Outline List 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Outline List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Outline List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Contemporary"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Elegant"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Professional"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Subtle 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Subtle 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Balloon Text"/>
  <w:LsdException Locked="false" Priority="39" Name="Table Grid"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Theme"/>
  <w:LsdException Locked="false" SemiHidden="true" Name="Placeholder Text"/>
  <w:LsdException Locked="false" Priority="1" QFormat="true" Name="No Spacing"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 1"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 1"/>
  <w:LsdException Locked="false" SemiHidden="true" Name="Revision"/>
  <w:LsdException Locked="false" Priority="34" QFormat="true"
   Name="List Paragraph"/>
  <w:LsdException Locked="false" Priority="29" QFormat="true" Name="Quote"/>
  <w:LsdException Locked="false" Priority="30" QFormat="true"
   Name="Intense Quote"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 1"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 1"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 2"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 2"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 2"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 3"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 3"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 3"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 4"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 4"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 4"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 5"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 5"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 5"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 6"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 6"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 6"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="19" QFormat="true"
   Name="Subtle Emphasis"/>
  <w:LsdException Locked="false" Priority="21" QFormat="true"
   Name="Intense Emphasis"/>
  <w:LsdException Locked="false" Priority="31" QFormat="true"
   Name="Subtle Reference"/>
  <w:LsdException Locked="false" Priority="32" QFormat="true"
   Name="Intense Reference"/>
  <w:LsdException Locked="false" Priority="33" QFormat="true" Name="Book Title"/>
  <w:LsdException Locked="false" Priority="37" SemiHidden="true"
   UnhideWhenUsed="true" Name="Bibliography"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="TOC Heading"/>
  <w:LsdException Locked="false" Priority="41" Name="Plain Table 1"/>
  <w:LsdException Locked="false" Priority="42" Name="Plain Table 2"/>
  <w:LsdException Locked="false" Priority="43" Name="Plain Table 3"/>
  <w:LsdException Locked="false" Priority="44" Name="Plain Table 4"/>
  <w:LsdException Locked="false" Priority="45" Name="Plain Table 5"/>
  <w:LsdException Locked="false" Priority="40" Name="Grid Table Light"/>
  <w:LsdException Locked="false" Priority="46" Name="Grid Table 1 Light"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark"/>
  <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful"/>
  <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 1"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 1"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 1"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 2"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 2"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 2"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 3"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 3"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 3"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 4"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 4"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 4"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 5"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 5"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 5"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 6"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 6"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 6"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark"/>
  <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful"/>
  <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 1"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 1"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 1"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 2"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 2"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 2"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 3"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 3"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 3"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 4"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 4"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 4"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 5"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 5"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 5"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 6"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 6"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 6"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 6"/>
 </w:LatentStyles>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;
	mso-font-alt:"\FF2D\FF33 \660E\671D";
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-pitch:fixed;
	mso-font-signature:1 134676480 16 0 131072 0;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;
	mso-font-alt:\BC14\D0D5;
	mso-font-charset:129;
	mso-generic-font-family:auto;
	mso-font-pitch:fixed;
	mso-font-signature:1 151388160 16 0 524288 0;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;
	mso-font-alt:\5B8B\4F53;
	mso-font-charset:134;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:1 135135232 16 0 262144 0;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;
	mso-font-alt:\65B0\7D30\660E\9AD4;
	mso-font-charset:136;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:1 134742016 16 0 1048576 0;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;
	mso-font-alt:"\FF2D\FF33 \30B4\30B7\30C3\30AF";
	mso-font-charset:128;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-536870145 1791491579 134217746 0 131231 0;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;
	mso-font-alt:\B3CB\C6C0;
	mso-font-charset:129;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:1 151388160 16 0 524288 0;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;
	mso-font-alt:\9ED1\4F53;
	mso-font-charset:134;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:1 135135232 16 0 262144 0;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;
	mso-font-alt:\7D30\660E\9AD4;
	mso-font-charset:136;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:1 134742016 16 0 1048576 0;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;
	mso-font-alt:\660E\671D;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-pitch:fixed;
	mso-font-signature:1 134676480 16 0 131072 0;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;
	mso-font-alt:\AD74\B9BC;
	mso-font-charset:129;
	mso-generic-font-family:roman;
	mso-font-pitch:fixed;
	mso-font-signature:1 151388160 16 0 524288 0;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;
	mso-font-charset:222;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:16777217 0 0 0 65536 0;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;
	mso-font-charset:222;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:16777217 0 0 0 65536 0;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:1;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:8192 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;
	mso-font-charset:1;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:262144 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:12583555 0 0 0 13 0;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:1;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;
	mso-font-charset:1;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;
	mso-font-charset:1;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:1;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;
	mso-font-charset:1;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:1;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:1;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;
	mso-font-charset:1;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;
	mso-font-alt:\6E38\30B4\30B7\30C3\30AF;
	mso-font-charset:128;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:1 134676480 16 0 131072 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;
	mso-font-alt:\7B49\7EBF;
	mso-font-charset:134;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:1 135135232 16 0 262144 0;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536859905 -1073732485 9 0 511 0;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536859905 -1073732485 9 0 511 0;}
@font-face
	{font-family:"Diverda Sans Com Light";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-alt:"Diverda Sans Com Light";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:auto;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Minion Pro";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-alt:"Minion Pro";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:auto;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;
	mso-font-charset:128;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-536870145 1791491579 134217746 0 131231 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN-US;
	mso-fareast-language:EN-US;}
h2
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 2 Char";
	mso-style-next:Normal;
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:2;
	font-size:13.0pt;
	font-family:"Calibri Light",sans-serif;
	mso-ascii-font-family:"Calibri Light";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Calibri Light";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#2E74B5;
	mso-themecolor:accent1;
	mso-themeshade:191;
	mso-ansi-language:EN-US;
	mso-fareast-language:EN-US;
	font-weight:normal;}
h4
	{mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Heading 4 Char";
	mso-margin-top-alt:auto;
	margin-right:0in;
	mso-margin-bottom-alt:auto;
	margin-left:0in;
	mso-pagination:widow-orphan;
	mso-outline-level:4;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-US;
	mso-fareast-language:EN-US;
	font-weight:bold;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-priority:99;
	mso-style-link:"Header Char";
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	tab-stops:center 3.25in right 6.5in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN-US;
	mso-fareast-language:EN-US;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-priority:99;
	mso-style-link:"Footer Char";
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	tab-stops:center 3.25in right 6.5in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN-US;
	mso-fareast-language:EN-US;}
a:link, span.MsoHyperlink
	{mso-style-priority:99;
	color:#0563C1;
	mso-themecolor:hyperlink;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{mso-style-noshow:yes;
	mso-style-priority:99;
	color:#954F72;
	mso-themecolor:followedhyperlink;
	text-decoration:underline;
	text-underline:single;}
p
	{mso-style-priority:99;
	mso-margin-top-alt:auto;
	margin-right:0in;
	mso-margin-bottom-alt:auto;
	margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-US;
	mso-fareast-language:EN-US;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN-US;
	mso-fareast-language:EN-US;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN-US;
	mso-fareast-language:EN-US;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN-US;
	mso-fareast-language:EN-US;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN-US;
	mso-fareast-language:EN-US;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 4";
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	font-family:"Times New Roman",serif;
	mso-ascii-font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	font-weight:bold;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:Header;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:Footer;}
span.apple-converted-space
	{mso-style-name:apple-converted-space;
	mso-style-unhide:no;}
span.screen-reader-text
	{mso-style-name:screen-reader-text;
	mso-style-unhide:no;}
span.z-TopofFormChar
	{mso-style-name:"z-Top of Form Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"z-Top of Form";
	mso-ansi-font-size:8.0pt;
	mso-bidi-font-size:8.0pt;
	font-family:"Arial",sans-serif;
	mso-ascii-font-family:Arial;
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:Arial;
	mso-bidi-font-family:Arial;
	display:none;
	mso-hide:all;}
span.z-BottomofFormChar
	{mso-style-name:"z-Bottom of Form Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"z-Bottom of Form";
	mso-ansi-font-size:8.0pt;
	mso-bidi-font-size:8.0pt;
	font-family:"Arial",sans-serif;
	mso-ascii-font-family:Arial;
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:Arial;
	mso-bidi-font-family:Arial;
	display:none;
	mso-hide:all;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	mso-style-unhide:no;
	mso-style-parent:"";
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	mso-layout-grid-align:none;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Diverda Sans Com Light",sans-serif;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-bidi-font-family:"Diverda Sans Com Light";
	color:black;
	mso-ansi-language:EN-US;
	mso-fareast-language:EN-US;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 2";
	mso-ansi-font-size:13.0pt;
	mso-bidi-font-size:13.0pt;
	font-family:"Calibri Light",sans-serif;
	mso-ascii-font-family:"Calibri Light";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Calibri Light";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#2E74B5;
	mso-themecolor:accent1;
	mso-themeshade:191;}
span.msoIns
	{mso-style-type:export-only;
	mso-style-name:"";
	text-decoration:underline;
	text-underline:single;
	color:teal;}
span.msoDel
	{mso-style-type:export-only;
	mso-style-name:"";
	text-decoration:line-through;
	color:red;}
.MsoChpDefault
	{mso-style-type:export-only;
	mso-default-props:yes;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN-US;
	mso-fareast-language:EN-US;}
.MsoPapDefault
	{mso-style-type:export-only;
	margin-bottom:8.0pt;
	line-height:107%;}
@page WordSection1
	{size:8.5in 11.0in;
	margin:1.0in 1.0in 1.0in 1.0in;
	mso-header-margin:.5in;
	mso-footer-margin:.5in;
	mso-paper-source:0;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 @list l0
	{mso-list-id:249312095;
	mso-list-template-ids:67698719;}
@list l0:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l0:level2
	{mso-level-text:"%1\.%2\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.55in;
	text-indent:-.3in;}
@list l0:level3
	{mso-level-text:"%1\.%2\.%3\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.85in;
	text-indent:-.35in;}
@list l0:level4
	{mso-level-text:"%1\.%2\.%3\.%4\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.2in;
	text-indent:-.45in;}
@list l0:level5
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.55in;
	text-indent:-.55in;}
@list l0:level6
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.9in;
	text-indent:-.65in;}
@list l0:level7
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.75in;}
@list l0:level8
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.6in;
	text-indent:-.85in;}
@list l0:level9
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-1.0in;}
@list l1
	{mso-list-id:410007609;
	mso-list-template-ids:67698719;}
@list l1:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l1:level2
	{mso-level-text:"%1\.%2\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.55in;
	text-indent:-.3in;}
@list l1:level3
	{mso-level-text:"%1\.%2\.%3\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.85in;
	text-indent:-.35in;}
@list l1:level4
	{mso-level-text:"%1\.%2\.%3\.%4\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.2in;
	text-indent:-.45in;}
@list l1:level5
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.55in;
	text-indent:-.55in;}
@list l1:level6
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.9in;
	text-indent:-.65in;}
@list l1:level7
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.75in;}
@list l1:level8
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.6in;
	text-indent:-.85in;}
@list l1:level9
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-1.0in;}
@list l2
	{mso-list-id:429470119;
	mso-list-template-ids:67698719;}
@list l2:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l2:level2
	{mso-level-text:"%1\.%2\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.55in;
	text-indent:-.3in;}
@list l2:level3
	{mso-level-text:"%1\.%2\.%3\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.85in;
	text-indent:-.35in;}
@list l2:level4
	{mso-level-text:"%1\.%2\.%3\.%4\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.2in;
	text-indent:-.45in;}
@list l2:level5
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.55in;
	text-indent:-.55in;}
@list l2:level6
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.9in;
	text-indent:-.65in;}
@list l2:level7
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.75in;}
@list l2:level8
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.6in;
	text-indent:-.85in;}
@list l2:level9
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-1.0in;}
@list l3
	{mso-list-id:497040227;
	mso-list-template-ids:67698719;}
@list l3:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l3:level2
	{mso-level-text:"%1\.%2\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.55in;
	text-indent:-.3in;}
@list l3:level3
	{mso-level-text:"%1\.%2\.%3\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.85in;
	text-indent:-.35in;}
@list l3:level4
	{mso-level-text:"%1\.%2\.%3\.%4\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.2in;
	text-indent:-.45in;}
@list l3:level5
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.55in;
	text-indent:-.55in;}
@list l3:level6
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.9in;
	text-indent:-.65in;}
@list l3:level7
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.75in;}
@list l3:level8
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.6in;
	text-indent:-.85in;}
@list l3:level9
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-1.0in;}
@list l4
	{mso-list-id:511726428;
	mso-list-template-ids:67698719;}
@list l4:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l4:level2
	{mso-level-text:"%1\.%2\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.55in;
	text-indent:-.3in;}
@list l4:level3
	{mso-level-text:"%1\.%2\.%3\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.85in;
	text-indent:-.35in;}
@list l4:level4
	{mso-level-text:"%1\.%2\.%3\.%4\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.2in;
	text-indent:-.45in;}
@list l4:level5
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.55in;
	text-indent:-.55in;}
@list l4:level6
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.9in;
	text-indent:-.65in;}
@list l4:level7
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.75in;}
@list l4:level8
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.6in;
	text-indent:-.85in;}
@list l4:level9
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-1.0in;}
@list l5
	{mso-list-id:614869473;
	mso-list-template-ids:67698719;}
@list l5:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l5:level2
	{mso-level-text:"%1\.%2\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.55in;
	text-indent:-.3in;}
@list l5:level3
	{mso-level-text:"%1\.%2\.%3\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.85in;
	text-indent:-.35in;}
@list l5:level4
	{mso-level-text:"%1\.%2\.%3\.%4\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.2in;
	text-indent:-.45in;}
@list l5:level5
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.55in;
	text-indent:-.55in;}
@list l5:level6
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.9in;
	text-indent:-.65in;}
@list l5:level7
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.75in;}
@list l5:level8
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.6in;
	text-indent:-.85in;}
@list l5:level9
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-1.0in;}
@list l6
	{mso-list-id:841357542;
	mso-list-template-ids:67698719;}
@list l6:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l6:level2
	{mso-level-text:"%1\.%2\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.55in;
	text-indent:-.3in;}
@list l6:level3
	{mso-level-text:"%1\.%2\.%3\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.85in;
	text-indent:-.35in;}
@list l6:level4
	{mso-level-text:"%1\.%2\.%3\.%4\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.2in;
	text-indent:-.45in;}
@list l6:level5
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.55in;
	text-indent:-.55in;}
@list l6:level6
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.9in;
	text-indent:-.65in;}
@list l6:level7
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.75in;}
@list l6:level8
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.6in;
	text-indent:-.85in;}
@list l6:level9
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-1.0in;}
@list l7
	{mso-list-id:901452891;
	mso-list-template-ids:67698719;}
@list l7:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l7:level2
	{mso-level-text:"%1\.%2\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.55in;
	text-indent:-.3in;}
@list l7:level3
	{mso-level-text:"%1\.%2\.%3\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.85in;
	text-indent:-.35in;}
@list l7:level4
	{mso-level-text:"%1\.%2\.%3\.%4\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.2in;
	text-indent:-.45in;}
@list l7:level5
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.55in;
	text-indent:-.55in;}
@list l7:level6
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.9in;
	text-indent:-.65in;}
@list l7:level7
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.75in;}
@list l7:level8
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.6in;
	text-indent:-.85in;}
@list l7:level9
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-1.0in;}
@list l8
	{mso-list-id:909802100;
	mso-list-template-ids:67698719;}
@list l8:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l8:level2
	{mso-level-text:"%1\.%2\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.55in;
	text-indent:-.3in;}
@list l8:level3
	{mso-level-text:"%1\.%2\.%3\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.85in;
	text-indent:-.35in;}
@list l8:level4
	{mso-level-text:"%1\.%2\.%3\.%4\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.2in;
	text-indent:-.45in;}
@list l8:level5
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.55in;
	text-indent:-.55in;}
@list l8:level6
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.9in;
	text-indent:-.65in;}
@list l8:level7
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.75in;}
@list l8:level8
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.6in;
	text-indent:-.85in;}
@list l8:level9
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-1.0in;}
@list l9
	{mso-list-id:955064756;
	mso-list-template-ids:67698719;}
@list l9:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l9:level2
	{mso-level-text:"%1\.%2\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.55in;
	text-indent:-.3in;}
@list l9:level3
	{mso-level-text:"%1\.%2\.%3\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.85in;
	text-indent:-.35in;}
@list l9:level4
	{mso-level-text:"%1\.%2\.%3\.%4\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.2in;
	text-indent:-.45in;}
@list l9:level5
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.55in;
	text-indent:-.55in;}
@list l9:level6
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.9in;
	text-indent:-.65in;}
@list l9:level7
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.75in;}
@list l9:level8
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.6in;
	text-indent:-.85in;}
@list l9:level9
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-1.0in;}
@list l10
	{mso-list-id:1111052058;
	mso-list-template-ids:67698719;}
@list l10:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l10:level2
	{mso-level-text:"%1\.%2\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.55in;
	text-indent:-.3in;}
@list l10:level3
	{mso-level-text:"%1\.%2\.%3\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.85in;
	text-indent:-.35in;}
@list l10:level4
	{mso-level-text:"%1\.%2\.%3\.%4\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.2in;
	text-indent:-.45in;}
@list l10:level5
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.55in;
	text-indent:-.55in;}
@list l10:level6
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.9in;
	text-indent:-.65in;}
@list l10:level7
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.75in;}
@list l10:level8
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.6in;
	text-indent:-.85in;}
@list l10:level9
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-1.0in;}
@list l11
	{mso-list-id:1200624314;
	mso-list-type:hybrid;
	mso-list-template-ids:991216996 67698703 67698713 67698715 67698703 67698713 67698715 67698703 67698713 67698715;}
@list l11:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l11:level2
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.75in;
	text-indent:-.25in;}
@list l11:level3
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	margin-left:1.25in;
	text-indent:-9.0pt;}
@list l11:level4
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.75in;
	text-indent:-.25in;}
@list l11:level5
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.25in;}
@list l11:level6
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	margin-left:2.75in;
	text-indent:-9.0pt;}
@list l11:level7
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.25in;
	text-indent:-.25in;}
@list l11:level8
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.75in;
	text-indent:-.25in;}
@list l11:level9
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	margin-left:4.25in;
	text-indent:-9.0pt;}
@list l12
	{mso-list-id:1230846418;
	mso-list-template-ids:67698719;}
@list l12:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l12:level2
	{mso-level-text:"%1\.%2\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.55in;
	text-indent:-.3in;}
@list l12:level3
	{mso-level-text:"%1\.%2\.%3\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.85in;
	text-indent:-.35in;}
@list l12:level4
	{mso-level-text:"%1\.%2\.%3\.%4\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.2in;
	text-indent:-.45in;}
@list l12:level5
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.55in;
	text-indent:-.55in;}
@list l12:level6
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.9in;
	text-indent:-.65in;}
@list l12:level7
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.75in;}
@list l12:level8
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.6in;
	text-indent:-.85in;}
@list l12:level9
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-1.0in;}
@list l13
	{mso-list-id:1239755550;
	mso-list-template-ids:67698719;}
@list l13:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l13:level2
	{mso-level-text:"%1\.%2\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.55in;
	text-indent:-.3in;}
@list l13:level3
	{mso-level-text:"%1\.%2\.%3\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.85in;
	text-indent:-.35in;}
@list l13:level4
	{mso-level-text:"%1\.%2\.%3\.%4\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.2in;
	text-indent:-.45in;}
@list l13:level5
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.55in;
	text-indent:-.55in;}
@list l13:level6
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.9in;
	text-indent:-.65in;}
@list l13:level7
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.75in;}
@list l13:level8
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.6in;
	text-indent:-.85in;}
@list l13:level9
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-1.0in;}
@list l14
	{mso-list-id:1243641297;
	mso-list-template-ids:67698719;}
@list l14:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l14:level2
	{mso-level-text:"%1\.%2\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.55in;
	text-indent:-.3in;}
@list l14:level3
	{mso-level-text:"%1\.%2\.%3\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.85in;
	text-indent:-.35in;}
@list l14:level4
	{mso-level-text:"%1\.%2\.%3\.%4\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.2in;
	text-indent:-.45in;}
@list l14:level5
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.55in;
	text-indent:-.55in;}
@list l14:level6
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.9in;
	text-indent:-.65in;}
@list l14:level7
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.75in;}
@list l14:level8
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.6in;
	text-indent:-.85in;}
@list l14:level9
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-1.0in;}
@list l15
	{mso-list-id:1251891563;
	mso-list-template-ids:67698719;}
@list l15:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l15:level2
	{mso-level-text:"%1\.%2\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.55in;
	text-indent:-.3in;}
@list l15:level3
	{mso-level-text:"%1\.%2\.%3\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.85in;
	text-indent:-.35in;}
@list l15:level4
	{mso-level-text:"%1\.%2\.%3\.%4\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.2in;
	text-indent:-.45in;}
@list l15:level5
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.55in;
	text-indent:-.55in;}
@list l15:level6
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.9in;
	text-indent:-.65in;}
@list l15:level7
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.75in;}
@list l15:level8
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.6in;
	text-indent:-.85in;}
@list l15:level9
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-1.0in;}
@list l16
	{mso-list-id:1448356284;
	mso-list-template-ids:67698719;}
@list l16:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l16:level2
	{mso-level-text:"%1\.%2\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.55in;
	text-indent:-.3in;}
@list l16:level3
	{mso-level-text:"%1\.%2\.%3\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.85in;
	text-indent:-.35in;}
@list l16:level4
	{mso-level-text:"%1\.%2\.%3\.%4\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.2in;
	text-indent:-.45in;}
@list l16:level5
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.55in;
	text-indent:-.55in;}
@list l16:level6
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.9in;
	text-indent:-.65in;}
@list l16:level7
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.75in;}
@list l16:level8
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.6in;
	text-indent:-.85in;}
@list l16:level9
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-1.0in;}
@list l17
	{mso-list-id:1486161051;
	mso-list-template-ids:67698719;}
@list l17:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l17:level2
	{mso-level-text:"%1\.%2\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.55in;
	text-indent:-.3in;}
@list l17:level3
	{mso-level-text:"%1\.%2\.%3\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.85in;
	text-indent:-.35in;}
@list l17:level4
	{mso-level-text:"%1\.%2\.%3\.%4\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.2in;
	text-indent:-.45in;}
@list l17:level5
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.55in;
	text-indent:-.55in;}
@list l17:level6
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.9in;
	text-indent:-.65in;}
@list l17:level7
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.75in;}
@list l17:level8
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.6in;
	text-indent:-.85in;}
@list l17:level9
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-1.0in;}
@list l18
	{mso-list-id:1516848764;
	mso-list-template-ids:67698719;}
@list l18:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l18:level2
	{mso-level-text:"%1\.%2\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.55in;
	text-indent:-.3in;}
@list l18:level3
	{mso-level-text:"%1\.%2\.%3\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.85in;
	text-indent:-.35in;}
@list l18:level4
	{mso-level-text:"%1\.%2\.%3\.%4\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.2in;
	text-indent:-.45in;}
@list l18:level5
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.55in;
	text-indent:-.55in;}
@list l18:level6
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.9in;
	text-indent:-.65in;}
@list l18:level7
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.75in;}
@list l18:level8
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.6in;
	text-indent:-.85in;}
@list l18:level9
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-1.0in;}
@list l19
	{mso-list-id:1602568530;
	mso-list-template-ids:67698719;}
@list l19:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l19:level2
	{mso-level-text:"%1\.%2\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.55in;
	text-indent:-.3in;}
@list l19:level3
	{mso-level-text:"%1\.%2\.%3\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.85in;
	text-indent:-.35in;}
@list l19:level4
	{mso-level-text:"%1\.%2\.%3\.%4\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.2in;
	text-indent:-.45in;}
@list l19:level5
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.55in;
	text-indent:-.55in;}
@list l19:level6
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.9in;
	text-indent:-.65in;}
@list l19:level7
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.75in;}
@list l19:level8
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.6in;
	text-indent:-.85in;}
@list l19:level9
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-1.0in;}
@list l20
	{mso-list-id:1625035782;
	mso-list-template-ids:67698719;}
@list l20:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l20:level2
	{mso-level-text:"%1\.%2\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.55in;
	text-indent:-.3in;}
@list l20:level3
	{mso-level-text:"%1\.%2\.%3\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.85in;
	text-indent:-.35in;}
@list l20:level4
	{mso-level-text:"%1\.%2\.%3\.%4\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.2in;
	text-indent:-.45in;}
@list l20:level5
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.55in;
	text-indent:-.55in;}
@list l20:level6
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.9in;
	text-indent:-.65in;}
@list l20:level7
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.75in;}
@list l20:level8
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.6in;
	text-indent:-.85in;}
@list l20:level9
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-1.0in;}
@list l21
	{mso-list-id:1678993529;
	mso-list-template-ids:67698719;}
@list l21:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l21:level2
	{mso-level-text:"%1\.%2\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.55in;
	text-indent:-.3in;}
@list l21:level3
	{mso-level-text:"%1\.%2\.%3\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.85in;
	text-indent:-.35in;}
@list l21:level4
	{mso-level-text:"%1\.%2\.%3\.%4\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.2in;
	text-indent:-.45in;}
@list l21:level5
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.55in;
	text-indent:-.55in;}
@list l21:level6
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.9in;
	text-indent:-.65in;}
@list l21:level7
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.75in;}
@list l21:level8
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.6in;
	text-indent:-.85in;}
@list l21:level9
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-1.0in;}
@list l22
	{mso-list-id:1691953099;
	mso-list-template-ids:67698719;}
@list l22:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l22:level2
	{mso-level-text:"%1\.%2\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.55in;
	text-indent:-.3in;}
@list l22:level3
	{mso-level-text:"%1\.%2\.%3\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.85in;
	text-indent:-.35in;}
@list l22:level4
	{mso-level-text:"%1\.%2\.%3\.%4\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.2in;
	text-indent:-.45in;}
@list l22:level5
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.55in;
	text-indent:-.55in;}
@list l22:level6
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.9in;
	text-indent:-.65in;}
@list l22:level7
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.75in;}
@list l22:level8
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.6in;
	text-indent:-.85in;}
@list l22:level9
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-1.0in;}
@list l23
	{mso-list-id:1705593442;
	mso-list-template-ids:67698719;}
@list l23:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l23:level2
	{mso-level-text:"%1\.%2\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.55in;
	text-indent:-.3in;}
@list l23:level3
	{mso-level-text:"%1\.%2\.%3\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.85in;
	text-indent:-.35in;}
@list l23:level4
	{mso-level-text:"%1\.%2\.%3\.%4\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.2in;
	text-indent:-.45in;}
@list l23:level5
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.55in;
	text-indent:-.55in;}
@list l23:level6
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.9in;
	text-indent:-.65in;}
@list l23:level7
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.75in;}
@list l23:level8
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.6in;
	text-indent:-.85in;}
@list l23:level9
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-1.0in;}
@list l24
	{mso-list-id:1754933507;
	mso-list-template-ids:67698719;}
@list l24:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l24:level2
	{mso-level-text:"%1\.%2\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.55in;
	text-indent:-.3in;}
@list l24:level3
	{mso-level-text:"%1\.%2\.%3\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.85in;
	text-indent:-.35in;}
@list l24:level4
	{mso-level-text:"%1\.%2\.%3\.%4\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.2in;
	text-indent:-.45in;}
@list l24:level5
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.55in;
	text-indent:-.55in;}
@list l24:level6
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.9in;
	text-indent:-.65in;}
@list l24:level7
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.75in;}
@list l24:level8
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.6in;
	text-indent:-.85in;}
@list l24:level9
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-1.0in;}
@list l25
	{mso-list-id:1814710614;
	mso-list-template-ids:67698719;}
@list l25:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l25:level2
	{mso-level-text:"%1\.%2\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.55in;
	text-indent:-.3in;}
@list l25:level3
	{mso-level-text:"%1\.%2\.%3\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.85in;
	text-indent:-.35in;}
@list l25:level4
	{mso-level-text:"%1\.%2\.%3\.%4\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.2in;
	text-indent:-.45in;}
@list l25:level5
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.55in;
	text-indent:-.55in;}
@list l25:level6
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.9in;
	text-indent:-.65in;}
@list l25:level7
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.75in;}
@list l25:level8
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.6in;
	text-indent:-.85in;}
@list l25:level9
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-1.0in;}
@list l26
	{mso-list-id:1886797399;
	mso-list-template-ids:67698719;}
@list l26:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l26:level2
	{mso-level-text:"%1\.%2\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.55in;
	text-indent:-.3in;}
@list l26:level3
	{mso-level-text:"%1\.%2\.%3\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.85in;
	text-indent:-.35in;}
@list l26:level4
	{mso-level-text:"%1\.%2\.%3\.%4\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.2in;
	text-indent:-.45in;}
@list l26:level5
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.55in;
	text-indent:-.55in;}
@list l26:level6
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.9in;
	text-indent:-.65in;}
@list l26:level7
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.75in;}
@list l26:level8
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.6in;
	text-indent:-.85in;}
@list l26:level9
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-1.0in;}
@list l27
	{mso-list-id:1933968479;
	mso-list-template-ids:67698719;}
@list l27:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l27:level2
	{mso-level-text:"%1\.%2\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.55in;
	text-indent:-.3in;}
@list l27:level3
	{mso-level-text:"%1\.%2\.%3\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.85in;
	text-indent:-.35in;}
@list l27:level4
	{mso-level-text:"%1\.%2\.%3\.%4\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.2in;
	text-indent:-.45in;}
@list l27:level5
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.55in;
	text-indent:-.55in;}
@list l27:level6
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.9in;
	text-indent:-.65in;}
@list l27:level7
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.75in;}
@list l27:level8
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.6in;
	text-indent:-.85in;}
@list l27:level9
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-1.0in;}
@list l28
	{mso-list-id:1940329132;
	mso-list-template-ids:67698719;}
@list l28:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l28:level2
	{mso-level-text:"%1\.%2\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.55in;
	text-indent:-.3in;}
@list l28:level3
	{mso-level-text:"%1\.%2\.%3\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.85in;
	text-indent:-.35in;}
@list l28:level4
	{mso-level-text:"%1\.%2\.%3\.%4\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.2in;
	text-indent:-.45in;}
@list l28:level5
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.55in;
	text-indent:-.55in;}
@list l28:level6
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.9in;
	text-indent:-.65in;}
@list l28:level7
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.75in;}
@list l28:level8
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.6in;
	text-indent:-.85in;}
@list l28:level9
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-1.0in;}
@list l29
	{mso-list-id:2001156635;
	mso-list-template-ids:67698719;}
@list l29:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l29:level2
	{mso-level-text:"%1\.%2\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.55in;
	text-indent:-.3in;}
@list l29:level3
	{mso-level-text:"%1\.%2\.%3\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.85in;
	text-indent:-.35in;}
@list l29:level4
	{mso-level-text:"%1\.%2\.%3\.%4\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.2in;
	text-indent:-.45in;}
@list l29:level5
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.55in;
	text-indent:-.55in;}
@list l29:level6
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.9in;
	text-indent:-.65in;}
@list l29:level7
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.75in;}
@list l29:level8
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.6in;
	text-indent:-.85in;}
@list l29:level9
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-1.0in;}
@list l30
	{mso-list-id:2008555880;
	mso-list-template-ids:67698719;}
@list l30:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l30:level2
	{mso-level-text:"%1\.%2\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.55in;
	text-indent:-.3in;}
@list l30:level3
	{mso-level-text:"%1\.%2\.%3\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.85in;
	text-indent:-.35in;}
@list l30:level4
	{mso-level-text:"%1\.%2\.%3\.%4\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.2in;
	text-indent:-.45in;}
@list l30:level5
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.55in;
	text-indent:-.55in;}
@list l30:level6
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.9in;
	text-indent:-.65in;}
@list l30:level7
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.75in;}
@list l30:level8
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.6in;
	text-indent:-.85in;}
@list l30:level9
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9\.";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-1.0in;}
ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin-top:0in;
	mso-para-margin-right:0in;
	mso-para-margin-bottom:8.0pt;
	mso-para-margin-left:0in;
	line-height:107%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN-US;
	mso-fareast-language:EN-US;}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="1026"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=EN-IN link="#0563C1" vlink="#954F72" style='tab-interval:.5in'>

<div class=WordSection1>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Infusion Drug Delivery Devices Market US$ 10.5 Billion by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>The global </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>infusion drug
delivery devices </span><span lang=EN-US style='font-size:10.0pt;line-height:
107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market to attain
US$ 10.5 Billion by 2023, growing at a CAGR of 5.7% over the forecast period.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Visit the global
infusion drug delivery devices market segmented by product (ambulatory pumps,
disposable pumps, enteral nutrition pumps, implantable pumps, insulin pumps,
syringe pumps, volumetric pumps); </span><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>by
geography and forecast 2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/infusion-drug-delivery-devices-market/">https://www.ihealthcareanalyst.com/report/infusion-drug-delivery-devices-market/</a>
</span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global infusion drug delivery devices market report provides market size
(Revenue USD Million 2015 to 2023), market share, trends and forecasts growth
trends (CAGR%, 2018 to 2023). The global infusion drug delivery devices market
research report is further segmented by geography into North America (U.S.,
Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific
(Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of
LA), and Rest of the World. <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global infusion drug delivery devices market report also provides the detailed
market landscape (market drivers, restraints, and opportunities), market
attractiveness analysis and tracks the major competitors operating in the
market by company overview, financial snapshot, key products, technologies and
services offered, market share analysis and recent trends in the global market.
<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Major
players operating in the global infusion drug delivery devices market and
profiled in this report include B. Braun Melsungen AG, Baxter Healthcare,
Becton Dickinson and Company, Cardinal Health, Inc., Cellnovo SA, CME America LLC,
CR Bard, Inc., Epic Medical PTE LTD, F. Hoffman-La Roche AG, Fresenius Kabi,
Halyard Health, Inc., ICU Medical, Inc., Insulet Corporation, Johnson &amp;
Johnson, Medline Industries, Inc., Medtronic PLC, Moog, Inc., Nestle SA, PFM
Medical, Inc., RMS Medical Products, Inc., Smiths Medical, Inc., Stryker
Corporation, Tandem Diabetes Care, Inc., Terumo Medical Corporation, Valeritas,
Inc., Vygon SA, and WalkMed Infusion LLC.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>1.<span
style='mso-tab-count:1'> </span>Product<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>1.1.<span
style='mso-tab-count:1'> </span>Ambulatory Pumps<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>1.2.<span
style='mso-tab-count:1'> </span>Disposable Pumps<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>1.3.<span
style='mso-tab-count:1'> </span>Enteral Nutrition Pumps <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>1.4.<span
style='mso-tab-count:1'> </span>Implantable Pumps<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>1.5.<span
style='mso-tab-count:1'> </span>Insulin Pumps<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>1.6.<span
style='mso-tab-count:1'> </span>Syringe Pumps<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>1.7.<span
style='mso-tab-count:1'> </span>Volumetric Pumps<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>2.<span
style='mso-tab-count:1'> </span>Geography (Region, Country)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>2.1.<span
style='mso-tab-count:1'> </span>North America (U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>2.2.<span
style='mso-tab-count:1'> </span>Europe (U.K., Germany, France, Italy,
Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>2.3.<span
style='mso-tab-count:1'> </span>Latin America (Brazil, Mexico, Rest of
LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>2.4.<span
style='mso-tab-count:1'> </span>Asia Pacific (Japan, China, India, Rest
of APAC)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>2.5.<span
style='mso-tab-count:1'> </span>Rest of the World (Middle East &amp;
Africa)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.<span
style='mso-tab-count:1'> </span>Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.1.<span
style='mso-tab-count:1'> </span>B. Braun Melsungen AG<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.2.<span
style='mso-tab-count:1'> </span>Baxter Healthcare<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.3.<span
style='mso-tab-count:1'> </span>Becton Dickinson and Company<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.4.<span
style='mso-tab-count:1'> </span>Cardinal Health, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.5.<span
style='mso-tab-count:1'> </span>Cellnovo SA<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.6.<span
style='mso-tab-count:1'> </span>CME America LLC<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.7.<span
style='mso-tab-count:1'> </span>CR Bard, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.8.<span
style='mso-tab-count:1'> </span>Epic Medical PTE LTD<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.9.<span
style='mso-tab-count:1'> </span>F. Hoffman-La Roche AG<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.10.<span
style='mso-tab-count:1'> </span>Fresenius Kabi<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.11.<span
style='mso-tab-count:1'> </span>Halyard Health, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.12.<span
style='mso-tab-count:1'> </span>ICU Medical, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.13.<span
style='mso-tab-count:1'> </span>Insulet Corporation<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.14.<span
style='mso-tab-count:1'> </span>Johnson &amp; Johnson<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.15.<span
style='mso-tab-count:1'> </span>Medline Industries, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.16.<span
style='mso-tab-count:1'> </span>Medtronic PLC<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.17.<span
style='mso-tab-count:1'> </span>Moog, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.18.<span
style='mso-tab-count:1'> </span>Nestle SA<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.19.<span
style='mso-tab-count:1'> </span>PFM Medical, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.20.<span
style='mso-tab-count:1'> </span>RMS Medical Products, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.21.<span
style='mso-tab-count:1'> </span>Smiths Medical, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.22.<span
style='mso-tab-count:1'> </span>Stryker Corporation<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.23.<span
style='mso-tab-count:1'> </span>Tandem Diabetes Care, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.24.<span
style='mso-tab-count:1'> </span>Terumo Medical Corporation<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.25.<span
style='mso-tab-count:1'> </span>Valeritas, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.26.<span
style='mso-tab-count:1'> </span>Vygon SA<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.27.<span
style='mso-tab-count:1'> </span>WalkMed Infusion LLC <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>&#8195;</span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>To request Table of Contents and Sample Pages
of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/infusion-drug-delivery-devices-market/">https://www.ihealthcareanalyst.com/report/infusion-drug-delivery-devices-market/</a>
</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>About Us<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at clients specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Contact Us<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2109, Mckelvey Hill Drive,<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Maryland Heights, MO 63043<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>United States<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Email: sales@ihealthcareanalyst.com<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Website: </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com"><span style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<b style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=all style='mso-special-character:line-break;
page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Respiratory Therapeutics Market US$ 40 Billion by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>The global </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>respiratory
therapeutics </span><span lang=EN-US style='font-size:10.0pt;line-height:107%;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market to attain
US$ 40 Billion by 2023, declining at a CAGR of 0.4% over the forecast period.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Visit the global respiratory
therapeutics market by drug class [asthma and COPD - LABA/ICS combination products,
leukotriene antagonists, inhaled corticosteroids (ICS), anticholinergics, short
acting beta-agonists (SABA), anticholinergics / beta agonists, long acting
beta-agonists (LABA), other drug classes]; allergic rhinitis (systemic
antihistamines, nasal preparations); </span><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>by
geography and forecast 2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/respiratory-therapeutics-market/"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/respiratory-therapeutics-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'> <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global respiratory therapeutics market report provides market size (Revenue USD
Million 2015 to 2023), market share, trends and forecasts growth trends (CAGR%,
2018 to 2023). The global respiratory therapeutics market research report is
further segmented by geography into North America (U.S., Canada), Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India,
Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the
World. <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global respiratory therapeutics market report also provides the detailed market
landscape (market drivers, restraints, and opportunities), market
attractiveness analysis and tracks the major competitors operating in the
market by company overview, financial snapshot, key products, technologies and
services offered, market share analysis and recent trends in the global market.
<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Major
players operating in the global respiratory therapeutics market and profiled in
this report include Adams Respiratory Therapeutics, Inc., Allergan plc,
AstraZeneca, Boehringer Ingelheim, F. Hoffmann-La Roche, GlaxoSmithKline, Merck
&amp; Co., Novartis, Respiratory Therapeutics Group, LLC, and Takeda
Pharmaceutical.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle><span lang=EN-US style='font-size:10.0pt;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>1.<span
style='mso-tab-count:1'> </span>Drug Class<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>1.1.<span
style='mso-tab-count:1'> </span>Asthma and COPD<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>1.1.1.<span
style='mso-tab-count:1'> </span>LABA/ICS combination products<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>1.1.2.<span
style='mso-tab-count:1'> </span>Leukotriene antagonists<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>1.1.3.<span
style='mso-tab-count:1'> </span>Inhaled corticosteroids (ICS)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>1.1.4.<span
style='mso-tab-count:1'> </span>Anticholinergics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>1.1.5.<span
style='mso-tab-count:1'> </span>Short acting beta-agonists (SABA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>1.1.6.<span
style='mso-tab-count:1'> </span>Anticholinergics / beta agonists<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>1.1.7.<span
style='mso-tab-count:1'> </span>Long acting beta-agonists (LABA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>1.1.8.<span
style='mso-tab-count:1'> </span>Other drug classes<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>1.2.<span
style='mso-tab-count:1'> </span>Allergic Rhinitis<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>1.2.1.<span
style='mso-tab-count:1'> </span>Systemic antihistamines<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>1.2.2.<span
style='mso-tab-count:1'> </span>Nasal preparations<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>2.<span
style='mso-tab-count:1'> </span>Geography (Region, Country)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>2.1.<span
style='mso-tab-count:1'> </span>North America (U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>2.2.<span
style='mso-tab-count:1'> </span>Europe (U.K., Germany, France, Italy,
Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>2.3.<span
style='mso-tab-count:1'> </span>Latin America (Brazil, Mexico, Rest of
LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>2.4.<span
style='mso-tab-count:1'> </span>Asia Pacific (Japan, China, India, Rest
of APAC)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>2.5.<span
style='mso-tab-count:1'> </span>Rest of the World (Middle East &amp;
Africa)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.<span
style='mso-tab-count:1'> </span>Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.1.<span
style='mso-tab-count:1'> </span>Adams Respiratory Therapeutics, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.2.<span
style='mso-tab-count:1'> </span>Allergan plc<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.3.<span
style='mso-tab-count:1'> </span>AstraZeneca<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.4.<span
style='mso-tab-count:1'> </span>Boehringer Ingelheim<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.5.<span
style='mso-tab-count:1'> </span>F. Hoffmann-La Roche<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.6.<span
style='mso-tab-count:1'> </span>GlaxoSmithKline<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.7.<span
style='mso-tab-count:1'> </span>Merck &amp; Co.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.8.<span
style='mso-tab-count:1'> </span>Novartis<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.9.<span
style='mso-tab-count:1'> </span>Respiratory Therapeutics Group, LLC<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.10.<span
style='mso-tab-count:1'> </span>Takeda Pharmaceutical<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>&#8195;</span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>To request Table of Contents and Sample Pages
of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/respiratory-therapeutics-market/">https://www.ihealthcareanalyst.com/report/respiratory-therapeutics-market/</a></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>About Us<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at clients specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Contact Us<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2109, Mckelvey Hill Drive,<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Maryland Heights, MO 63043<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>United States<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Email: sales@ihealthcareanalyst.com<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Website: </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com"><span style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<b style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=all style='mso-special-character:line-break;
page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Spinal Cord Stimulation Devices Market US$ 5.3 Billion by 2023 <o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global spinal cord stimulation devices market expected to reach US$ 5.3 billion
by 2023, growing at CAGR 13.3% over the forecast period, </span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>due to fast
advancing applications and technologies, allowing more effective and
individualized treatment for patients</span><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global </span><span lang=EN-US style='font-size:10.0pt;line-height:107%;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>spinal cord
stimulation devices </span><span lang=EN-US style='font-size:10.0pt;line-height:
107%;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>market research report provides market size
(Revenue USD Million 2015 to 2023), market share analysis, growth trends and
forecast (CAGR%, 2018 to 2023). The global </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>spinal cord stimulation devices </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market
research report is further segmented by geography into North America (U.S.,
Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany,
France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of
APAC), and Rest of the World. In addition, the global </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>spinal cord stimulation devices </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market
report provides the detailed market landscape (market drivers, restraints,
opportunities), market attractiveness analysis, and market profitability
analysis by key products and regions or countries.<span
style='mso-spacerun:yes'> </span>The report also tracks the major competitors
operating in the global market by company overview, financial snapshot, major
products, technologies, services offered and recent developments.</span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Visit
</span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Spinal Cord Stimulation Devices Market by
Product/Device Type (Rechargeable, Non-rechargeable); Application (Degenerative
Disk Disease, Failed Back Syndrome, Multiple Back Operations, Unsuccessful Disk
Surgery, Complex Regional Pain Syndrome, Arachnoiditis or Lumbar Adhesive
Arachnoiditis); End User (Hospitals, Ambulatory Surgery Centers) and Forecast
2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/spinal-cord-stimulation-devices-market/"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/spinal-cord-stimulation-devices-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'> <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Major players operating in the global
spinal cord stimulation devices market and profiled in this report include
Abbott Laboratories, Inc. (St. Jude Medical, Inc.), Boston Scientific Corp.,
Medtronic PLC, Nevro Corp., Saluda Medical, and Stimwave Technologies. Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l1 level1 lfo23'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Product/Device
Type<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l1 level2 lfo23'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rechargeable <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l1 level2 lfo23'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Non-rechargeable<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l1 level1 lfo23'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Application <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l1 level2 lfo23'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Degenerative Disk
Disease (DDD) <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l1 level2 lfo23'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Failed Back
Syndrome (FBS)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l1 level2 lfo23'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Multiple Back
Operations <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l1 level2 lfo23'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Unsuccessful Disk
Surgery <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l1 level2 lfo23'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Complex Regional
Pain Syndrome (CRPS)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l1 level2 lfo23'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Arachnoiditis or
Lumbar Adhesive Arachnoiditis<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l1 level1 lfo23'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>End User<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l1 level2 lfo23'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Hospitals <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l1 level2 lfo23'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Ambulatory
Surgery Centers (ASCs)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l1 level1 lfo23'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Geography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l1 level2 lfo23'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>North America
(U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l1 level2 lfo23'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Latin America
(Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l1 level2 lfo23'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l1 level2 lfo23'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Asia Pacific
(Japan, China, India, Rest of APAC<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l1 level2 lfo23'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rest of the World<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l1 level1 lfo23'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l1 level2 lfo23'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Abbott
Laboratories, Inc. (St. Jude Medical, Inc.)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l1 level2 lfo23'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Boston Scientific
Corp.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l1 level2 lfo23'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Medtronic PLC<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l1 level2 lfo23'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Nevro Corp.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l1 level2 lfo23'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Saluda Medical<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;mso-add-space:auto;
text-indent:-.3in;mso-list:l1 level2 lfo23'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Stimwave
Technologies. Inc.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'>To request Table of Contents and
Sample Pages of this report visit:</span><span lang=EN-US style='font-size:
10.0pt;line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/spinal-cord-stimulation-devices-market/"><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/report/spinal-cord-stimulation-devices-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>
<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>About Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst,
Inc. is a global healthcare market research and consulting company providing
market analysis, and competitive intelligence services to global clients. The
company publishes syndicate, custom and consulting grade healthcare reports
covering animal healthcare, biotechnology, clinical diagnostics, healthcare
informatics, healthcare services, medical devices, medical equipment, and
pharmaceuticals.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at clients specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>Contact Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com"><span style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'><o:p></o:p></span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black;mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='mso-special-character:line-break;page-break-before:
always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Hemophilia Treatment Market US$ 17 Billion by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>The global </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>hemophilia
treatment </span><span lang=EN-US style='font-size:10.0pt;line-height:107%;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market to attain
US$ 17 Billion by 2023, growing at a CAGR of 5.5% over the forecast period.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>While less than 1 million people
suffer from hemophilia A or B globally, they are among some of the most costly
patients to treat because of frequent transfusions, costly medicines and often
have a poor health prognosis, particularly in the absence of treatment. There
are ~39,000 patients with haemophilia A and ~10,000 patients with haemophilia B
across the EU5 countries (France, Germany, Italy, Spain and the United Kingdom)
plus the United States.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Visit the global hemophilia
treatment market by indication (hemophilia A, hemophilia B, hemophilia with inhibitors,
von Willebrand disease); by product class [recombinant coagulation factor
(factor VIII, factor IX, hemophilia with inhibitors, von Willebrand disease),
plasma-derived coagulation factor (factor VIII factor IX, hemophilia with
inhibitors, von Willebrand disease)]; by treatment regime [prophylaxis (factor
VIII, factor IX, inhibitors, von Willebrand disease), on-demand (factor VIII,
factor IX, inhibitors, von Willebrand disease)]; by patient [adult<span
style='mso-spacerun:yes'> </span>hemophilia a, hemophilia b, hemophilia with
inhibitors, von Willebrand disease), pediatric (hemophilia A, hemophilia B,
hemophilia with inhibitors, von Willebrand disease)]; and by distribution
channel (e-commerce, hospital pharmacies, retail pharmacies); </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>by geography and forecast 2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/hemophilia-treatment-market/"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/hemophilia-treatment-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'> <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global hemophilia treatment market report provides market size (Revenue USD
Million 2015 to 2023), market share, trends and forecasts growth trends (CAGR%,
2018 to 2023). The global hemophilia treatment market research report is
further segmented by geography into North America (U.S., Canada), Latin America
(Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest
of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the
World. The global hemophilia drugs market report also provides the detailed
market landscape (market drivers, restraints, and opportunities), market attractiveness
analysis and tracks the major competitors operating in the market by company
overview, financial snapshot, key products, technologies and services offered,
market share analysis and recent trends in the global market. <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto;
text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Major
players operating in the global hemophilia treatment market and included in
this report are Bayer AG, Biogen Idec, Biomarin, Biotest AG, CSL Behring, F.
Hoffmann-La Roche Ltd., Grifols, Kedrion, Novo Nordisk A/S, Octapharma AG,
Pfizer, Inc., and Shire Plc (Baxter/Baxalta).<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>1.<span
style='mso-tab-count:1'> </span>Indication<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>1.1.<span
style='mso-tab-count:1'> </span>Hemophilia A <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>1.2.<span
style='mso-tab-count:1'> </span>Hemophilia B <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>1.3.<span
style='mso-tab-count:1'> </span>Hemophilia with Inhibitors<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>1.4.<span
style='mso-tab-count:1'> </span>von Willebrand disease<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>2.<span
style='mso-tab-count:1'> </span>Product Class<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>2.1.<span
style='mso-tab-count:1'> </span>Recombinant Coagulation Factor<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>2.1.1.<span
style='mso-tab-count:1'> </span>Factor VIII<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>2.1.2.<span
style='mso-tab-count:1'> </span>Factor IX<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>2.1.3.<span
style='mso-tab-count:1'> </span>Hemophilia with Inhibitors<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>2.1.4.<span
style='mso-tab-count:1'> </span>von Willebrand disease<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>2.2.<span
style='mso-tab-count:1'> </span>Plasma Derived Coagulation Factor<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>2.2.1.<span
style='mso-tab-count:1'> </span>Factor VIII<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>2.2.2.<span
style='mso-tab-count:1'> </span>Factor IX<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>2.2.3.<span
style='mso-tab-count:1'> </span>Hemophilia with Inhibitors<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>2.2.4.<span
style='mso-tab-count:1'> </span>von Willebrand disease<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.<span
style='mso-tab-count:1'> </span>Treatment Regime<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.1.<span
style='mso-tab-count:1'> </span>Prophylaxis<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.1.1.<span
style='mso-tab-count:1'> </span>Factor VIII<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.1.2.<span
style='mso-tab-count:1'> </span>Factor IX<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.1.3.<span
style='mso-tab-count:1'> </span>Hemophilia with Inhibitors<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.1.4.<span
style='mso-tab-count:1'> </span>von Willebrand disease<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.2.<span
style='mso-tab-count:1'> </span>On-Demand <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.2.1.<span
style='mso-tab-count:1'> </span>Factor VIII<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.2.2.<span
style='mso-tab-count:1'> </span>Factor IX<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.2.3.<span
style='mso-tab-count:1'> </span>Hemophilia with Inhibitors<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>3.2.4.<span
style='mso-tab-count:1'> </span>von Willebrand disease<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>4.<span
style='mso-tab-count:1'> </span>Patient<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>4.1.<span
style='mso-tab-count:1'> </span>Adult <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>4.1.1.<span
style='mso-tab-count:1'> </span>Hemophilia A <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>4.1.2.<span
style='mso-tab-count:1'> </span>Hemophilia B <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>4.1.3.<span
style='mso-tab-count:1'> </span>Hemophilia with Inhibitors<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>4.1.4.<span
style='mso-tab-count:1'> </span>von Willebrand disease<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>4.2.<span
style='mso-tab-count:1'> </span>Pediatric<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>4.2.1.<span
style='mso-tab-count:1'> </span>Hemophilia A <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>4.2.2.<span
style='mso-tab-count:1'> </span>Hemophilia B <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>4.2.3.<span
style='mso-tab-count:1'> </span>Hemophilia with Inhibitors<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>4.2.4.<span
style='mso-tab-count:1'> </span>von Willebrand disease<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>5.<span
style='mso-tab-count:1'> </span>Distribution Channel <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>5.1.<span
style='mso-tab-count:1'> </span>E-commerce<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>5.2.<span
style='mso-tab-count:1'> </span>Hospital Pharmacies<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>5.3.<span
style='mso-tab-count:1'> </span>Retail Pharmacies<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>6.<span
style='mso-tab-count:1'> </span>Geography (Region, Country)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>6.1.<span
style='mso-tab-count:1'> </span>North America (U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>6.2.<span
style='mso-tab-count:1'> </span>Europe (U.K., Germany, France, Italy,
Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>6.3.<span
style='mso-tab-count:1'> </span>Latin America (Brazil, Mexico, Rest of
LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>6.4.<span
style='mso-tab-count:1'> </span>Asia Pacific (Japan, China, India, Rest
of APAC)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>6.5.<span
style='mso-tab-count:1'> </span>Rest of the World (Middle East &amp; Africa)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>7.<span
style='mso-tab-count:1'> </span>Company Profiles <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>7.1.<span
style='mso-tab-count:1'> </span>Bayer AG<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>7.2.<span
style='mso-tab-count:1'> </span>Biogen Idec<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>7.3.<span
style='mso-tab-count:1'> </span>Biomarin<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>7.4.<span
style='mso-tab-count:1'> </span>Biotest AG<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>7.5.<span
style='mso-tab-count:1'> </span>CSL Behring<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>7.6.<span
style='mso-tab-count:1'> </span>F. Hoffmann-La Roche Ltd.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>7.7.<span
style='mso-tab-count:1'> </span>Grifols<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>7.8.<span
style='mso-tab-count:1'> </span>Kedrion<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>7.9.<span
style='mso-tab-count:1'> </span>Novo Nordisk A/S<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>7.10.<span
style='mso-tab-count:1'> </span>Octapharma AG<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>7.11.<span
style='mso-tab-count:1'> </span>Pfizer, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>7.12.<span
style='mso-tab-count:1'> </span>Shire Plc (Baxter/Baxalta)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>To request Table of Contents and Sample Pages
of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/hemophilia-treatment-market/">https://www.ihealthcareanalyst.com/report/hemophilia-treatment-market/</a>
</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>About Us<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at clients specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Contact Us<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2109, Mckelvey Hill Drive,<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Maryland Heights, MO 63043<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>United States<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Email: sales@ihealthcareanalyst.com<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Website: </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com"><span style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<b style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=all style='mso-special-character:line-break;
page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Robotic-Assisted Surgical (RAS) Devices Market US$ 5.7 Billion by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>The global </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>robotic-assisted
surgical (RAS) devices </span><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market
to attain US$ 5.7 Billion by 2023, growing at a CAGR of 8.6% over the forecast
period.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Visit the global robotic-assisted
surgical (RAS) devices market by device (robotic-assisted systems, instruments
and accessories, services); by clinical application (general surgery, urology,
orthopedic, neurosurgery, cardiovascular, gynecology, radiology, transplant,
gastrointestinal, other); </span><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>by geography and
forecast 2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/robotic-assisted-surgical-devices-market/">https://www.ihealthcareanalyst.com/report/robotic-assisted-surgical-devices-market/</a>
</span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The global robotic-assisted
surgical (RAS) devices market report provides market size (Revenue US$ Million
2015 to 2023), market share, trends and forecasts growth trends (CAGR%, 2018 to
2023). The global robotic-assisted surgical (RAS) devices market research
report is further segmented by geography into North America (U.S., Canada),
Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan,
China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and
Rest of the World. The global robotic-assisted surgical (RAS) devices market
report also provides the detailed market landscape (market drivers, restraints,
opportunities), market attractiveness analysis and also tracks the major
competitors operating in the market by company overview, financial snapshot,
key products, technologies and services offered, market share analysis and
recent trends in the global market.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Major players
operating in the global robotic-assisted surgical (RAS) devices market and
profiled in this report include Accuray, Inc., AKTORmed , FlexDex Surgical ,
Hansen Medical/Auris Surgical Robotics Inc., Intuitive Surgical, Inc., Mazor
Robotics, Medrobotics Corporation, Renishaw plc, Smith &amp; Nephew (Blue Belt
Technologies), Stereotaxis, Inc., Stryker Corporation (MAKO), Titan Medical,
Inc., TransEnterix, Inc., and Zimmer Biomet Holdings, Inc. (Medtech SA).<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.55in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>1. Device Type<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>1.1.<span style='mso-tab-count:1'> </span>Robotic-Assisted
Systems (RAS)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>1.2.<span style='mso-tab-count:1'> </span>Instruments
and Accessories<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>1.3.<span style='mso-tab-count:1'> </span>Services<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2. Application<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2.1.<span style='mso-tab-count:1'> </span>General
surgery<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2.2.<span style='mso-tab-count:1'> </span>Urology<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2.3.<span style='mso-tab-count:1'> </span>Orthopedic<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2.4.<span style='mso-tab-count:1'> </span>Neurosurgery<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2.5.<span style='mso-tab-count:1'> </span>Cardiovascular<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2.6.<span style='mso-tab-count:1'> </span>Gynecology<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2.7.<span style='mso-tab-count:1'> </span>Radiology<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2.8.<span style='mso-tab-count:1'> </span>Transplant<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2.9.<span style='mso-tab-count:1'> </span>Gastrointestinal<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2.10.<span style='mso-tab-count:1'> </span>Other<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3. Geography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.1.<span style='mso-tab-count:1'> </span>North
America (U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.2.<span style='mso-tab-count:1'> </span>Latin
America (Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.3.<span style='mso-tab-count:1'> </span>Europe
(U.K., Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.4.<span style='mso-tab-count:1'> </span>Asia
Pacific (Japan, China, India, Rest of APAC<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.5.<span style='mso-tab-count:1'> </span>Rest
of the World<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4. Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4.1.<span style='mso-tab-count:1'> </span>Accuray,
Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4.2.<span style='mso-tab-count:1'> </span>AKTORmed<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4.3.<span style='mso-tab-count:1'> </span>FlexDex
Surgical<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4.4.<span style='mso-tab-count:1'> </span>Hansen
Medical/Auris Surgical Robotics Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4.5.<span style='mso-tab-count:1'> </span>Intuitive
Surgical, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4.6.<span style='mso-tab-count:1'> </span>Mazor
Robotics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4.7.<span style='mso-tab-count:1'> </span>Medrobotics
Corporation<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4.8.<span style='mso-tab-count:1'> </span>Renishaw
plc<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4.9.<span style='mso-tab-count:1'> </span>Smith
&amp; Nephew (Blue Belt Technologies)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4.10.<span style='mso-tab-count:1'> </span>Stereotaxis,
Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4.11.<span style='mso-tab-count:1'> </span>Stryker
Corporation (MAKO)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4.12.<span style='mso-tab-count:1'> </span>Titan
Medical, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4.13.<span style='mso-tab-count:1'> </span>TransEnterix,
Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4.14.<span style='mso-tab-count:1'> </span>Zimmer
Biomet Holdings, Inc. (Medtech SA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>To request Table of Contents and Sample Pages
of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/robotic-assisted-surgical-devices-market/">https://www.ihealthcareanalyst.com/report/robotic-assisted-surgical-devices-market/</a>
</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>About Us<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at clients specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Contact Us<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2109, Mckelvey Hill Drive,<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Maryland Heights, MO 63043<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>United States<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Email: sales@ihealthcareanalyst.com<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Website: </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com"><span style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<b style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=all style='mso-special-character:line-break;
page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Transdermal Drug Delivery Devices Market US$ 8.7 Billion by 2023, Trends and
Forecast<o:p></o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>The global </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>transdermal drug
delivery devices </span><span lang=EN-US style='font-size:10.0pt;line-height:
107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market to attain
US$ 8.7 Billion by 2023, growing at a CAGR of 3.3% over the forecast period.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Visit the global transdermal
drug delivery devices market segmentation is based on technology (passive
transdermal transport systems, active transdermal transport systems); clinical
application [cardiovascular disease management (CVD), neurological disorder
management, hormone replacement therapy (HRT), pain management, genitourinary disorder
management]; patch-based pharmaceutical products [clonidine and nitroglycerin
products (CVD), neurological disorder treatment products, estrogen replacement
products (HRT), pain management products, urologic treatment products]; </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>by geography and forecast 2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/transdermal-drug-delivery-devices-market/">https://www.ihealthcareanalyst.com/report/transdermal-drug-delivery-devices-market/</a>
</span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The global transdermal
drug delivery devices market report provides market size (Revenue US$ Million
2015 to 2023), market share, trends and forecasts growth trends (CAGR%, 2018 to
2023). The global transdermal drug delivery devices market research report is
further segmented by geography into North America (U.S., Canada), Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India,
Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the
World. The global transdermal drug delivery devices market report also provides
the detailed market landscape (market drivers, restraints, opportunities),
market attractiveness analysis and also tracks the major competitors operating
in the market by company overview, financial snapshot, key products,
technologies and services offered, market share analysis and recent trends in
the global market.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Major players
operating in the global transdermal drug delivery devices market and profiled
in this report include 3M Drug Delivery Systems, Allergan, Inc., Mylan
Technologies, Inc./Mylan, Noven Therapeutics, Hisamitsu Pharmaceutical Co.,
Inc., Novartis AG, Johnson &amp; Johnson, Mylan N.V., Boehringer Ingelheim
GmbH, Bayer AG, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Acrux
Limited, Echo Therapeutics, Inc., and Endo Pharmaceuticals Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.55in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>1. Technology<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>1.1.<span style='mso-tab-count:1'> </span>Passive
Transdermal Transport Systems<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>1.2.<span style='mso-tab-count:1'> </span>Active
Transdermal Transport Systems<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2. Clinical Application<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2.1.<span style='mso-tab-count:1'> </span>Cardiovascular
Disease Management (CVD)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2.2.<span style='mso-tab-count:1'> </span>Neurological
Disorder Management<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2.3.<span style='mso-tab-count:1'> </span>Hormone
Replacement Therapy (HRT)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2.4.<span style='mso-tab-count:1'> </span>Pain
Management<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2.5.<span style='mso-tab-count:1'> </span>Genitourinary
Disorder Management<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3. Patch-Based Pharmaceutical Products<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.1.<span style='mso-tab-count:1'> </span>Clonidine
and Nitroglycerin Products (CVD)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.2.<span style='mso-tab-count:1'> </span>Neurological
Disorder Treatment Products<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.3.<span style='mso-tab-count:1'> </span>Estrogen
Replacement Products (HRT)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.4.<span style='mso-tab-count:1'> </span>Pain
Management Products<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.5.<span style='mso-tab-count:1'> </span>Urologic
Treatment Products<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4. Geography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4.1.<span style='mso-tab-count:1'> </span>North
America (U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4.2.<span style='mso-tab-count:1'> </span>Latin
America (Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4.3.<span style='mso-tab-count:1'> </span>Europe
(U.K., Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4.4.<span style='mso-tab-count:1'> </span>Asia
Pacific (Japan, China, India, Rest of APAC<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4.5.<span style='mso-tab-count:1'> </span>Rest
of the World<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>5. Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>5.1. 3M Drug Delivery Systems,<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>5.2.<span style='mso-tab-count:1'> </span>Acrux
Limited<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>5.3.<span style='mso-tab-count:1'> </span>Allergan,
Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>5.4.<span style='mso-tab-count:1'> </span>Bayer
AG<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>5.5.<span style='mso-tab-count:1'> </span>Boehringer
Ingelheim GmbH<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>5.6.<span style='mso-tab-count:1'> </span>Bristol-Myers
Squibb Company<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>5.7.<span style='mso-tab-count:1'> </span>Echo
Therapeutics, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>5.8.<span style='mso-tab-count:1'> </span>Endo
Pharmaceuticals Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>5.9.<span style='mso-tab-count:1'> </span>GlaxoSmithKline
plc<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>5.10.<span style='mso-tab-count:1'> </span>Hisamitsu
Pharmaceutical Co., Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>5.11.<span style='mso-tab-count:1'> </span>Johnson
&amp; Johnson<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>5.12.<span style='mso-tab-count:1'> </span>Mylan
Technologies, Inc./Mylan N.V.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>5.13.<span style='mso-tab-count:1'> </span>Novartis
AG<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>5.14.<span style='mso-tab-count:1'> </span>Noven
Therapeutics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>To request Table of Contents and Sample Pages
of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/transdermal-drug-delivery-devices-market/">https://www.ihealthcareanalyst.com/report/transdermal-drug-delivery-devices-market/</a>
<span style='mso-spacerun:yes'></span></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>About Us<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at clients specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Contact Us<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2109, Mckelvey Hill Drive,<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Maryland Heights, MO 63043<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>United States<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Email: sales@ihealthcareanalyst.com<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Website: </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com"><span style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<b style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=all style='mso-special-character:line-break;
page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Injection Drug Delivery Devices Market US$ 8 Billion by 2023, Trends and
Forecast<o:p></o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>The global </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>injection drug
delivery devices </span><span lang=EN-US style='font-size:10.0pt;line-height:
107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market to attain
US$ 8 Billion by 2023, growing at a CAGR of 5.6% over the forecast period.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Visit the global injection
drug delivery devices market by product type [syringe/needles products
(standard syringes/needles, safety syringes/needles); and vascular access
devices (short peripheral catheters, midline catheters, peripherally inserted
central catheters, central venous catheters, implantable ports)]; </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>by geography and forecast 2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/injection-drug-delivery-devices-market/">https://www.ihealthcareanalyst.com/report/injection-drug-delivery-devices-market/</a>
</span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The global injection
drug delivery devices market report provides market size (Revenue US$ Million
2015 to 2023), market share, trends and forecasts growth trends (CAGR%, 2018 to
2023). The global injection drug delivery devices market research report is
further segmented by geography into North America (U.S., Canada), Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India,
Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the
World. The global injection drug delivery devices market report also provides
the detailed market landscape (market drivers, restraints, opportunities), market
attractiveness analysis and also tracks the major competitors operating in the
market by company overview, financial snapshot, key products, technologies and
services offered, market share analysis and recent trends in the global market.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Major players
operating in the global injection drug delivery devices market and profiled in
this report include Air-Tite Products Co., Inc., AngioDynamics, Inc., B. Braun
Melsungen AG, Becton Dickinson and Company, Cook Medical/Cook Group, CR Bard,
Inc., Health Line International Corporation, Medical Components (dba Medcomp),
Medtronic Minimally Invasive Therapies/Medtronic PLC, Navilyst Medical, Inc.,
Nipro Medical Corporation, Perouse Medical SAS/Vygon, Inc., Retractable
Technologies, Inc., Smiths Medical/Smiths Group PLC, Sol-Millennium Medical,
Inc., Teleflex Medical/Teleflex, Inc., Terumo Medical/Terumo Corporation, and
US Medical Instruments, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.55in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>1. Product Type<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>1.1.<span style='mso-tab-count:1'> </span>Syringe/Needles
Products<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>1.1.1.<span style='mso-tab-count:1'> </span>Standard
Syringes/Needles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>1.1.2.<span style='mso-tab-count:1'> </span>Safety
Syringes/Needles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>1.2.<span style='mso-tab-count:1'> </span>Vascular
Access Devices (VADs)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>1.2.1.<span style='mso-tab-count:1'> </span>Short
Peripheral Catheters (SPCs)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>1.2.2.<span style='mso-tab-count:1'> </span>Midline
Catheters<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>1.2.3.<span style='mso-tab-count:1'> </span>Peripherally
Inserted Central Catheters (PICCs)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>1.2.4.<span style='mso-tab-count:1'> </span>Central
Venous Catheters (CVCs)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>1.2.5.<span style='mso-tab-count:1'> </span>Implantable
Ports<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2. Geography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2.1.<span style='mso-tab-count:1'> </span>North
America (U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2.2.<span style='mso-tab-count:1'> </span>Latin
America (Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2.3.<span style='mso-tab-count:1'> </span>Europe
(U.K., Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2.4.<span style='mso-tab-count:1'> </span>Asia
Pacific (Japan, China, India, Rest of APAC<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2.5.<span style='mso-tab-count:1'> </span>Rest
of the World<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3. Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.1.<span style='mso-tab-count:1'> </span>Air-Tite
Products Co., Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.2.<span style='mso-tab-count:1'> </span>AngioDynamics,
Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.3.<span style='mso-tab-count:1'> </span>B.
Braun Melsungen AG<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.4.<span style='mso-tab-count:1'> </span>Becton
Dickinson and Company<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.5.<span style='mso-tab-count:1'> </span>Cook
Medical/Cook Group<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.6.<span style='mso-tab-count:1'> </span>CR
Bard, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.7.<span style='mso-tab-count:1'> </span>Health
Line International Corporation<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.8.<span style='mso-tab-count:1'> </span>Medical
Components (dba Medcomp)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.9.<span style='mso-tab-count:1'> </span>Medtronic
Minimally Invasive Therapies/Medtronic PLC<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.10.<span style='mso-tab-count:1'> </span>Navilyst
Medical, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.11.<span style='mso-tab-count:1'> </span>Nipro
Medical Corporation<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.12.<span style='mso-tab-count:1'> </span>Perouse
Medical SAS/Vygon, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.13.<span style='mso-tab-count:1'> </span>Retractable
Technologies, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.14.<span style='mso-tab-count:1'> </span>Smiths
Medical/Smiths Group PLC<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.15.<span style='mso-tab-count:1'> </span>Sol-Millennium
Medical, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.16.<span style='mso-tab-count:1'> </span>Teleflex
Medical/Teleflex, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.17.<span style='mso-tab-count:1'> </span>Terumo
Medical/Terumo Corporation<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.18.<span style='mso-tab-count:1'> </span>US
Medical Instruments, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>To request Table of Contents and Sample Pages
of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/injection-drug-delivery-devices-market/">https://www.ihealthcareanalyst.com/report/injection-drug-delivery-devices-market/</a>
</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>About Us<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at clients specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Contact Us<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2109, Mckelvey Hill Drive,<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Maryland Heights, MO 63043<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>United States<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Email: sales@ihealthcareanalyst.com<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Website: </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com"><span style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<b style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=all style='mso-special-character:line-break;
page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Ophthalmic Drugs Market US$ 10 Billion by 2023, Trends and Forecast<o:p></o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>The global </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>ophthalmic drugs </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>market to attain US$ 10 Billion by 2023,
growing at a CAGR of 4.8% over the forecast period.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Visit the global
ophthalmic drugs market by disease type (allergy, dry eye disorder, glaucoma,
retinal disorder), and dispense type (over-the-counter, prescription); </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>by geography and forecast 2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/ophthalmic-drugs-market/">https://www.ihealthcareanalyst.com/report/ophthalmic-drugs-market/</a>
</span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The global
ophthalmic drugs market report provides market size (Revenue US$ Million 2015
to 2023), market share, trends and forecasts growth trends (CAGR%, 2018 to
2023). The global ophthalmic drugs market research report is further segmented
by geography into North America (U.S., Canada), Europe (U.K., Germany, France,
Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC),
Latin America (Brazil, Mexico, Rest of LA), and Rest of the World. The global
ophthalmic drugs market report also provides the detailed market landscape
(market drivers, restraints, opportunities), market attractiveness analysis and
also tracks the major competitors operating in the market by company overview,
financial snapshot, key products, technologies and services offered, market
share analysis and recent trends in the global market.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Major players
operating in the global ophthalmic drugs market and profiled in this report
include Abbott Healthcare, Allergan Plc, Bayer, Johnson &amp; Johnson, Merck
&amp; Co., Novartis AG, Pfizer, Inc., Renegeron, Santen Pharmaceuticals Company
Ltd., and Valeant Pharmaceuticals, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.55in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>1. Disease Type<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>1.1.<span style='mso-tab-count:1'> </span>Allergy<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>1.2.<span style='mso-tab-count:1'> </span>Dry
Eye Disorder<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>1.3.<span style='mso-tab-count:1'> </span>Glaucoma<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>1.4.<span style='mso-tab-count:1'> </span>Retinal
Disorder<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2. Dispense Type<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2.1.<span style='mso-tab-count:1'> </span>Over-the-Counter<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2.2.<span style='mso-tab-count:1'> </span>Prescription<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3. Geography (Region, Country)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.1.<span style='mso-tab-count:1'> </span>North
America (U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.2.<span style='mso-tab-count:1'> </span>Europe
(U.K., Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.3.<span style='mso-tab-count:1'> </span>Latin
America (Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.4.<span style='mso-tab-count:1'> </span>Asia
Pacific (Japan, China, India, Rest of APAC)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.5.<span style='mso-tab-count:1'> </span>Rest
of the World (Middle East &amp; Africa)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4. Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4.1.<span style='mso-tab-count:1'> </span>Abbott
Healthcare<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4.2.<span style='mso-tab-count:1'> </span>Allergan
Plc<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4.3.<span style='mso-tab-count:1'> </span>Bayer<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4.4.<span style='mso-tab-count:1'> </span>Johnson
&amp; Johnson<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4.5.<span style='mso-tab-count:1'> </span>Merck
&amp; Co.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4.6.<span style='mso-tab-count:1'> </span>Novartis
AG<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4.7.<span style='mso-tab-count:1'> </span>Pfizer,
Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4.8.<span style='mso-tab-count:1'> </span>Renegeron<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4.9.<span style='mso-tab-count:1'> </span>Santen
Pharmaceuticals Company Ltd.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>4.10.<span style='mso-tab-count:1'> </span>Valeant
Pharmaceuticals, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>To request Table of Contents and Sample Pages
of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/ophthalmic-drugs-market/">https://www.ihealthcareanalyst.com/report/ophthalmic-drugs-market/</a></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>About Us<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at clients specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Contact Us<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2109, Mckelvey Hill Drive,<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Maryland Heights, MO 63043<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>United States<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Email: sales@ihealthcareanalyst.com<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Website: </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com"><span style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<b style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=all style='mso-special-character:line-break;
page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Spinal Implants Market US$ 6.6 Billion by 2023, Trends and Forecast</span></b><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'> <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>The global </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>spinal implants </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>market to attain US$ 6.6 Billion by 2023,
growing at a CAGR of 4.3% over the forecast period.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Visit spinal implants market by product
[spinal fusion instrumentation (anterior cervical plates, interbody fusion
devices and pedicle screws), dynamic stabilization devices (interspinous
process spacers and pedicle screw-based dynamic stabilization devices),
vertebral compression fracture treatments (balloon kyphoplasty/percutaneous
vertebral augmentation systems and vertebroplasty products), artificial
cervical and lumbar discs, other motion preserving devices (annulus repair); </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>by geography and forecast 2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/spinal-implants-market/">https://www.ihealthcareanalyst.com/report/spinal-implants-market/</a>
</span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-spacerun:yes'></span><o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global spinal implants market research report provides market size (Revenue USD
Million 2015 to 2023), market share analysis, growth trends and forecast
(CAGR%, 2018 to 2023). The global spinal implants market research report is
further segmented by geography into North America (U.S., Canada), Latin America
(Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest
of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the
World. In addition, the global spinal implants market report provides the
detailed market landscape (market drivers, restraints, opportunities), market
attractiveness analysis, and market profitability analysis by key products and
regions or countries.<span style='mso-spacerun:yes'> </span>The report also
tracks the major competitors operating in the global market by company
overview, financial snapshot, major products, technologies, services offered
and recent developments.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Major
players operating in the global spinal implants market include Alphatec Spine,
Amedica, Atlas Spine, AxioMed Spine, B. Braun Melsungen AG, Benvenue Medical,
Biotechni, Carefusion, Crosstrees Medical, DiscGenics, Depuy Synthes/Johnson
&amp; Johnson, DFINE, Exactech, Globus Medical, Heraeus Medical, Integra
LifeSciences Corp., Intrinsic Therapeutics, ISTO Technologies, K2M, Life Spine,
LDR, Medicrea, Medtronic plc, Mekanika, Mesoblast, Ltd., NuVasive, Inc., Ortho
Development, Orthofix, Orthopaedic &amp; Spine Development, Osseon, LLC,
Paradigm Spine, PINA Medizintechnik Vertriebs AG, Pioneer Surgical, Premia
Spine, Signus Medical, Simpirica Spine, Sintea Plustek, Spinal Elements, Spinal
Kinetics, Inc., SpineVision, SpineWave, Stryker, Synimed, Teknimed, Ulrich
Medical USA, VertiFlex, and Zimmer Biomet.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.55in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>1. Product<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>1.1.<span style='mso-tab-count:1'> </span>Spinal
Fusion Instrumentation (Anterior Cervical Plates, Interbody Fusion Devices and
Pedicle Screws)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>1.2.<span style='mso-tab-count:1'> </span>Dynamic
Stabilization Devices (Interspinous Process Spacers and Pedicle Screw-Based
Dynamic Stabilization Devices)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>1.3.<span style='mso-tab-count:1'> </span>Vertebral
Compression Fracture Treatments (Balloon Kyphoplasty/Percutaneous Vertebral
Augmentation Systems and Vertebroplasty Products)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>1.4.<span style='mso-tab-count:1'> </span>Artificial
Cervical and Lumbar Discs<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>1.5.<span style='mso-tab-count:1'> </span>Other
Motion Preserving Devices (Annulus Repair)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2. Geography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2.1.<span style='mso-tab-count:1'> </span>North
America (U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2.2.<span style='mso-tab-count:1'> </span>Latin
America (Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2.3.<span style='mso-tab-count:1'> </span>Europe
(U.K., Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2.4.<span style='mso-tab-count:1'> </span>Asia
Pacific (Japan, China, India, Rest of APAC<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>2.5.<span style='mso-tab-count:1'> </span>Rest
of the World<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3. Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.1.<span style='mso-tab-count:1'> </span>Alphatec
Spine<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.2.<span style='mso-tab-count:1'> </span>Amedica<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.3.<span style='mso-tab-count:1'> </span>Atlas
Spine<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.4.<span style='mso-tab-count:1'> </span>AxioMed
Spine<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.5.<span style='mso-tab-count:1'> </span>B.
Braun Melsungen AG<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.6.<span style='mso-tab-count:1'> </span>Benvenue
Medical<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.7.<span style='mso-tab-count:1'> </span>Biotechni<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.8.<span style='mso-tab-count:1'> </span>Carefusion<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.9.<span style='mso-tab-count:1'> </span>Crosstrees
Medical<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.10.<span style='mso-tab-count:1'> </span>DiscGenics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.11.<span style='mso-tab-count:1'> </span>Depuy
Synthes (Johnson &amp; Johnson)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.12.<span style='mso-tab-count:1'> </span>DFINE<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.13.<span style='mso-tab-count:1'> </span>Exactech<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.14.<span style='mso-tab-count:1'> </span>Globus
Medical<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.15.<span style='mso-tab-count:1'> </span>Heraeus
Medical<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.16.<span style='mso-tab-count:1'> </span>Integra
LifeSciences Corp.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.17.<span style='mso-tab-count:1'> </span>Intrinsic
Therapeutics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.18.<span style='mso-tab-count:1'> </span>ISTO
Technologies<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.19.<span style='mso-tab-count:1'> </span>K2M<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.20.<span style='mso-tab-count:1'> </span>Life
Spine<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.21.<span style='mso-tab-count:1'> </span>LDR<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.22.<span style='mso-tab-count:1'> </span>Medicrea<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.23.<span style='mso-tab-count:1'> </span>Medtronic
plc<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.24.<span style='mso-tab-count:1'> </span>Mekanika<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.25.<span style='mso-tab-count:1'> </span>Mesoblast,
Ltd.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.26.<span style='mso-tab-count:1'> </span>NuVasive,
Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.27.<span style='mso-tab-count:1'> </span>Ortho
Development<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.28.<span style='mso-tab-count:1'> </span>Orthofix<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.29.<span style='mso-tab-count:1'> </span>Orthopaedic
&amp; Spine Development<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.30.<span style='mso-tab-count:1'> </span>Osseon,
LLC<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.31.<span style='mso-tab-count:1'> </span>Paradigm
Spine<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.32.<span style='mso-tab-count:1'> </span>PINA
Medizintechnik Vertriebs AG<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.33.<span style='mso-tab-count:1'> </span>Pioneer
Surgical<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.34.<span style='mso-tab-count:1'> </span>Premia
Spine<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.35.<span style='mso-tab-count:1'> </span>Signus
Medical<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.36.<span style='mso-tab-count:1'> </span>Simpirica
Spine<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.37.<span style='mso-tab-count:1'> </span>Sintea
Plustek<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.38.<span style='mso-tab-count:1'> </span>Spinal
Elements<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.39.<span style='mso-tab-count:1'> </span>Spinal
Kinetics, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.40.<span style='mso-tab-count:1'> </span>SpineVision<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.41.<span style='mso-tab-count:1'> </span>SpineWave<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.42.<span style='mso-tab-count:1'> </span>Stryker<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.43.<span style='mso-tab-count:1'> </span>Synimed<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.44.<span style='mso-tab-count:1'> </span>Teknimed<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.45.<span style='mso-tab-count:1'> </span>Ulrich
Medical USA<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.46.<span style='mso-tab-count:1'> </span>VertiFlex<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>3.47.<span style='mso-tab-count:1'> </span>Zimmer
Biomet<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>To request Table of Contents and Sample Pages
of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/spinal-implants-market/">https://www.ihealthcareanalyst.com/report/spinal-implants-market/</a></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>About Us<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at clients specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Contact Us<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2109, Mckelvey Hill Drive,<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Maryland Heights, MO 63043<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>United States<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Email: sales@ihealthcareanalyst.com<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Website: </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com"><span style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<b style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=all style='mso-special-character:line-break;
page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Gastroesophageal Cancer Drugs Market US$ 10.9 Billion by 2023, Trends and
Forecast<o:p></o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>The global gastroesophageal cancer drugs market
to attain US$ 10.9 Billion by 2023, growing at a CAGR of 18.1% over the
forecast period.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The most common types of esophageal
cancer are squamous cell carcinoma and adenocarcinoma. Smoking and heavy
alcohol use increase the risk of esophageal squamous cell carcinoma. Gastroesophageal
reflux disease and Barrett esophagus may increase the risk of esophageal
adenocarcinoma. Esophageal cancer is often diagnosed at an advanced stage
because there are no early signs or symptoms.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Visit </span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>gastroesophageal
cancer drugs </span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market
by drug class (angiogenesis inhibitors, CTLA4 inhibitors, cytotoxic agents,
HER2 inhibitors, MMP9 inhibitors, PD1 inhibitors, PDL1 inhibitors); </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>by geography and forecast 2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/gastroesophageal-cancer-drugs-market/"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/gastroesophageal-cancer-drugs-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'> <o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global </span><span lang=EN-US style='font-size:10.0pt;line-height:107%;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>gastroesophageal
cancer drugs </span><span lang=EN-US style='font-size:10.0pt;line-height:107%;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>market research report provides market size
(Revenue US$ Million 2015 to 2023), market share analysis, growth trends and
forecast (CAGR%, 2018 to 2023). The global </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>gastroesophageal cancer </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market
research report is further segmented by geography into North America (U.S.,
Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany,
France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of
APAC), and Rest of the World. In addition, the global </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>gastroesophageal cancer </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market
report provides the detailed market landscape (market drivers, restraints, opportunities),
market attractiveness analysis, and market profitability analysis by key products
and regions or countries. The report also tracks the major competitors
operating in the global market by company overview, financial snapshot, major
products, technologies, services offered and recent developments.</span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Major
players operating in the global gastroesophageal cancer market and profiled in
this report include Astellas Pharma, Bayer HealthCare, BeiGene, Boston
Biomedical, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Gilead Sciences, LSK
BioPharma, Merck KGaA, Merck Serono, Ono Pharmaceutical, Pfizer, Servier
Laboratories, Shionogi, Sumitomo Dainippon Pharma, and Taiho Oncology.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l14 level1 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Drug Class<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Angiogenesis
inhibitors<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>CTLA4 inhibitors<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Cytotoxic agents<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>HER2 inhibitors<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>MMP9 inhibitors<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>PD1 inhibitors<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>PDL1 inhibitors<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l14 level1 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Geography
(Region, Country)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>North America
(U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Asia Pacific
(Japan, China, India, Rest of APAC)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Latin America
(Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rest of the World<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l14 level1 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Astellas Pharma<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Bayer HealthCare<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>BeiGene<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Boston Biomedical<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Bristol-Myers
Squibb<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Celgene<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Daiichi Sankyo<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Gilead Sciences<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>LSK BioPharma<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.10.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Merck KGaA<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.11.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Merck Serono<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.12.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Ono
Pharmaceutical<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.13.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Pfizer<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.14.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Servier<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.15.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Shionogi<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.16.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Sumitomo Dainippon
Pharma<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.17.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Taiho Oncology<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>To request Table of Contents and Sample Pages
of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/gastroesophageal-cancer-drugs-market/">https://www.ihealthcareanalyst.com/report/gastroesophageal-cancer-drugs-market/</a>
</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>About Us<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at clients specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Contact Us<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2109, Mckelvey Hill Drive,<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Maryland Heights, MO 63043<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>United States<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Email: sales@ihealthcareanalyst.com<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Website: </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com"><span style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<b style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=all style='mso-special-character:line-break;
page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Joint Arthroplasty Devices Market US$ 18.5 Billion by 2023, Trends and Forecast<o:p></o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>The global joint arthroscopy devices market to
attain US$ 18.5 Billion by 2023, growing at a CAGR of 4.6% over the forecast
period.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Visit joint arthroscopy devices market
by procedure type (value &amp; volume)  ankle arthroplasty; elbow arthroplasty
(total elbow replacement, hemiarthroplasty); hip arthroplasty (total hip
arthroplasty  cemented hip arthroplasty, cementless hip arthroplasty, hybrid
hip replacement, partial hip arthroplasty, hip resurfacing, revision hip
surgeries); knee arthroplasty (total knee arthroplasty, unicondylar knee
arthroplasty, revision knee arthroplasty); shoulder arthroplasty (total
shoulder arthroplasty, reverse total shoulder arthroplasty, shoulder
hemiarthroplasty, shoulder resurfacing, revision shoulder arthroplasty); by
geography and forecast 2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/joint-arthroplasty-devices-market/">https://www.ihealthcareanalyst.com/report/joint-arthroplasty-devices-market/</a>
</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global joint arthroplasty devices market research report provides market size
(Revenue US$ Million 2015 to 2023), market share analysis, growth trends and
forecast (CAGR%, 2018 to 2023). The global market research report is further
segmented by geography into North America (U.S., Canada), Latin America
(Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest
of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the
World. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Major
players operating in the market include Adler Ortho, Arthrex, B. Braun
Melsungen, BioPro, Corin, DePuy Synthes (Johnson &amp; Johnson), DJO Global,
Evolutis, Exactech, FH Orthopedics, Implantcast, Implants International,
Integra LifeSciences, JRI Orthopedics, Lima Corporate, Mathys, MatOrtho,
Medacta International, MicroPort Scientific, Smith &amp; Nephew, Stryker,
Tornier, Waldemar Link, Wright Medical Group, and Zimmer Biomet.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.<span style='mso-tab-count:1'> </span>Procedure
Type (Value &amp; Volume)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.1.<span style='mso-tab-count:1'> </span>Ankle
Arthroplasty<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.2.<span style='mso-tab-count:1'> </span>Elbow
Arthroplasty<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.2.1.<span style='mso-tab-count:1'> </span>Total
Elbow Replacement<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.2.2.<span style='mso-tab-count:1'> </span>Hemiarthroplasty<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.3.<span style='mso-tab-count:1'> </span>Hip
Arthroplasty<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.3.1.<span style='mso-tab-count:1'> </span>Total
Hip Arthroplasty (THA)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.3.2.<span style='mso-tab-count:1'> </span>Cemented
Hip Arthroplasty<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.3.3.<span style='mso-tab-count:1'> </span>Cementless
Hip Arthroplasty<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.3.4.<span style='mso-tab-count:1'> </span>Hybrid
Hip Replacement<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.3.5.<span style='mso-tab-count:1'> </span>Partial
Hip Arthroplasty<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.3.6.<span style='mso-tab-count:1'> </span>Hip
Resurfacing<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.3.7.<span style='mso-tab-count:1'> </span>Revision
Hip Surgeries<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.4.<span style='mso-tab-count:1'> </span>Knee
Arthroplasty<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.4.1.<span style='mso-tab-count:1'> </span>Total
Knee Arthroplasty (TKA)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.4.2.<span style='mso-tab-count:1'> </span>Unicondylar
Knee Arthroplasty<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.4.3.<span style='mso-tab-count:1'> </span>Revision
Knee Arthroplasty<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.5.<span style='mso-tab-count:1'> </span>Shoulder
Arthroplasty<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.5.1.<span style='mso-tab-count:1'> </span>Total
Shoulder Arthroplasty (TSA)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.5.2.<span style='mso-tab-count:1'> </span>Reverse
Total Shoulder Arthroplasty (RTSA)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.5.3.<span style='mso-tab-count:1'> </span>Shoulder
Hemiarthroplasty<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.5.4.<span style='mso-tab-count:1'> </span>Shoulder
Resurfacing<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.5.5.<span style='mso-tab-count:1'> </span>Revision
Shoulder Arthroplasty<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.<span style='mso-tab-count:1'> </span>Geography<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.1.<span style='mso-tab-count:1'> </span>North
America (U.S., Canada)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.2.<span style='mso-tab-count:1'> </span>Latin
America (Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.3.<span style='mso-tab-count:1'> </span>Europe
(U.K., Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.4.<span style='mso-tab-count:1'> </span>Asia
Pacific (Japan, China, India, Rest of APAC<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.5.<span style='mso-tab-count:1'> </span>Rest
of the World<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.<span style='mso-tab-count:1'> </span>Company
Profiles<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.1.<span style='mso-tab-count:1'> </span>Adler
Ortho<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.2.<span style='mso-tab-count:1'> </span>Arthrex<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.3.<span style='mso-tab-count:1'> </span>B.
Braun Melsungen<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.4.<span style='mso-tab-count:1'> </span>BioPro<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.5.<span style='mso-tab-count:1'> </span>Corin<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.6.<span style='mso-tab-count:1'> </span>DePuy
Synthes (Johnson &amp; Johnson)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.7.<span style='mso-tab-count:1'> </span>DJO
Global<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.8.<span style='mso-tab-count:1'> </span>Evolutis<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.9.<span style='mso-tab-count:1'> </span>Exactech<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.10.<span style='mso-tab-count:1'> </span>FH
Orthopedics<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.11.<span style='mso-tab-count:1'> </span>Implantcast<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.12.<span style='mso-tab-count:1'> </span>Implants
International<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.13.<span style='mso-tab-count:1'> </span>Integra
LifeSciences<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.14.<span style='mso-tab-count:1'> </span>JRI
Orthopedics<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.15.<span style='mso-tab-count:1'> </span>Lima
Corporate<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.16.<span style='mso-tab-count:1'> </span>Mathys<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.17.<span style='mso-tab-count:1'> </span>MatOrtho<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.18.<span style='mso-tab-count:1'> </span>Medacta
International<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.19.<span style='mso-tab-count:1'> </span>MicroPort
Scientific<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.20.<span style='mso-tab-count:1'> </span>Smith
&amp; Nephew<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.21.<span style='mso-tab-count:1'> </span>Stryker<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.22.<span style='mso-tab-count:1'> </span>Tornier<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.23.<span style='mso-tab-count:1'> </span>Waldemar
Link<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.24.<span style='mso-tab-count:1'> </span>Wright
Medical Group<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.25.<span style='mso-tab-count:1'> </span>Zimmer
Biomet<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>To request Table of Contents and Sample Pages
of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/joint-arthroplasty-devices-market/">https://www.ihealthcareanalyst.com/report/joint-arthroplasty-devices-market/</a><span
style='mso-spacerun:yes'> </span></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>About Us<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at clients specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Contact Us<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2109, Mckelvey Hill Drive,<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Maryland Heights, MO 63043<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>United States<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Email: sales@ihealthcareanalyst.com<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Website: </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com"><span style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<b style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=all style='mso-special-character:line-break;
page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Arthroscopy and Sport Medicine Devices Market US$ 7.0 Billion by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>The global arthroscopy and sport medicine
devices market to attain US$ 7.0 Billion by 2023, growing at a CAGR of 4% over
the forecast period.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Visit arthroscopy and sport medicine devices
market by <span style='mso-spacerun:yes'></span>product  arthroscopy products
(arthroscopic visualization products, fluid management products, manual
arthroscopy instruments, powered arthroscopy instruments), and soft tissue
fixation devices (cruciate ligament fixation devices, hip fixation devices,
meniscal fixation devices, shoulder fixation devices); by geography and
forecast 2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/arthroscopy-sport-medicine-devices-market/">https://www.ihealthcareanalyst.com/report/arthroscopy-sport-medicine-devices-market/</a>
</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The global arthroscopy and sport
medicine devices market research report provides market size (Revenue US$
Million 2015 to 2023), market share analysis, growth trends and forecast
(CAGR%, 2018 to 2023). The global market research report is further segmented
by geography into North America (U.S., Canada), Latin America (Brazil, Mexico,
Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia
Pacific (Japan, China, India, Rest of APAC), and Rest of the World. <o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Major players operating in the market
include Athos, Arthrex, Inc., ConMed Corp., DePuy Mitek Inc. (Johnson &amp;
Johnson), DJO Global, GE Healthcare, Medtronic, Smith &amp; Nephew PLC, Stryker
Corp., Tornier, Inc., Zimmer Biomet Holdings, Inc., Karl Storz
Endoscopy-America, and Richard Wolf Medical Instruments Corp.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.<span style='mso-tab-count:1'> </span>Product/Device
Type<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.1.<span style='mso-tab-count:1'> </span>Arthroscopy
Products<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.1.1.<span style='mso-tab-count:1'> </span>Arthroscopic
Visualization Products<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.1.2.<span style='mso-tab-count:1'> </span>Fluid
Management Products<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.1.3.<span style='mso-tab-count:1'> </span>Manual
Arthroscopy Instruments<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.1.4.<span style='mso-tab-count:1'> </span>Powered
Arthroscopy Instruments<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.2.<span style='mso-tab-count:1'> </span>Soft
Tissue Fixation Devices<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.2.1.<span style='mso-tab-count:1'> </span>Cruciate
Ligament Fixation Devices<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.2.2.<span style='mso-tab-count:1'> </span>Hip
Fixation Devices<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.2.3.<span style='mso-tab-count:1'> </span>Meniscal
Fixation Devices<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.2.4.<span style='mso-tab-count:1'> </span>Shoulder
Fixation Devices<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.<span style='mso-tab-count:1'> </span>Geography<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.1.<span style='mso-tab-count:1'> </span>North
America (U.S., Canada)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.2.<span style='mso-tab-count:1'> </span>Latin
America (Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.3.<span style='mso-tab-count:1'> </span>Europe
(U.K., Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.4.<span style='mso-tab-count:1'> </span>Asia
Pacific (Japan, China, India, Rest of APAC<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.5.<span style='mso-tab-count:1'> </span>Rest
of the World<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.<span style='mso-tab-count:1'> </span>Company
Profiles<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.1.<span style='mso-tab-count:1'> </span>Athos<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.2.<span style='mso-tab-count:1'> </span>Arthrex,
Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.3.<span style='mso-tab-count:1'> </span>ConMed
Corp.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.4.<span style='mso-tab-count:1'> </span>DePuy
Mitek Inc. (Johnson &amp; Johnson)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.5.<span style='mso-tab-count:1'> </span>DJO
Global<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.6.<span style='mso-tab-count:1'> </span>GE
Healthcare<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.7.<span style='mso-tab-count:1'> </span>Medtronic<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.8.<span style='mso-tab-count:1'> </span>Smith
&amp; Nephew PLC<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.9.<span style='mso-tab-count:1'> </span>Stryker
Corp.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.10.<span style='mso-tab-count:1'> </span>Tornier,
Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.11.<span style='mso-tab-count:1'> </span>Zimmer
Biomet Holdings, Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.12.<span style='mso-tab-count:1'> </span>Karl
Storz Endoscopy-America<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.13.<span style='mso-tab-count:1'> </span>Richard
Wolf Medical Instruments Corp.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>To request Table of Contents and Sample Pages
of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/arthroscopy-sport-medicine-devices-market/">https://www.ihealthcareanalyst.com/report/arthroscopy-sport-medicine-devices-market/</a>
</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>About Us<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at clients specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Contact Us<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2109, Mckelvey Hill Drive,<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Maryland Heights, MO 63043<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>United States<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Email: sales@ihealthcareanalyst.com<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Website: </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com"><span style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<b style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=all style='mso-special-character:line-break;
page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Alzheimers Disease Treatment Market US$ 13.2 Billion by 2023, Trends and
Forecast<o:p></o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>The global Alzheimers disease treatment market
to attain US$ 13.2 Billion by 2023, growing at a CAGR of 19.7% over the
forecast period.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Visit Alzheimers disease treatment market by
drug class (API)  acetylcholinesterase inhibitors (donepezil, galantamine,
rivastigmine), immunoglobulin (gammagard liquid), N-methyl-daspartate (NMDA)
receptor antagonist (memantine); by geography and forecast 2015-2023 at </span><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/alzheimers-disease-treatment-market/">https://www.ihealthcareanalyst.com/report/alzheimers-disease-treatment-market/</a></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>The global Alzheimers disease treatment market
report provides market size (Revenue US$ Million 2015 to 2023), market share
and forecasts growth trends (CAGR%, 2018 to 2023). The global Alzheimers
disease market report also provides the detailed market landscape (market
drivers, restraints, opportunities), market attractiveness analysis and
profiles of major competitors in the global market including company overview,
financial snapshot, key products, technologies and services offered, and recent
developments. The research report is divided by geography into North America
(U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India,
Rest of APAC), and Rest of the World.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Major players operating in the global
Alzheimers market include Abbott Laboratories, AC Immune, Affiris,
AstraZeneca, Baxter International, Biogen Inc., Bristol-Myers Squibb, Eisai,
Eli Lilly, Janssen Pharmaceuticals (Johnson &amp; Johnson), Lundbeck, Merck
&amp; Co., Neurim Pharmaceuticals, Novartis, Pfizer, Roche (Genentech), TauRx
Therapeutics, vTv Therapeutics, and Warner-Lambert.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.<span style='mso-tab-count:1'> </span>Drug
Class (API)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.1.<span style='mso-tab-count:1'> </span>Acetylcholinesterase
(AChE) Inhibitors<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.1.1.<span style='mso-tab-count:1'> </span>Donepezil<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.1.2.<span style='mso-tab-count:1'> </span>Galantamine<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.1.3.<span style='mso-tab-count:1'> </span>Rivastigmine<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.2.<span style='mso-tab-count:1'> </span>Immunoglobulin<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.2.1.<span style='mso-tab-count:1'> </span>Gammagard
Liquid<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.3.<span style='mso-tab-count:1'> </span>N-Methyl-Daspartate
(NMDA) Receptor Antagonist<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.3.1.<span style='mso-tab-count:1'> </span>Memantine<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.<span style='mso-tab-count:1'> </span>Geography<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.1.<span style='mso-tab-count:1'> </span>North
America (U.S., Canada)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.2.<span style='mso-tab-count:1'> </span>Latin
America (Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.3.<span style='mso-tab-count:1'> </span>Europe
(U.K., Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.4.<span style='mso-tab-count:1'> </span>Asia
Pacific (Japan, China, India, Rest of APAC)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.5.<span style='mso-tab-count:1'> </span>Rest
of the World<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.<span style='mso-tab-count:1'> </span>Company
Profiles<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.1.<span style='mso-tab-count:1'> </span>Abbott
Laboratories<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.2.<span style='mso-tab-count:1'> </span>AC
Immune<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.3.<span style='mso-tab-count:1'> </span>Affiris<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.4.<span style='mso-tab-count:1'> </span>AstraZeneca<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.5.<span style='mso-tab-count:1'> </span>Baxter
International<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.6.<span style='mso-tab-count:1'> </span>Biogen
Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.7.<span style='mso-tab-count:1'> </span>Bristol-Myers
Squibb<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.8.<span style='mso-tab-count:1'> </span>Eisai<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.9.<span style='mso-tab-count:1'> </span>Eli
Lilly<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.10.<span style='mso-tab-count:1'> </span>Janssen
Pharmaceuticals (Johnson &amp; Johnson)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.11.<span style='mso-tab-count:1'> </span>Lundbeck<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.12.<span style='mso-tab-count:1'> </span>Merck
&amp; Co.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.13.<span style='mso-tab-count:1'> </span>Neurim
Pharmaceuticals<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.14.<span style='mso-tab-count:1'> </span>Novartis<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.15.<span style='mso-tab-count:1'> </span>Pfizer<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.16.<span style='mso-tab-count:1'> </span>Roche
(Genentech)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.17.<span style='mso-tab-count:1'> </span>TauRx
Therapeutics<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.18.<span style='mso-tab-count:1'> </span>vTv
Therapeutics<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.19.<span style='mso-tab-count:1'> </span>Warner-Lambert<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>To request Table of Contents and Sample Pages
of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/alzheimers-disease-treatment-market/">https://www.ihealthcareanalyst.com/report/alzheimers-disease-treatment-market/</a></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>About Us<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at clients specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Contact Us<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2109, Mckelvey Hill Drive,<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Maryland Heights, MO 63043<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>United States<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Email: sales@ihealthcareanalyst.com<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Website: </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com"><span style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<b style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=all style='mso-special-character:line-break;
page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Ostomy Drainage Bags Market US$ 3.1 Billion by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>The global ostomy drainage bags market to attain
US$ 3.1 Billion by 2023, growing at a CAGR of 4.3% over the forecast period.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Visit ostomy drainage bags market by product
(colostomy bags, ileostomy bags, urostomy bags, continent ileostomy bags,
continent urostomy bags); by usage (single-use ostomy drainage bags, multi-use
drainage bags); by clinical application (colorectal cancer, bladder cancer,
colonic diverticulitis, inflammatory bowel disease, other diseases as crohns
disease, ulcerative colitis); by sales channel (hospitals, community) and
forecast 2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/ostomy-drainage-bags-market/"><span
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/ostomy-drainage-bags-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>The global ostomy drainage bags market report
provides market size (Revenue US$ Million 2015 to 2023), market share and
forecasts growth trends (CAGR%, 2018 to 2023). The global ostomy drainage bags
market report also provides the detailed market landscape (market drivers,
restraints, opportunities), market attractiveness analysis and profiles of
major competitors in the global market including company overview, financial
snapshot, key products, technologies and services offered, and recent
developments. The research report is divided by geography into North America
(U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India,
Rest of APAC), and Rest of the World.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Major players included in this report are
Alcare Co., Ltd., B. Braun Melsungen AG, Coloplast A/S, ConvaTec, Inc.,
Flexicare Medical Limited, Hollister Incorporated, Pelcin Healthcare Ltd.,
Salts Healthcare Ltd., and Welland Medical Ltd.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1. Product<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.1 Colostomy Bags<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.2 Ileostomy Bags<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.3 Urostomy Bags<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.4 Continent Ileostomy Bags<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.5 Continent Urostomy Bags<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2. Usage<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.1 Single-use Ostomy Drainage Bags<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.2 Multi-use Ostomy Drainage Bags<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3. Clinical Application<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.1 Colorectal Cancer <o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.2 Bladder Cancer <o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.3 Colonic Diverticulitis <o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.4 Inflammatory Bowel Disease <o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.5 Other Diseases (Crohns Disease,
Ulcerative Colitis)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>4. Sales Channel<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>4.1 Hospitals <o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>4.2 Community <o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>5. Geography (Region, Country)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>5.1 North America (U.S., Canada)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>5.2 Latin America (Brazil, Mexico,
Rest of LA)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>5.3 Europe (U.K., Germany, France,
Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>5.4 Asia Pacific (Japan, China, India,
Rest of APAC)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>5.5 Rest of the World<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>6. Company Profiles<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>6.1 Alcare Co. Ltd.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>6.2 B. Braun Melsungen AG<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>6.3 Coloplast A/S<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>6.4 ConvaTec, Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>6.5 Hollister, Inc. (Dansac)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>6.6 Pelcin Healthcare Ltd.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>6.7 Salts Healthcare Ltd.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>6.8 Welland Medical Ltd.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>To request Table of Contents and Sample Pages
of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/ostomy-drainage-bags-market/">https://www.ihealthcareanalyst.com/report/ostomy-drainage-bags-market/</a>
</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>About Us<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at clients specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Contact Us<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2109, Mckelvey Hill Drive,<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Maryland Heights, MO 63043<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>United States<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Email: sales@ihealthcareanalyst.com<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Website: </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com"><span style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br
clear=all style='mso-special-character:line-break;page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><b style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:
10.0pt;line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Obesity Treatment Devices Market US$ 3.2 Billion by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The global obesity treatment devices market
expected to reach US$ 3.2 billion by 2023, growing at CAGR 10.5% over the forecast
period.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Visit the global obesity treatment
devices market by device type (gastric banding systems, gastric balloon
systems, gastric electrical stimulation systems, gastric emptying systems or
gastric aspiration systems, other emerging devices  endoluminal bypass liners,
oral appliances); and surgery procedure (Roux-en-Y gastric bypass surgery,
adjustable gastric band, laparoscopic sleeve gastrectomy, biliopancreatic
diversion with duodenal switch, revisions, other surgical procedures), </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>by
geography </span><span lang=EN-US style='font-size:10.0pt;line-height:107%;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>and forecast 2015-2023
</span><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>at
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/obesity-treatment-devices-market/"><span
style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/obesity-treatment-devices-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
</span><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The global obesity treatment devices
market research report provides market size (Revenue US$ Million 2015 to 2023),
market share analysis, growth trends and forecast (CAGR%, 2018 to 2023). The
global obesity treatment devices market research report is further segmented by
geography into North America (U.S., Canada), Latin America (Brazil, Mexico,
Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia
Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In
addition, the global obesity treatment devices market report provides the
detailed market landscape (market drivers, restraints, opportunities), market
attractiveness analysis, and market profitability analysis by key products and
regions or countries.<span style='mso-spacerun:yes'> </span>The report also
tracks the major competitors operating in the global market by company
overview, financial snapshot, major products, technologies, services offered
and recent developments.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Major players include Allergan, Inc.,
Apollo Endosurgery, Inc., Aspire Medical, Inc. (Aspire Bariatrics), Boston
Scientific Corp., Cousin Biotech, CR Bard, Inc., EnteroMedics, Inc., GI
Dynamics, Inc., GI Windows, Inc., Johnson &amp; Johnson, Leptos Biomedical,
Mediflex Surgical Products, Medtronic, Inc., ReShape Medical, Inc., Satiety,
Inc., Spatz FGIA, Inc., and TransEnterix, Inc.<o:p></o:p></span></p>

<p style='background:white'><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-font-family:Arial;color:black'>1.&nbsp;<strong><span
style='font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial'>Device Type</span></strong><br>
1.1. Gastric Banding Systems<br>
1.2. Gastric Balloon Systems<br>
1.3. Gastric Electrical Stimulation Systems<br>
1.4. Gastric Emptying Systems (Gastric Aspiration Systems)<br>
1.5. Other Emerging Devices (Endoluminal bypass liners, Oral appliances)<o:p></o:p></span></p>

<p style='background:white'><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-font-family:Arial;color:black'>2.&nbsp;<strong><span
style='font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial'>Surgery Procedure</span></strong><br>
2.1. Roux-en-Y Gastric Bypass Surgery (RNY)<br>
2.2. Adjustable Gastric Band<br>
2.3. Laparoscopic Sleeve Gastrectomy<br>
2.4. Biliopancreatic Diversion with Duodenal Switch (BPD/DS)<br>
2.5. Revisions<br>
2.6. Other Surgical Procedures<o:p></o:p></span></p>

<p style='background:white'><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-font-family:Arial;color:black'>3.&nbsp;<strong><span
style='font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial'>Geography</span></strong><br>
3.1. North America (U.S., Canada)<br>
3.2. Latin America (Brazil, Mexico, Rest of LA)<br>
3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)<br>
3.4. Asia Pacific (Japan, China, India, Rest of APAC<br>
3.5. Rest of the World<o:p></o:p></span></p>

<p style='background:white'><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-font-family:Arial;color:black'>4.&nbsp;<strong><span
style='font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial'>Company Profiles</span></strong><br>
4.1. Allergan, Inc.<br>
4.2. Apollo Endosurgery, Inc.<br>
4.3. Aspire Medical, Inc. (Aspire Bariatrics)<br>
4.4. Boston Scientific Corp.<br>
4.5. Cousin Biotech<br>
4.6. CR Bard, Inc.<br>
4.7. EnteroMedics, Inc.<br>
4.8. GI Dynamics, Inc.<br>
4.9. GI Windows, Inc.<br>
4.10. Johnson &amp; Johnson<br>
4.11. Leptos Biomedical<br>
4.12. Mediflex Surgical Products<br>
4.13. Medtronic, Inc.<br>
4.14. ReShape Medical, Inc.<br>
4.15. Satiety, Inc.<br>
4.16. Spatz FGIA, Inc.<br>
4.17. TransEnterix, Inc.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>To request Table of Contents and Sample Pages
of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/obesity-treatment-devices-market/">https://www.ihealthcareanalyst.com/report/obesity-treatment-devices-market/</a></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>About Us<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at clients specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Contact Us<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2109, Mckelvey Hill Drive,<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Maryland Heights, MO 63043<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>United States<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Email: sales@ihealthcareanalyst.com<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Website: </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com"><span style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<b style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=all style='mso-special-character:line-break;
page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><b style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:
10.0pt;line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Implantable Cardiac Rhythm Management (CRM) Devices Market US$ 13.5 Billion by
2023<o:p></o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The global implantable cardiac rhythm
management devices market expected to reach US$ 13.5 billion by 2023, growing
at CAGR 4.5% over the forecast period.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Cardiac rhythm management (CRM)
includes implantable devices, leads and accessories as well as external devices
to treat and manage arrhythmia-related diseases. Visit global implantable
cardiac rhythm management devices market by device type (cardiac
resynchronization therapy systems  CRT defibrillators, CRT pacemakers;
implantable cardioverter defibrillators systems; implantable pacemaker
systems), </span><span lang=EN-US style='font-size:10.0pt;line-height:107%;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>by geography </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>and Forecast 2015-2023 </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>at
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/implantable-cardiac-rhythm-management-devices-market/">https://www.ihealthcareanalyst.com/report/implantable-cardiac-rhythm-management-devices-market/</a>
</span><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<p style='background:white'><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family:
Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;
mso-bidi-theme-font:minor-latin'>The global implantable CRM devices market
research report is further segmented by geography into North America (U.S.,
Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany,
France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of
APAC), and Rest of the World. In addition, the global implantable cardiac
rhythm management devices market report provides the detailed market landscape
(market drivers, restraints, opportunities), market attractiveness analysis,
and market profitability analysis by key products and regions or
countries.<span style='mso-spacerun:yes'> </span>The report also tracks the
major competitors operating in the global market by company overview, financial
snapshot, major products, technologies, services offered and recent developments.<o:p></o:p></span></p>

<p style='background:white'><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family:
Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;
mso-bidi-theme-font:minor-latin'>Major players operating in the global
implantable CRM devices market and profiled in this report include Abbott
Laboratories Inc. (St. Jude Medical), Biotronik SE &amp; Co. KG, Boston
Scientific Corp., LivaNova PLC, and Medtronic PLC.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1. Device Type<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.1.<span style='mso-tab-count:1'> </span>Cardiac
Resynchronization Therapy (CRT) Systems<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.1.1.<span style='mso-tab-count:1'> </span>CRT
Defibrillators (CRTDs)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.1.2.<span style='mso-tab-count:1'> </span>CRT
Pacemakers (CRT-Ps)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.2.<span style='mso-tab-count:1'> </span>Implantable
Cardioverter Defibrillators (ICD) Systems<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.3.<span style='mso-tab-count:1'> </span>Implantable
Pacemaker Systems<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2. Geography<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.1.<span style='mso-tab-count:1'> </span>North
America (U.S., Canada)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.2.<span style='mso-tab-count:1'> </span>Latin
America (Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.3.<span style='mso-tab-count:1'> </span>Europe
(U.K., Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.4.<span style='mso-tab-count:1'> </span>Asia
Pacific (Japan, China, India, Rest of APAC<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.5.<span style='mso-tab-count:1'> </span>Rest
of the World<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3. Company Profiles<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.1.<span style='mso-tab-count:1'> </span>Abbott
Laboratories Inc. (St. Jude Medical)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.2.<span style='mso-tab-count:1'> </span>Biotronik
SE &amp; Co. KG<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.3.<span style='mso-tab-count:1'> </span>Boston
Scientific Corp.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.4.<span style='mso-tab-count:1'> </span>LivaNova
PLC<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.5.<span style='mso-tab-count:1'> </span>Medtronic
PLC <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>To request Table of Contents and Sample Pages
of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/implantable-cardiac-rhythm-management-devices-market/">https://www.ihealthcareanalyst.com/report/implantable-cardiac-rhythm-management-devices-market/</a>
</span><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>About Us<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at clients specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Contact Us<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2109, Mckelvey Hill Drive,<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Maryland Heights, MO 63043<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>United States<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Email: sales@ihealthcareanalyst.com<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Website: </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com"><span style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<b style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=all style='mso-special-character:line-break;
page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><b style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:
10.0pt;line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Aortic Endografts Market US$ 3 Billion by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The global aortic endografts market
expected to reach US$ 3 billion by 2023, growing at CAGR 6.9% over the forecast
period.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The endograft is a fabric-covered
metallic stent that is inserted into an abdominal aortic aneurysm without need
for a surgical approach and its resulting side effects. An endograft comprises
one of two types of stented grafts: abdominal aortic aneurysm (AAA) and
thoracic aortic aneurysm (TAA). <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Visit global aortic endografts market by
device type (abdominal aortic endografts, thoracic aortic endografts,
fenestrated and branched aortic endografts, and flow diverting aortic endografts),
</span><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>by
geography </span><span lang=EN-US style='font-size:10.0pt;line-height:107%;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>and Forecast
2015-2023 </span><span lang=EN-US style='font-size:10.0pt;line-height:107%;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/aortic-endografts-market/"><span
style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/aortic-endografts-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
</span><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The global aortic endografts market
research report provides market size (Revenue US$ Million 2015 to 2023), market
share analysis, growth trends and forecast (CAGR%, 2018 to 2023). The global
aortic endografts market research report is further segmented by geography into
North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA),
Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan,
China, India, Rest of APAC), and Rest of the World. In addition, the global
aortic endografts market report provides the detailed market landscape (market
drivers, restraints, opportunities), market attractiveness analysis, and market
profitability analysis by key products and regions or countries.<span
style='mso-spacerun:yes'> </span>The report also tracks the major competitors
operating in the global market by company overview, financial snapshot, major
products, technologies, services offered and recent developments.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Major players operating in the global
aortic endografts market and profiled in this report include Bolton Medical,
Braile Biomedica, Cardiatis, Cook Medical, Cordis (Cardinal Health), Endologix,
Inc., Endospan, Jotec, Lombard Medical Technologies Plc, Medtronic Plc,
Microport Medical, Nano Endoluminal, Terumo Medical Corp., Transcatheter
Technologies, TriVascular, Inc., Vascutek, and W. L. Gore and Associates.<o:p></o:p></span></p>

<p style='background:white'><b style='mso-bidi-font-weight:normal'><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri Light",sans-serif;
mso-ascii-theme-font:major-latin;mso-hansi-theme-font:major-latin;mso-bidi-font-family:
Arial;color:black'>1.&nbsp;</span></b><strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri Light",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-font-family:Arial;
color:black;font-weight:normal;mso-bidi-font-weight:bold'>Device Type</span></strong><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri Light",sans-serif;mso-ascii-theme-font:major-latin;
mso-hansi-theme-font:major-latin;mso-bidi-font-family:Arial;color:black'><br>
</span></b><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri Light",sans-serif;
mso-ascii-theme-font:major-latin;mso-hansi-theme-font:major-latin;mso-bidi-font-family:
Arial;color:black'>1.1. Abdominal Aortic Endografts<br>
1.2. Thoracic Aortic Endografts<br>
1.3. Fenestrated and Branched Aortic Endografts<br>
1.4. Flow Diverting Aortic Endografts<o:p></o:p></span></p>

<p style='background:white'><b style='mso-bidi-font-weight:normal'><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri Light",sans-serif;
mso-ascii-theme-font:major-latin;mso-hansi-theme-font:major-latin;mso-bidi-font-family:
Arial;color:black'>2.&nbsp;</span></b><strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri Light",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-font-family:Arial;
color:black;font-weight:normal;mso-bidi-font-weight:bold'>Geography</span></strong><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri Light",sans-serif;mso-ascii-theme-font:major-latin;
mso-hansi-theme-font:major-latin;mso-bidi-font-family:Arial;color:black'><br>
</span></b><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri Light",sans-serif;
mso-ascii-theme-font:major-latin;mso-hansi-theme-font:major-latin;mso-bidi-font-family:
Arial;color:black'>2.1. North America (U.S., Canada)<br>
2.2. Latin America (Brazil, Mexico, Rest of LA)<br>
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)<br>
2.4. Asia Pacific (Japan, China, India, Rest of APAC<br>
2.5. Rest of the World<o:p></o:p></span></p>

<p style='background:white'><b style='mso-bidi-font-weight:normal'><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri Light",sans-serif;
mso-ascii-theme-font:major-latin;mso-hansi-theme-font:major-latin;mso-bidi-font-family:
Arial;color:black'>3.&nbsp;</span></b><strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri Light",sans-serif;mso-ascii-theme-font:
major-latin;mso-hansi-theme-font:major-latin;mso-bidi-font-family:Arial;
color:black;font-weight:normal;mso-bidi-font-weight:bold'>Company Profiles</span></strong><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri Light",sans-serif;mso-ascii-theme-font:major-latin;
mso-hansi-theme-font:major-latin;mso-bidi-font-family:Arial;color:black'><br>
</span></b><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri Light",sans-serif;
mso-ascii-theme-font:major-latin;mso-hansi-theme-font:major-latin;mso-bidi-font-family:
Arial;color:black'>3.1. Bolton Medical<br>
3.2. Braile Biomedica<br>
3.3. Cardiatis<br>
3.4. Cook Medical<br>
3.5. Cordis (Cardinal Health)<br>
3.6. Endologix, Inc.<br>
3.7. Endospan<br>
3.8. Jotec<br>
3.9. Lombard Medical Technologies Plc<br>
3.10. Medtronic Plc<br>
3.11. Microport Medical<br>
3.12. Nano Endoluminal<br>
3.13. Terumo Medical Corp.<br>
3.14. Transcatheter Technologies<br>
3.15. TriVascular Inc.<br>
3.16. Vascutek<br>
3.17. W. L. Gore and Associates<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>To request Table of Contents and Sample Pages
of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/aortic-endografts-market/"><span
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/aortic-endografts-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'> <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>About Us<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at clients specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Contact Us<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2109, Mckelvey Hill Drive,<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Maryland Heights, MO 63043<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>United States<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Email: sales@ihealthcareanalyst.com<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Website: </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com"><span style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br
clear=all style='mso-special-character:line-break;page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Systemic Lupus Erythematosus and Lupus Nephritis Drugs Market US$ 2.1 Billion by
2023<o:p></o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The global systemic lupus
erythematosus and lupus nephritis drugs market expected to reach US$ 2.1 billion
by 2023, growing at CAGR 7.2% over the forecast period. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Systemic lupus erythematosus (SLE) is
a prototypic autoimmune disease that is characterized by systemic chronic
inflammation that can affect multiple major organ systems. A major contributor
to morbidity and mortality among patients with SLE is renal involvement, known
as lupus nephritis (LN).<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Visit the global systemic lupus erythematosus
and lupus nephritis drugs market segmentation is based on drug class
(antimalarials, biologics, immunosuppressives, steroids), by geography </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>and Forecast 2015-2023 </span><span lang=EN-US style='font-size:
10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/systemic-lupus-erythematosus-lupus-nephritis-drugs-market/">https://www.ihealthcareanalyst.com/report/systemic-lupus-erythematosus-lupus-nephritis-drugs-market/</a><span
style='mso-spacerun:yes'> </span></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The global systemic lupus erythematosus
and lupus nephritis drugs market research report provides market size (Revenue
US$ Million 2015 to 2023), market share analysis, growth trends and forecast
(CAGR%, 2018 to 2023). The global systemic lupus erythematosus and lupus
nephritis drugs market research report is further segmented by geography into
North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA),
Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan,
China, India, Rest of APAC), and Rest of the World. In addition, the global
systemic lupus erythematosus and lupus nephritis drugs market report provides
the detailed market landscape (market drivers, restraints, opportunities),
market attractiveness analysis, and market profitability analysis by key products
and regions or countries.<span style='mso-spacerun:yes'> </span>The report
also tracks the major competitors operating in the global market by company
overview, financial snapshot, major products, technologies, services offered
and recent developments.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Major players operating in the global
systemic lupus erythematosus and lupus nephritis drugs market and profiled in
this report include Active Biotech, Anthera, Biogen Idec, Bristol-Myers Squibb,
Eli Lilly, Galapagos NV, Genentech (Roche), GlaxoSmithKline, Immunomedics,
ImmuPharma, Invion, Johnson &amp; Johnson, MedImmune, Merck Serono, Pfizer,
SuppreMol, Teva Pharmaceutical Industries Ltd., and UCB (Union Chimique Belge).<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1. Drug Class<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.1.<span style='mso-tab-count:1'> </span>Antimalarials<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.2.<span style='mso-tab-count:1'> </span>Biologics<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.3.<span style='mso-tab-count:1'> </span>Immunosuppressives<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.4.<span style='mso-tab-count:1'> </span>Steroids<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2. Geography<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.1.<span style='mso-tab-count:1'> </span>North
America (U.S., Canada)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.2.<span style='mso-tab-count:1'> </span>Latin
America (Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.3.<span style='mso-tab-count:1'> </span>Europe
(U.K., Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.4.<span style='mso-tab-count:1'> </span>Asia
Pacific (Japan, China, India, Rest of APAC)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.5.<span style='mso-tab-count:1'> </span>Rest
of the World<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3. Company Profiles<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.1.<span style='mso-tab-count:1'> </span>Active
Biotech<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.2.<span style='mso-tab-count:1'> </span>Anthera<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.3.<span style='mso-tab-count:1'> </span>Biogen
Idec<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.4.<span style='mso-tab-count:1'> </span>Bristol-Myers
Squibb<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.5.<span style='mso-tab-count:1'> </span>Eli
Lilly<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.6.<span style='mso-tab-count:1'> </span>Galapagos
NV<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.7.<span style='mso-tab-count:1'> </span>Genentech
(Roche)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.8.<span style='mso-tab-count:1'> </span>GlaxoSmithKline<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.9.<span style='mso-tab-count:1'> </span>Immunomedics<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.10.<span style='mso-tab-count:1'> </span>ImmuPharma<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.11.<span style='mso-tab-count:1'> </span>Invion<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.12.<span style='mso-tab-count:1'> </span>Johnson
&amp; Johnson<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.13.<span style='mso-tab-count:1'> </span>MedImmune<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.14.<span style='mso-tab-count:1'> </span>Merck
Serono<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.15.<span style='mso-tab-count:1'> </span>Pfizer<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.16.<span style='mso-tab-count:1'> </span>SuppreMol<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.17.<span style='mso-tab-count:1'> </span>Teva
Pharmaceutical Industries Ltd.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.18.<span style='mso-tab-count:1'> </span>UCB
(Union Chimique Belge)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>To request Table of Contents and
Sample Pages of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/systemic-lupus-erythematosus-lupus-nephritis-drugs-market/">https://www.ihealthcareanalyst.com/report/systemic-lupus-erythematosus-lupus-nephritis-drugs-market/</a>
</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>About Us<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at clients specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Contact Us<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2109, Mckelvey Hill Drive,<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Maryland Heights, MO 63043<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>United States<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Email: sales@ihealthcareanalyst.com<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Website: </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com"><span style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><br
style='mso-special-character:line-break'>
<![if !supportLineBreakNewLine]><br style='mso-special-character:line-break'>
<![endif]><o:p></o:p></span></b></p>

<b style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=all style='mso-special-character:line-break;
page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Osteoporosis Diagnostics Market US$ 425 Million by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Osteoporosis disease is characterized
by thinning and deterioration of bone tissue with loss of calcification and
density, and it can progress over time. Women and older adults are more at risk
for developing osteoporosis. Heredity, low body weight, and chronic use of
certain medications (such as steroids) are also risk factors for the disease. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Visit global osteoporosis diagnostics
market by product type (bone densitometry systems, and bone remodeling
biochemical marker tests), by geography </span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>and
Forecast 2015-2023 </span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>at
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/osteoporosis-diagnostics-market/">https://www.ihealthcareanalyst.com/report/osteoporosis-diagnostics-market/</a>
</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The global osteoporosis diagnostics
market research report provides market size (Revenue US$ Million 2015 to 2023),
market share analysis, growth trends and forecast (CAGR%, 2018 to 2023). The
global osteoporosis diagnostics market research report is further segmented by
geography into North America (U.S., Canada), Latin America (Brazil, Mexico,
Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia
Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In
addition, the global osteoporosis diagnostics market report provides the
detailed market landscape (market drivers, restraints, opportunities), market
attractiveness analysis, and market profitability analysis by key products and
regions or countries.<span style='mso-spacerun:yes'> </span>The report also
tracks the major competitors operating in the global market by company
overview, financial snapshot, major products, technologies, services offered
and recent developments.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Major players operating in the global
osteoporosis diagnostics market and profiled in this report include Alere,
Inc., BeamMed, Beckman Coulter, Inc., CompuMed, Inc., Diagnostic Medical
Systems, Furuno Electric Company, GE Healthcare, Hitachi Medical Systems,
Hologic, Immunodiagnostic Systems Ltd., Orion Diagnostica, Quest Diagnostics,
Inc., Quidel Corp., Roche Diagnostics, Sectra AB, and Swissray International,
Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1. Product Type<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.1.<span style='mso-tab-count:1'> </span>Bone
Densitometry Systems<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.2.<span style='mso-tab-count:1'> </span>Bone
Remodeling Biochemical Marker Tests<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2. Geography<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.1.<span style='mso-tab-count:1'> </span>North
America (U.S., Canada)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.2.<span style='mso-tab-count:1'> </span>Latin
America (Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.3.<span style='mso-tab-count:1'> </span>Europe
(U.K., Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.4.<span style='mso-tab-count:1'> </span>Asia
Pacific (Japan, China, India, Rest of APAC<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.5.<span style='mso-tab-count:1'> </span>Rest
of the World<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3. Company Profiles<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.1.<span style='mso-tab-count:1'> </span>Alere,
Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.2.<span style='mso-tab-count:1'> </span>BeamMed<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.3.<span style='mso-tab-count:1'> </span>Beckman
Coulter, Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.4.<span style='mso-tab-count:1'> </span>CompuMed,
Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.5.<span style='mso-tab-count:1'> </span>Diagnostic
Medical Systems<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.6.<span style='mso-tab-count:1'> </span>Furuno
Electric Company<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.7.<span style='mso-tab-count:1'> </span>GE
Healthcare<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.8.<span style='mso-tab-count:1'> </span>Hitachi
Medical Systems<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.9.<span style='mso-tab-count:1'> </span>Hologic<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.10.<span style='mso-tab-count:1'> </span>Immunodiagnostic
Systems Ltd.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.11.<span style='mso-tab-count:1'> </span>Orion
Diagnostica<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.12.<span style='mso-tab-count:1'> </span>Quest
Diagnostics, Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.13.<span style='mso-tab-count:1'> </span>Quidel
Corp.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.14.<span style='mso-tab-count:1'> </span>Roche
Diagnostics<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.15.<span style='mso-tab-count:1'> </span>Sectra
AB<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.16.<span style='mso-tab-count:1'> </span>Swissray
International, Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>To request Table of Contents and
Sample Pages of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/osteoporosis-diagnostics-market/">https://www.ihealthcareanalyst.com/report/osteoporosis-diagnostics-market/</a>
</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Global osteosynthesis devices market
type of device used (internal fixation devices  intramedullary rods and nails,
screws and plates, spinal fixation devices, wires and pins; external fixation
devices  fracture fixation devices, radius fracture, tibia fracture and pelvis
fracture fixation devices, bone lengthening devices, etc.), materials used (degradable
and non-degradable).<span style='mso-spacerun:yes'> </span></span><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/osteosynthesis-devices-market/"><span
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/osteosynthesis-devices-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'> <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Global osteoporosis drugs market by
drug classes (bisphosphonates, calcitonin, parathyroid hormone therapy drugs,
RANK ligand inhibitors, selective estrogen receptor modulators, etc.), clinical
pipeline analysis of phase 1, 2 and 3 drugs (Odanacatib, Romosozumab, etc.). </span><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/osteoporosis-drugs-market/"><span
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/osteoporosis-drugs-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'> <o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>About Us<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc. is a global healthcare
market research and consulting company providing market analysis, and
competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at clients specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Contact Us<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2109, Mckelvey Hill Drive,<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Maryland Heights, MO 63043<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>United States<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Email: sales@ihealthcareanalyst.com<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Website: </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com"><span style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><br>
<br>
<br style='mso-special-character:line-break'>
<![if !supportLineBreakNewLine]><br style='mso-special-character:line-break'>
<![endif]><o:p></o:p></span></b></p>

<b style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=all style='mso-special-character:line-break;
page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Cystic Fibrosis (CF) Drugs Market US$ 6.9 Billion by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The global cystic fibrosis (CF) drugs market
expected to reach US$ 6.9 billion by 2023, growing at CAGR 14.9% over the
forecast period. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The CF treatment options include:
airway-clearance techniques and medications to clear mucus from the lungs;
proactive treatment of infections; pancreatic enzyme replacement therapy
(PERT); optimal nutrition; and an active lifestyle. Ivacaftor (Kalydeco) was
the first drug approved by the US Food and Drug Administration (FDA) in 2012,
however it remains very expensive.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Visit the global cystic fibrosis drugs
market by drug class  anti-infectives, CF transmembrane conductance regulator
(CFTR) modulators, mucolytics, and pancreatic enzyme replacement therapy (PERT),
by geography </span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>and Forecast 2015-2023 </span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>at </span><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/cystic-fibrosis-drugs-market/"><span
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/cystic-fibrosis-drugs-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'> <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The global cystic fibrosis drugs
market research report provides market size (Revenue US$ Million 2015 to 2023),
market share analysis, growth trends and forecast (CAGR%, 2018 to 2023). The
global cystic fibrosis drugs market research report is further segmented by
geography into North America (U.S., Canada), Latin America (Brazil, Mexico,
Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia
Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In
addition, the global cystic fibrosis drugs market report provides the detailed
market landscape (market drivers, restraints, opportunities), market
attractiveness analysis, and market profitability analysis by key products and
regions or countries.<span style='mso-spacerun:yes'> </span>The report also
tracks the major competitors operating in the global market by company
overview, financial snapshot, major products, technologies, services offered
and recent developments.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Major players operating in the global
cystic fibrosis drugs market and profiled in this report include AbbVie,
AlgiPharma, Aptalis Pharma, Cystic Fibrosis Foundation (CFF), Eli Lilly,
Genentech (Roche), Grifols, Insmed, KaloBios Pharmaceuticals, N30
Pharmaceuticals, NovaBiotics, Novartis, Pharmaxis, PTC Therapeutics, Savara
Pharmaceuticals, UK Cystic Fibrosis Gene Therapy Consortium (CFGTC), and Vertex
Pharmaceuticals.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.<span style='mso-tab-count:1'> </span>Drug
Class<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.1.<span style='mso-tab-count:1'> </span>Anti-infectives<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.2.<span style='mso-tab-count:1'> </span>CF
Transmembrane Conductance Regulator (CFTR) modulators<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.3.<span style='mso-tab-count:1'> </span>Mucolytics<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>1.4.<span style='mso-tab-count:1'> </span>Pancreatic
Enzyme Replacement Therapy (PERT)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.<span style='mso-tab-count:1'> </span>Geography<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.1.<span style='mso-tab-count:1'> </span>North
America (U.S., Canada)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.2.<span style='mso-tab-count:1'> </span>Latin
America (Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.3.<span style='mso-tab-count:1'> </span>Europe
(U.K., Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.4.<span style='mso-tab-count:1'> </span>Asia
Pacific (Japan, China, India, Rest of APAC)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2.5.<span style='mso-tab-count:1'> </span>Rest
of the World<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.<span style='mso-tab-count:1'> </span>Company
Profiles<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.1.<span style='mso-tab-count:1'> </span>AbbVie<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.2.<span style='mso-tab-count:1'> </span>AlgiPharma<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.3.<span style='mso-tab-count:1'> </span>Aptalis
Pharma<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.4.<span style='mso-tab-count:1'> </span>Cystic
Fibrosis Foundation (CFF)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.5.<span style='mso-tab-count:1'> </span>Eli
Lilly<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.6.<span style='mso-tab-count:1'> </span>Genentech
(Roche)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.7.<span style='mso-tab-count:1'> </span>Grifols<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.8.<span style='mso-tab-count:1'> </span>Insmed<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.9.<span style='mso-tab-count:1'> </span>KaloBios
Pharmaceuticals<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.10.<span style='mso-tab-count:1'> </span>N30
Pharmaceuticals<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.11.<span style='mso-tab-count:1'> </span>NovaBiotics<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.12.<span style='mso-tab-count:1'> </span>Novartis<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.13.<span style='mso-tab-count:1'> </span>Pharmaxis<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.14.<span style='mso-tab-count:1'> </span>PTC
Therapeutics<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.15.<span style='mso-tab-count:1'> </span>Savara
Pharmaceuticals<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.16.<span style='mso-tab-count:1'> </span>UK
Cystic Fibrosis Gene Therapy Consortium (CFGTC)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>3.17.<span style='mso-tab-count:1'> </span>Vertex
Pharmaceuticals<br style='mso-special-character:line-break'>
<![if !supportLineBreakNewLine]><br style='mso-special-character:line-break'>
<![endif]><o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>To request Table of Contents and
Sample Pages of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/cystic-fibrosis-drugs-market/">https://www.ihealthcareanalyst.com/report/cystic-fibrosis-drugs-market/</a></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>About Us<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at clients specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Contact Us<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2109, Mckelvey Hill Drive,<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Maryland Heights, MO 63043<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>United States<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Email: sales@ihealthcareanalyst.com<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Website: </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com"><span style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br
clear=all style='mso-special-character:line-break;page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Chronic Lymphocytic Leukemia (CLL) Drugs Market US$ 7.6 Billion by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The global chronic lymphocytic
leukemia (CLL) drugs market expected to reach US$ 7.6 billion by 2023, growing
at CAGR 13.8% over the forecast period. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Chronic lymphocytic leukemia is one of
the most common forms of leukemia. </span><span lang=EN-US><a
href="https://www.cancer.org"><span style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>American
Cancer Society</span></a></span><span lang=EN-US style='font-size:10.0pt;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'> estimates about 20,110 new cases of chronic
lymphocytic leukemia in the United States for 2017. CLL accounts for about
one-quarter of the new cases of leukemia. The main treatments used includes chemotherapy,
monoclonal antibodies, targeted therapy, supportive care, and stem cell
transplant. There are 2 general categories of systemic therapy used for CLL:
chemotherapy and targeted therapy.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Visit
Chronic Lymphocytic Leukemia Drugs Market by Drug Class (Brand)  Chemotherapy
(Bendamustine); Kinase Inhibitors - Ibrutinib (</span><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Imbruvica</span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>),
Idelalisib (</span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Zydelig</span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>); Monoclonal Antibodies - Obinutuzumab (</span><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Gazyva</span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>),
Ofatumumab </span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>(Arzerra),
</span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Rituximab (</span><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Rituxan</span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>)
and Forecast 2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/chronic-lymphocytic-leukemia-drugs-market/"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/chronic-lymphocytic-leukemia-drugs-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global </span><span lang=EN-US style='font-size:10.0pt;line-height:107%;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>chronic
lymphocytic leukemia drugs </span><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>market research report provides market
size (Revenue USD Million 2015 to 2023), market share analysis, growth trends
and forecast (CAGR%, 2018 to 2023). The global </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>chronic lymphocytic leukemia drugs </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market
research report is further segmented by geography into North America (U.S.,
Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany,
France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of
APAC), and Rest of the World. In addition, the global </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>chronic lymphocytic leukemia drugs </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market
report provides the detailed market landscape (market drivers, restraints,
opportunities), market attractiveness analysis, and market profitability
analysis by key products and regions or countries.<span
style='mso-spacerun:yes'> </span>The report also tracks the major competitors
operating in the global market by company overview, financial snapshot, major
products, technologies, services offered and recent developments.</span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Major
players operating in the global chronic lymphocytic leukemia drugs market and
profiled in this report include AbbVie, Angstrom Pharmaceuticals, AstraZeneca,
Celgene, Cyclacel, Gilead Sciences, Infinity, MedImmune, MorphoSys, Novartis,
NOXXON Pharma, Roche, Teva Pharmaceutical Industries Ltd., and TG Therapeutics.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l18 level1 lfo31'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Drug Class
(Brand)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l18 level2 lfo31'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Chemotherapy<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l18 level3 lfo31'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Bendamustine<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l18 level2 lfo31'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Kinase Inhibitors<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l18 level3 lfo31'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Ibrutinib (</span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Imbruvica</span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l18 level3 lfo31'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Idelalisib (</span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Zydelig</span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l18 level2 lfo31'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Monoclonal
Antibodies<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l18 level3 lfo31'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Obinutuzumab (</span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Gazyva</span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l18 level3 lfo31'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Ofatumumab </span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>(Arzerra)</span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l18 level3 lfo31'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rituximab (</span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rituxan</span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l18 level1 lfo31'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Geography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l18 level2 lfo31'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>North America
(U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l18 level2 lfo31'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Latin America
(Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l18 level2 lfo31'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l18 level2 lfo31'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Asia Pacific (Japan,
China, India, Rest of APAC)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l18 level2 lfo31'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rest of the World<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l18 level1 lfo31'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l18 level2 lfo31'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>AbbVie<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l18 level2 lfo31'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Angstrom
Pharmaceuticals<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l18 level2 lfo31'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>AstraZeneca<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l18 level2 lfo31'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Celgene<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l18 level2 lfo31'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Cyclacel<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l18 level2 lfo31'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Gilead Sciences<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l18 level2 lfo31'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Infinity<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l18 level2 lfo31'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>MedImmune<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l18 level2 lfo31'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>MorphoSys<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l18 level2 lfo31'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.10.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Novartis<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l18 level2 lfo31'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.11.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>NOXXON Pharma<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l18 level2 lfo31'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.12.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Roche<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l18 level2 lfo31'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.13.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Teva
Pharmaceutical Industries Ltd.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;mso-add-space:auto;
text-indent:-.3in;mso-list:l18 level2 lfo31'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.14.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>TG Therapeutics<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><br>
To request Table of Contents and Sample Pages of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/chronic-lymphocytic-leukemia-drugs-market/"><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/report/chronic-lymphocytic-leukemia-drugs-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-size:11.0pt;line-height:107%'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>About Us<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at clients specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Contact Us<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2109, Mckelvey Hill Drive,<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Maryland Heights, MO 63043<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>United States<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Email: sales@ihealthcareanalyst.com<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Website:
https://www.ihealthcareanalyst.com<b style='mso-bidi-font-weight:normal'><br
clear=all style='mso-special-character:line-break;page-break-before:always'>
<o:p></o:p></b></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Antithrombotic Drugs Market US$ 28.5 Billion by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The global antithrombotic drugs market
expected to reach US$ 28.5 billion by 2023, growing at CAGR 2% over the forecast
period. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Antithrombotic drugs in routine use
include antiplatelet drugs (aspirin, clopidogrel, and glycoprotein IIb/IIIa
receptor antagonists) and anticoagulants (unfractionated and low molecular
weight heparin, warfarin, and direct thrombin inhibitors). The use of
antithrombotic therapy in acute coronary syndromes has reduced the incidence of
death and Q wave myocardial infarction dramatically in recent years. Antithrombotic
drugs are categorized into three broad types: platelet aggregation inhibitors
(PAIs), fibrinolytics and anticoagulants. Antithrombotic therapy has reduced
the risk of blood clots in leg veins (also known as deep-vein thrombosis or
DVT), a condition that can lead to death from pulmonary embolism by more than
70 percent. And most importantly, it has markedly reduced death from heart
attacks, the risk of stroke in people with heart irregularities (atrial
fibrillation), and the risk of major stroke in patients with mini-strokes.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Visit Antithrombotic Drugs Market by
Drug Type - Platelet Aggregation Inhibitors (PAIs); Fibrinolytics;
Anticoagulants - Low-Molecular-Weight Heparins (LMWHs), Vitamin K Antagonists
(VKAs), Direct Thrombin Inhibitors (DTIs), Direct Factor Xa Inhibitors (FXa);
Other Antithrombotic Agents and Forecast 2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/antithrombotic-drugs-market/"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/antithrombotic-drugs-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'> <o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
106%'><span lang=EN-US style='font-size:10.0pt;line-height:106%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global </span><span lang=EN-US style='font-size:10.0pt;line-height:106%;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>antithrombotic
drugs </span><span lang=EN-US style='font-size:10.0pt;line-height:106%;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>market research report provides market size
(Revenue USD Million 2015 to 2023), market share analysis, growth trends and
forecast (CAGR%, 2018 to 2023). The global </span><span lang=EN-US
style='font-size:10.0pt;line-height:106%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>antithrombotic drugs </span><span lang=EN-US
style='font-size:10.0pt;line-height:106%;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market research
report is further segmented by geography into North America (U.S., Canada),
Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France,
Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC),
and Rest of the World. In addition, the global </span><span lang=EN-US
style='font-size:10.0pt;line-height:106%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>antithrombotic drugs </span><span lang=EN-US
style='font-size:10.0pt;line-height:106%;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market report
provides the detailed market landscape (market drivers, restraints,
opportunities), market attractiveness analysis, and market profitability
analysis by key products and regions or countries.<span
style='mso-spacerun:yes'> </span>The report also tracks the major competitors
operating in the global market by company overview, financial snapshot, major
products, technologies, services offered and recent developments.</span><span
lang=EN-US style='font-size:10.0pt;line-height:106%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Major
players operating in the global antithrombotic drugs market and profiled in
this report include Armetheon, Armetheon, Bayer, Boehringer Ingelheim,
Bristol-Myers Squib, Daiichi Sankyo, D</span><span lang=EN-US style='font-size:
10.0pt;font-family:"MS Gothic";mso-bidi-font-family:"MS Gothic"'>&#8209;</span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>Pharm, Endotis Pharma, Janssen, Lundbeck, Merck &amp; Co., Pfizer,
Portola Pharmaceuticals, Regado Biosciences, Roche, TeaRx, and The Medicines
Company.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l19 level1 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Drug Type<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l19 level2 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Platelet Aggregation
Inhibitors (PAIs)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l19 level2 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Fibrinolytics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l19 level2 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Anticoagulants<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l19 level3 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Low-Molecular-Weight
Heparins (LMWHs) <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l19 level3 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Vitamin K
Antagonists (VKAs)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l19 level3 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Direct Thrombin
Inhibitors (DTIs)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l19 level3 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Direct Factor Xa
Inhibitors (FXa)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l19 level2 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Other
Antithrombotic Agents<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l19 level1 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Geography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l19 level2 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>North America
(U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l19 level2 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Latin America
(Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l19 level2 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l19 level2 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Asia Pacific
(Japan, China, India, Rest of APAC)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l19 level2 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rest of the World<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l19 level1 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l19 level2 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Armetheon <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l19 level2 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Armetheon <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l19 level2 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Bayer<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l19 level2 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Boehringer
Ingelheim<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l19 level2 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Bristol-Myers Squib
<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l19 level2 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Daiichi Sankyo<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l19 level2 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>D</span><span
lang=EN-US style='font-size:10.0pt;font-family:"MS Gothic";mso-bidi-font-family:
"MS Gothic"'>&#8209;</span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Pharm <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l19 level2 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Endotis Pharma<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l19 level2 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Janssen <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l19 level2 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.10.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Lundbeck <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l19 level2 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.11.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Merck &amp; Co. <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l19 level2 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.12.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Pfizer<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l19 level2 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.13.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Portola
Pharmaceuticals <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l19 level2 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.14.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Regado
Biosciences<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l19 level2 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.15.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Roche <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l19 level2 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.16.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>TeaRx<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;mso-add-space:auto;
text-indent:-.3in;mso-list:l19 level2 lfo30'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.17.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The Medicines
Company <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><br>
To request Table of Contents and Sample Pages of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/antithrombotic-drugs-market/"><span
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/antithrombotic-drugs-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'> <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>About Us<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare
services, medical devices, medical equipment, and pharmaceuticals.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at clients specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Contact Us<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst, Inc.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>2109, Mckelvey Hill Drive,<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Maryland Heights, MO 63043<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>United States<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Email: sales@ihealthcareanalyst.com<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Website:
https://www.ihealthcareanalyst.com<b style='mso-bidi-font-weight:normal'><br
clear=all style='mso-special-character:line-break;page-break-before:always'>
<o:p></o:p></b></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Blood Cancer Molecular Diagnostics Market US$ 4 Billion by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The global blood cancer molecular
diagnostics market expected to reach US$ 4 billion by 2023, growing at CAGR 30.1%
over the forecast period. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Acute lymphoblastic leukemia (ALL) is
characterized by the production of immature white blood cells, whereas Chronic
lymphocytic leukemia (CLL), leukemia of the B-cells is the most common form of
leukemia in adults. Treatments include chemotherapy, biological agents, and
transplant. Lymphomas are a broad group of blood cancers that affect T and B
cell lymphocytes. Treatments of lymphomas include chemotherapy, radiation
therapy, and bone marrow transplantation. Molecular diagnostic tests detect
mutations in DNA or RNA that are associated with blood cancers. The Federal
Drug Administration (FDA), Centers for Medicare &amp; Medicaid Services, and
Clinical Laboratory Improvement Act (CLIA) regulate clinical molecular tests
like all other clinical laboratory tests.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><br>
Visit Blood Cancer Molecular Diagnostics Market by Technology Platform (RT-PCR,
DNA Microarray, Lab-On-A-Chip (LOAC), Next Generation Sequencing (NGS),
Multiplex Conventional); by Application or Cancer Type (Leukemia, Lymphoma) and
Forecast 2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/blood-cancer-molecular-diagnostics-market/">https://www.ihealthcareanalyst.com/report/blood-cancer-molecular-diagnostics-market/</a>
</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global blood </span><span lang=EN-US style='font-size:10.0pt;line-height:107%;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>cancer molecular
diagnostics </span><span lang=EN-US style='font-size:10.0pt;line-height:107%;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>market segmentation is based on</span><span
lang=EN-US> </span><span lang=EN-US style='font-size:10.0pt;line-height:107%;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>technology platform (RT-PCR, DNA microarray,
Lab-On-A-Chip (LOAC), next generation sequencing (NGS), multiplex
conventional); by application or cancer type (leukemia, lymphoma)</span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global blood</span><span lang=EN-US style='font-size:10.0pt;line-height:107%;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'> cancer molecular
diagnostics</span><span lang=EN-US style='font-size:10.0pt;line-height:107%;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'> market research report provides market size
(Revenue USD Million 2015 to 2023), market share analysis, growth trends and
forecast (CAGR%, 2018 to 2023). The global blood</span><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'> cancer molecular diagnostics</span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
market research report is further segmented by geography into North America
(U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India,
Rest of APAC), and Rest of the World. In addition, the global blood</span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'> cancer molecular diagnostics</span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
market report provides the detailed market landscape (market drivers,
restraints, opportunities), market attractiveness analysis, and market
profitability analysis by key products and regions or countries. The report
also tracks the major competitors operating in the global market by company
overview, financial snapshot, major products, technologies, services offered
and recent developments.</span><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Major
players operating in the global </span><span lang=EN-US style='font-size:10.0pt;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>blood</span><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'> cancer
molecular diagnostics market and profiled in this report include Asuragen, Biological
Dynamics, BlueGnome (Illumina), Cancer Genetics, Inc., Cepheid, Inc., Clarient,
Inc. (GE Healthcare), Combimatrix Corp., Foundation One, Insight Genetics,
Inc., InVivoScribe Technologies, Inc., Ipsogen (Qiagen), Mnchner Leukmie
Labor, Sequenta, Inc., Signature Genomics, and SkylineDx BV.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l3 level1 lfo29'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Technology
Platform<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l3 level2 lfo29'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>RT-PCR <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l3 level2 lfo29'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>DNA Microarray <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l3 level2 lfo29'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Lab-On-A-Chip
(LOAC)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l3 level2 lfo29'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Next Generation
Sequencing (NGS)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l3 level2 lfo29'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Multiplex
Conventional <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l3 level1 lfo29'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Application
(Cancer Type)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l3 level2 lfo29'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Leukemia <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l3 level2 lfo29'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Lymphoma <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l3 level1 lfo29'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Geography
(Region, Country)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l3 level2 lfo29'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>North America
(U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l3 level2 lfo29'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l3 level2 lfo29'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Asia Pacific
(Japan, China, India, Rest of APAC)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l3 level2 lfo29'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Latin America
(Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l3 level2 lfo29'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rest of the World<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l3 level1 lfo29'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l3 level2 lfo29'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Asuragen<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l3 level2 lfo29'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Biological
Dynamics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l3 level2 lfo29'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>BlueGnome
(Illumina)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l3 level2 lfo29'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Cancer Genetics,
Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l3 level2 lfo29'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Cepheid, Inc. <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l3 level2 lfo29'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Clarient, Inc.
(GE Healthcare)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l3 level2 lfo29'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Combimatrix Corp.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l3 level2 lfo29'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Foundation One<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l3 level2 lfo29'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Insight Genetics,
Inc. <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l3 level2 lfo29'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.10.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>InVivoScribe
Technologies, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l3 level2 lfo29'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.11.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Ipsogen (Qiagen)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l3 level2 lfo29'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.12.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Mnchner Leukmie
Labor<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l3 level2 lfo29'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.13.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Sequenta, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l3 level2 lfo29'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.14.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Signature
Genomics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;mso-add-space:auto;
text-indent:-.3in;mso-list:l3 level2 lfo29'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.15.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>SkylineDx BV<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'>To request Table of Contents and
Sample Pages of this report visit:</span><span lang=EN-US style='font-size:
10.0pt;line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
</span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-size:11.0pt;
line-height:107%'><o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/blood-cancer-molecular-diagnostics-market/">https://www.ihealthcareanalyst.com/report/blood-cancer-molecular-diagnostics-market/</a>
</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><strong><span
lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>About Us</span></strong><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst,
Inc. is a global healthcare market research and consulting company providing
market analysis, and competitive intelligence services to global clients. The
company publishes syndicate, custom and consulting grade healthcare reports
covering animal healthcare, biotechnology, clinical diagnostics, healthcare
informatics, healthcare services, medical devices, medical equipment, and
pharmaceuticals.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at clients specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>Contact Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com"><span style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'><o:p></o:p></span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black;mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='mso-special-character:line-break;page-break-before:
always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Cancer Molecular Diagnostics Market US$ 23.3 Billion by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The global cancer molecular
diagnostics market expected to reach US$ 23.3 billion by 2023, growing at CAGR 26.6%
over the forecast period. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Diagnostic
tests are at the forefront of medical innovation, providing vital insights into
patient health and transforming cancer care. Molecular diagnostics have
transformed the way to approach cancer care, and promise to be a critical
contributor to further progress. It can help differentiate cancer from benign
tumors (i.e., growths that are not harmful) and can further help identify the
type of tissue in which the cancer originated (e.g., breast, lung, skin, etc.).
<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Visit Cancer Molecular Diagnostics Market by
Technology Platform (RT-PCR, DNA Microarray, Lab-On-A-Chip (LOAC), Next
Generation Sequencing (NGS), Multiplex Conventional, Next Generation Capture,
Protein Microarray, Others); by Application or Cancer Type (Breast Cancer,
Colorectal Cancer, Cervical Cancer, Lung Cancer, Precancer, Prostate Cancer,
Melanoma, Leukemia, Lymphoma, Pancreatic Cancer, Bladder Cancer, Chest Cancer,
Brain Cancer, Thyroid Cancer, Kidney Cancer, Ovarian Cancer, Stomach Cancer,
Others) and Forecast 2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/cancer-molecular-diagnostics-market/">https://www.ihealthcareanalyst.com/report/cancer-molecular-diagnostics-market/</a>
<span style='mso-spacerun:yes'></span></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global </span><span lang=EN-US style='font-size:10.0pt;line-height:107%;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>cancer molecular
diagnostics</span><span lang=EN-US style='font-size:10.0pt;line-height:107%;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'> market research report provides market size
(Revenue USD Million 2015 to 2023), market share analysis, growth trends and
forecast (CAGR%, 2018 to 2023). The global </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>cancer molecular diagnostics</span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
market research report is further segmented by geography into North America
(U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India,
Rest of APAC), and Rest of the World. In addition, the global </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>cancer molecular diagnostics</span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
market report provides the detailed market landscape (market drivers,
restraints, opportunities), market attractiveness analysis, and market
profitability analysis by key products and regions or countries. The report
also tracks the major competitors operating in the global market by company
overview, financial snapshot, major products, technologies, services offered
and recent developments.</span><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Major
players operating in the global cancer molecular diagnostics market and
profiled in this report include Abbott Laboratories, Becton, Dickinson and
Company, Cepheid, Inc., Hoffmann-La Roche Ltd., Hologic, Inc., Qiagen, Siemens
Healthcare, and others.<br style='mso-special-character:line-break'>
<![if !supportLineBreakNewLine]><br style='mso-special-character:line-break'>
<![endif]><o:p></o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l14 level1 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Technology
Platform<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>RT-PCR <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>DNA Microarray <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Lab-On-A-Chip
(LOAC)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Next Generation
Sequencing (NGS)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Multiplex Conventional
<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Next Generation
Capture <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Protein
Microarray <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Others<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l14 level1 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Application
(Cancer Type)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Breast Cancer<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Colorectal Cancer
<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Cervical Cancer <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Lung Cancer <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Precancer<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Prostate Cancer <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Melanoma <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Leukemia <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Lymphoma <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.10.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Pancreatic Cancer
<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.11.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Bladder Cancer <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.12.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Chest Cancer <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.13.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Brain Cancer <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.14.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Thyroid Cancer <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.15.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Kidney Cancer <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.16.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Ovarian Cancer <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.17.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Stomach Cancer <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.18.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Others<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l14 level1 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Geography
(Region, Country)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>North America
(U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Asia Pacific
(Japan, China, India, Rest of APAC)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Latin America
(Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rest of the World<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l14 level1 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>7.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Abbott
Laboratories<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>7.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Becton, Dickinson
and Company<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>7.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Cepheid, Inc. <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>7.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Hoffmann-La Roche
Ltd.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>7.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Hologic, Inc. <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>7.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Qiagen <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l14 level2 lfo28'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>7.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Siemens
Healthcare<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'>To request Table of Contents and
Sample Pages of this report visit:</span><span lang=EN-US style='font-size:
10.0pt;line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
</span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-size:11.0pt;
line-height:107%'><o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/cancer-molecular-diagnostics-market/">https://www.ihealthcareanalyst.com/report/cancer-molecular-diagnostics-market/</a>
</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><strong><span
lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>About Us</span></strong><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst,
Inc. is a global healthcare market research and consulting company providing
market analysis, and competitive intelligence services to global clients. The
company publishes syndicate, custom and consulting grade healthcare reports
covering animal healthcare, biotechnology, clinical diagnostics, healthcare
informatics, healthcare services, medical devices, medical equipment, and
pharmaceuticals.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at clients specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>Contact Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span><b style='mso-bidi-font-weight:
normal'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><br clear=all style='mso-special-character:
line-break;page-break-before:always'>
<o:p></o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Nebulizer and Spacer for pMDI Devices Market US$ 1.9 Billion by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The global nebulizer and spacer for
pMDI devices market expected to reach US$ 1.9 billion by 2023, growing at CAGR 6.6%
over the forecast period. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The global nebulizer and spacer for
pMDI devices market segmentation is based on device type (nebulizer, spacer for
pMDIs), and by geography (region and country). The report provides market size
(Revenue US$ Million) and volume (number of units in thousand) from 2015 to
2023, market share analysis, growth trends and forecast (CAGR%, 2018 to 2023). <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Drug delivery mechanisms using
aerosols are an integral part of the treatment of respiratory disorders (e.g.
asthma, obstructive lung disorders, cystic fibrosis, pulmonary arterial
hypertension, infectious pulmonary disease). Inhalation drug delivery devices
such as MDIs, DPIs and nebulizers have been a large part of asthma/ COPD
inhaler success over the last 10 years. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Visit Nebulizer and Spacer for pMDI Devices
Market by Device Type (Nebulizer, Spacer for MDIs), by Geography (North
America, Europe, Asia Pacific, Latin America, RoW), Key Competitors,
Distribution Channels and Forecast 2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/nebulizer-spacer-pmdi-devices-market/"><span
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/nebulizer-spacer-pmdi-devices-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'> <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Visit Inhalation Drug Delivery Devices Market
by Device Type (Asthma Devices, COPD Devices), and Technology (Dry Powder
Inhalers; Metered Dose Inhalers  Breath-actuated MDIs, Spacers for MDIs;
Nebulizers) and Forecast 2015-2023 </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/inhalation-drug-delivery-devices-market/"><span
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/inhalation-drug-delivery-devices-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'> <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The global nebulizer and spacer for
pMDI devices market research report is further segmented by geography into
North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA),
Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan,
China, India, Rest of APAC), and Rest of the World. In addition, the global
nebulizer and spacer devices market report provides the detailed market
landscape (market drivers, restraints, opportunities), market attractiveness
analysis, and market profitability analysis by key products and regions or
countries.&nbsp; The report also tracks the major competitors operating in the
global market by company overview, financial snapshot, major products,
technologies, services offered and recent developments.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Major players operating in the global
nebulization devices market include Philips Respironics, Omron Healthcare,
Graham-Field Health Products, Inc., PARI Respiratory Equipment, Inc., and
Others (Aerogen, Allied Healthcare Products, GE Healthcare, Drive
Medical/DeVilbiss Healthcare, ResMed, Salter Labs Inc., etc.).<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Major players operating in the global
spacer for pMDI devices for pMDIs (open tube and reverse-flow) market include
Monaghan Medical Corporation, Chiesi Farmaceutici S.p.A., Respiratory Delivery
Systems, Inc., Merck &amp; Co., Inc., Smiths Medical, Inc., Philips Respironics
(Respironics, Inc.), and Destal Industries, Inc.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Major manufacturing companies
operating in global Valved Holding Chambers (VHCs) market include
GlaxoSmithKline, Monaghan Medical Corporation, AstraZeneca, SunMed, Mylan
Specialty L.P., FSC Pediatrics, AM Systems, Thayer Medical, Philips
Respironics, Salter Labs, Merck &amp; Co., Inc., Menarini Group, PARI Respiratory
Equipment, Inc., nSpire Health Ltd., Rhne-Poulenc S.A., Laboratory Aldo-Union,
S.A., Medical Developments International, and Henry Ford Allegiance Health.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The report also includes information
on regulatory requirement, medical insurance, and description on traditional
and emerging distribution channels for global nebulizer and spacer devices
market.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Device Type<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.55in;mso-add-space:auto;
text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Nebulizer<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Spacer for MDIs<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l21 level1 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Geography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>North America
(U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Latin America
(Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Asia Pacific
(Japan, China, India, Rest of APAC<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rest of the World<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l21 level1 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.55in;mso-add-space:auto;text-align:justify;
text-indent:-.3in;line-height:107%;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Nebulization Devices Market <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.1.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Aerogen<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.1.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Allied Healthcare Products<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.1.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Drive Medical/DeVilbiss Healthcare<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.1.4.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>GE Healthcare<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.1.5.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Graham-Field Health Products, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.1.6.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Omron Healthcare<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.1.7.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>PARI Respiratory Equipment, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.1.8.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Philips Respironics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.1.9.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>ResMed<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.1.10.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Salter Labs Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.55in;mso-add-space:auto;text-align:justify;
text-indent:-.3in;line-height:107%;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Spacer for pMDI Devices (Open Tube and
Reverse-Flow) Market <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.2.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Chiesi Farmaceutici S.p.A.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.2.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Destal Industries, Inc. <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.2.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Merck &amp; Co., Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.2.4.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Monaghan Medical Corporation<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.2.5.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Philips Respironics (Respironics, Inc.)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.2.6.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Respiratory Delivery Systems, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.2.7.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Smiths Medical, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.55in;mso-add-space:auto;text-align:justify;
text-indent:-.3in;line-height:107%;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Valved Holding Chambers (VHCs) Market <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.3.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>AM Systems<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.3.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>AstraZeneca<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.3.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>FSC Pediatrics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.3.4.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>GlaxoSmithKline<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.3.5.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Henry Ford Allegiance Health<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.3.6.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Laboratory Aldo-Union, S.A. <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.3.7.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Medical Developments International<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.3.8.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Menarini Group<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.3.9.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Merck &amp; Co., Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.3.10.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Monaghan Medical Corporation<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.3.11.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Mylan Specialty L.P.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.3.12.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>nSpire Health Ltd.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.3.13.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>PARI Respiratory Equipment, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.3.14.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Philips Respironics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.3.15.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Rhne-Poulenc S.A.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.3.16.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Salter Labs<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.3.17.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>SunMed<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;mso-add-space:auto;text-align:justify;
text-indent:-.35in;line-height:107%;mso-list:l21 level3 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>3.3.18.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Thayer Medical<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'>To request Table of Contents and
Sample Pages of this report visit:</span><span lang=EN-US style='font-size:
10.0pt;line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
</span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-size:11.0pt;
line-height:107%'><o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/nebulizer-spacer-pmdi-devices-market/">https://www.ihealthcareanalyst.com/report/nebulizer-spacer-pmdi-devices-market/</a>
</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><strong><span
lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>About Us</span></strong><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst,
Inc. is a global healthcare market research and consulting company providing
market analysis, and competitive intelligence services to global clients. The
company publishes syndicate, custom and consulting grade healthcare reports
covering animal healthcare, biotechnology, clinical diagnostics, healthcare
informatics, healthcare services, medical devices, medical equipment, and
pharmaceuticals.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at clients specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>Contact Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span><b style='mso-bidi-font-weight:
normal'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><br clear=all style='mso-special-character:
line-break;page-break-before:always'>
<o:p></o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Minimally Invasive Weight Loss (Bariatric) Devices Market US$ 313 Million by
2023<o:p></o:p></span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global minimally invasive weight loss (bariatric) devices market expected to
reach US$ 313 million by 2023, growing at CAGR 14.8% over the forecast period, </span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>due to increasing
preference and adoption of minimally invasive surgical procedures worldwide,
and technological advancement in developing next-generation robotic products.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Visit
Minimally Invasive Weight Loss (Bariatric) Devices Market by Device Type (Laparoscopic
Adjustable Gastric Banding (LAGB) Systems / Lap-Band / Realize Band, Intragastric
Balloon Systems / BIB System, Implantable Neuroregulators and Gastric
Electrical Stimulation Systems / GES) and Forecast 2015-2023 at </span><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/minimally-invasive-weight-loss-bariatric-devices-market/"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/minimally-invasive-weight-loss-bariatric-devices-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'> <o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Minimally
invasive </span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>bariatric
surgeries are performed for patients with morbid obesity or obesity with
secondary medical issues. Laparoscopic </span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>minimally
invasive weight loss (bariatric) </span><span lang=EN-US style='font-size:10.0pt;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>approaches offer the same potentially life-saving
results as traditional open obesity surgery, but with significantly less pain
and fewer complications, such as wound infections and hernias. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Laparoscopic Adjustable Gastric Band
(LAGB) is the most common procedure done in Europe, where a silastic band
placed around the proximal stomach percutaneously allowing for tightening or
loosening via a subcutaneous port. Lap-Band System obtained U.S. FDA approval
in 2001. The latest models include Lap-Band AP-L and Lap-Band AP-S. The Realize
Adjustable Gastric Band obtained FDA approval in 2007. Two other adjustable
gastric bands are in use outside of the United States: Heliogast and Midband.
Neither band has been approved by the FDA. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Intragastric Balloon System is a
weight-loss system that uses a gastric balloon that occupies space in the
stomach.</span><span lang=EN-US> </span><span lang=EN-US style='font-size:10.0pt;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Currently there are three FDA approved
balloons in the USA. Gastric balloon devices have been approved in many
countries, among them Australia, Canada, Mexico, India, and several European
and South American countries. Two different balloon devices available in the
United States and approved by the FDA include ReShape Integrated Dual Balloon
System (ReShape Dual Balloon) and Orbera. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Gastric electrical stimulation (GES)
for gastroparesis has been in use for more than a decade with proven beneficial
effect on symptoms, quality of life and nutritional status. Currently the only
GES device used in the U.S. is the Enterra Therapy System, which is approved by
the Food and Drug Administration (FDA) under a humanitarian device exemption. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The global </span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>minimally
invasive weight loss (bariatric) devices </span><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>market segmentation is based on</span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'> device type (laparoscopic adjustable gastric banding systems /
lap-band / realize band, intragastric balloon systems / BIB system, implantable
neuroregulators and gastric electrical stimulation systems / GES).<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global </span><span lang=EN-US style='font-size:10.0pt;line-height:107%;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>minimally
invasive weight loss (bariatric) devices </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market research
report provides market size (Revenue USD Million 2015 to 2023), market share
analysis, growth trends and forecast (CAGR%, 2018 to 2023). The global </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>minimally invasive weight loss (bariatric)
devices </span><span lang=EN-US style='font-size:10.0pt;line-height:107%;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>market research report is further segmented by
geography into North America (U.S., Canada), Latin America (Brazil, Mexico,
Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia
Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In
addition, the global </span><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>minimally
invasive weight loss (bariatric) devices </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market report
provides the detailed market landscape (market drivers, restraints,
opportunities), market attractiveness analysis, and market profitability
analysis by key products and regions or countries.<span
style='mso-spacerun:yes'> </span>The report also tracks the major competitors
operating in the global market by company overview, financial snapshot, major
products, technologies, services offered and recent developments.</span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Major
players operating in the global minimally invasive weight loss (bariatric)
devices market and profiled in this report include Allurion Technologies, Apollo
Endosurgery, Helioscopie, Obalon Therapeutics, ReShape Medical, Spatz FGIA, EnteroMedics,
MetaCure Inc., Aspire Bariatrics Inc., BarioSurg Inc., BAROnova Inc., GI
Dynamics Inc., GI Windows Inc., and Scientific Intake Ltd.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l22 level1 lfo27'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Device Type<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l22 level2 lfo27'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Laparoscopic
Adjustable Gastric Banding (LAGB) Systems / Lap-Band / Realize Band<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l22 level2 lfo27'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Intragastric
Balloon Systems (BIB System)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l22 level2 lfo27'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Implantable
Neuroregulators and Gastric Electrical Stimulation Systems (GES)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l22 level1 lfo27'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Geography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l22 level2 lfo27'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>North America
(U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l22 level2 lfo27'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Latin America
(Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l22 level2 lfo27'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l22 level2 lfo27'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Asia Pacific
(Japan, China, India, Rest of APAC<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l22 level2 lfo27'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rest of the World<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l22 level1 lfo27'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l22 level2 lfo27'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Intragastric
Balloon Systems<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l22 level3 lfo27'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Allurion
Technologies<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l22 level3 lfo27'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Apollo
Endosurgery<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l22 level3 lfo27'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Helioscopie<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l22 level3 lfo27'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Obalon
Therapeutics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l22 level3 lfo27'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.1.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>ReShape Medical<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l22 level3 lfo27'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.1.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Spatz FGIA<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l22 level2 lfo27'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Implantable
Neuroregulators and Gastric Electrical Stimulation Systems<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l22 level3 lfo27'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>EnteroMedics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l22 level3 lfo27'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>MetaCure Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l22 level2 lfo27'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Emerging
Technologies<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l22 level3 lfo27'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Aspire Bariatrics
Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l22 level3 lfo27'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>BarioSurg Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l22 level3 lfo27'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>BAROnova Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l22 level3 lfo27'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>GI Dynamics Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l22 level3 lfo27'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>GI Windows Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l22 level3 lfo27'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.3.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Scientific Intake
Ltd.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'>To request Table of Contents and
Sample Pages of this report visit:</span><span lang=EN-US style='font-size:
10.0pt;line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
</span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-size:11.0pt;
line-height:107%'><o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/minimally-invasive-weight-loss-bariatric-devices-market/">https://www.ihealthcareanalyst.com/report/minimally-invasive-weight-loss-bariatric-devices-market/</a></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><strong><span
lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>About Us</span></strong><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst,
Inc. is a global healthcare market research and consulting company providing
market analysis, and competitive intelligence services to global clients. The
company publishes syndicate, custom and consulting grade healthcare reports
covering animal healthcare, biotechnology, clinical diagnostics, healthcare
informatics, healthcare services, medical devices, medical equipment, and
pharmaceuticals.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at clients specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>Contact Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><br
clear=all style='mso-special-character:line-break;page-break-before:always'>
</span><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'><o:p></o:p></span></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Atopic Dermatitis (AD) Treatment Market US$ 7 Billion by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global atopic dermatitis (AD) treatment market expected to reach US$ 7 billion by
2023, growing at CAGR 11% over the forecast period, </span><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>due to the launch of new products </span><span
lang=EN-US style='font-size:9.0pt;mso-bidi-font-family:"Minion Pro";color:#211D1E'>such
as, Dupilumab and Crisaborole, as well as </span><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>off-label use of systemic therapies
for AD treatment.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Visit
Atopic Dermatitis (AD) Treatment Market by Drug Class (Brand) - Interleukin
Inhibitors - Dupilumab (</span><span lang=EN-US style='font-size:10.0pt;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Dupixent)</span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>;
Phosphodiesterase-4 (PDE4) Inhibitors - Crisaborole (</span><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Eucrisa</span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>);
Systemic Therapy (Phototherapy); Topical Corticosteroids; Topical Immunomodulators
/</span><span lang=EN-US> </span><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Topical
Calcineurin Inhibitors </span><span lang=EN-US style='color:black;background:
white'>(TCI)</span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'> - Pimecrolimus (Elidel), Tacrolimus (Protopic)
and Forecast 2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/atopic-dermatitis-treatment-market/"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/atopic-dermatitis-treatment-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'> <o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Atopic dermatitis affects up to 30% of
children and 10% of adults, and is common in both developed and developing
countries. Two new medicines on the brink of entering the market  dupilumab, a
biologic for severe disease, and crisaborole, a topical small molecule drug for
milder disease  could herald a new era in the management of this condition,
which has seen no major changes to the way it has been treated for over 15 years.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Atopic dermatitis can have a
devastating effect on quality of life, but there have been no major changes to
the way it has been treated for over 15 years. Now, two new therapies:
dupilumab, a biologic for severe disease, and crisaborole, a topical small molecule
drug for milder disease could herald a new era in the treatment of this
distressing condition.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Population-based studies in the United
States suggest that prevalence is about 10.7% for children and 7.2% for adults.
Incidence of AD has increased 2- to 3-fold in industrialized nations, impacting
approximately 15% to 20% of children and 1% to 3% of adults worldwide. AD has a
wide-ranging impact on a patients quality of life and the burden from direct
and indirect costs (approximately $37.7 billion in out-of-pocket costs) is
shared by the families and caregivers of patients with AD.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Severe side-effects of current
therapies have limited the growth of AD market, highlighting the unmet need for
safe and effective treatment options. However, recent launch of two
breakthrough therapies namely Pfizers Eucrisa (first PDE-4 inhibitor) and
Sanofis Dupixent (first biologic) have significantly changed the market
dynamics. Characterized by large under-diagnosed patient pool, high prevalence
among adults as well as children and potential molecules in development, global
AD market is anticipated to grow at a significant rate over the forecast
period.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Sanofis and Regenerons Dupixent
(dupilumab), which was approved by the Food and Drug Administration (FDA) in
March 2017, is estimated to achieve peak annual sales of $4 billion. Pfizers
Eucrisa (Crisaborole), which was acquired for $5.2 billion in a merger with
Anacor and approved by the FDA in December 2016, is estimated to achieve peak
annual sales of $2 billion. The majority of its target market is expected to
comprise mild-to-moderate cases, with up to ~60 percent pediatric and
adolescent patients.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Factors such as increase in prevalence
of atopic dermatitis, higher treatment compliance, growing prevalence of food
allergies exacerbating atopic dermatitis and favorable reimbursement policies
in some countries are driving the market growth of AD treatment worldwide.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Due to the higher number of unmet
needs, vendors in the market are focusing in developing ideal treatment,
promising pipeline molecule, rising access for the treatment medication in some
developing countries, increase in incidence of atopic dermatitis would fuel the
growth of AD treatment market during forecast period.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>However, generic erosion, poor patient
compliance in some countries and adverse effects associated with the use of
medication is negatively impacting the growth of AD treatment market.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Pipeline molecules in the clinical
phases II and III include Tralokinumab, ANB-020, Baricitinib, BMS-981164, Lebrikizumab,
Mepolizumab, MM36, Nemolizumab, PF-04965842, Tezepelumab, Upadacitinib, ZPL-389,
and MEDI-9314 are expected to show strong AD treatment market growth during
forecast period. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>North America dominated the global AD
treatment market due to large number of target population, higher treatment
awareness, swift adoption of novel medications, and better reimbursement
policies.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The global </span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>atopic
dermatitis treatment </span><span lang=EN-US style='font-size:10.0pt;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>market segmentation is based on</span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'> drug class (brand) - interleukin inhibitors - dupilumab (</span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Dupixent)</span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>; phosphodiesterase-4 (PDE4) inhibitors - crisaborole (</span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Eucrisa</span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>); systemic therapy (phototherapy); topical corticosteroids; topical
immunomodulators /</span><span lang=EN-US> </span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>topical
calcineurin inhibitors </span><span lang=EN-US style='color:black;background:
white'>(TCI)</span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'> - pimecrolimus (Elidel), and tacrolimus
(Protopic).<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global </span><span lang=EN-US style='font-size:10.0pt;line-height:107%;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>atopic dermatitis
treatment</span><span lang=EN-US style='font-size:10.0pt;line-height:107%;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'> market research report provides market size
(Revenue USD Million 2015 to 2023), market share analysis, growth trends and
forecast (CAGR%, 2018 to 2023). The global </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>atopic dermatitis treatment</span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
market research report is further segmented by geography into North America
(U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India,
Rest of APAC), and Rest of the World. In addition, the global </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>atopic dermatitis treatment</span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
market report provides the detailed market landscape (market drivers,
restraints, opportunities), market attractiveness analysis, and market
profitability analysis by key products and regions or countries.<span
style='mso-spacerun:yes'> </span>The report also tracks the major competitors
operating in the global market by company overview, financial snapshot, major
products, technologies, services offered and recent developments.</span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Major players operating in the global atopic
dermatitis treatment market and profiled in this report include AbbVie Inc., AnaptysBio,
AstraZeneca</span><span lang=EN-US>, </span><span lang=EN-US style='font-size:
10.0pt;line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Bristol-Myers
Squibb, Chugai, Eli Lilly &amp; Company, Galderma, GlaxoSmithKline, LEO Pharma A/S,
Medimetriks, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., F. Hoffmann-La
Roche AG, Sanofi S.A., Valeant Pharmaceuticals, and Ziarco.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l26 level1 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Drug Class
(Brand)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l26 level2 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Interleukin
Inhibitors<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l26 level3 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Dupilumab (</span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Dupixent)</span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l26 level2 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Phosphodiesterase-4
(PDE4) Inhibitors<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l26 level3 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Crisaborole (</span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Eucrisa</span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l26 level2 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Systemic Therapy
(Phototherapy)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l26 level2 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Topical
Corticosteroids<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l26 level2 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Topical
Immunomodulators/</span><span lang=EN-US> </span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Topical
Calcineurin Inhibitors </span><span lang=EN-US style='color:black;background:
white'>(TCI)</span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l26 level3 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.5.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Pimecrolimus
(Elidel)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l26 level3 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.5.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Tacrolimus
(Protopic)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l26 level1 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Geography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l26 level2 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>North America
(U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l26 level2 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Latin America
(Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l26 level2 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l26 level2 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Asia Pacific (Japan,
China, India, Rest of APAC<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l26 level2 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rest of the World<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l26 level1 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l26 level2 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>AbbVie Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l26 level2 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>AnaptysBio<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l26 level2 lfo26'><![if !supportLists]><span
lang=EN-US style='mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><span
style='mso-list:Ignore'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>AstraZeneca</span><span
lang=EN-US> </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l26 level2 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Bristol-Myers
Squibb<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l26 level2 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Chugai<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l26 level2 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Eli Lilly &amp;
Company<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l26 level2 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Galderma<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l26 level2 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>GlaxoSmithKline<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l26 level2 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>LEO Pharma A/S<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l26 level2 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.10.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Medimetriks<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l26 level2 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.11.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Novartis<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l26 level2 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.12.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Pfizer<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l26 level2 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.13.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Regeneron
Pharmaceuticals Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l26 level2 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.14.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>F. Hoffmann-La
Roche AG <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l26 level2 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.15.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Sanofi S.A.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l26 level2 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.16.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Valeant
Pharmaceuticals<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;mso-add-space:auto;
text-indent:-.3in;mso-list:l26 level2 lfo26'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.17.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Ziarco<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'>To request Table of Contents and
Sample Pages of this report visit:</span><span lang=EN-US style='font-size:
10.0pt;line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
</span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-size:11.0pt;
line-height:107%'><o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/atopic-dermatitis-treatment-market/">https://www.ihealthcareanalyst.com/report/atopic-dermatitis-treatment-market/</a></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><strong><span
lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>About Us</span></strong><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst,
Inc. is a global healthcare market research and consulting company providing
market analysis, and competitive intelligence services to global clients. The
company publishes syndicate, custom and consulting grade healthcare reports
covering animal healthcare, biotechnology, clinical diagnostics, healthcare
informatics, healthcare services, medical devices, medical equipment, and
pharmaceuticals.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at clients specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>Contact Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><br
clear=all style='mso-special-character:line-break;page-break-before:always'>
</span><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'><o:p></o:p></span></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Endoscopic Pelvic Surgery Devices Market US$ 17 Billion by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global endoscopic pelvic surgery devices market expected to reach US$ 17
billion by 2023, growing at CAGR 5.1% over the forecast period, </span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>due to
technological advancements in endoscopic instrumentation and higher demand for
minimally invasive surgeries worldwide</span><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>. </span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Moreover, significant
demand and FDA approvals are likely to boost the </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/endoscopy-devices-market/"><span
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>global endoscopy devices market</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>, which is
estimated to reach US$ 42.6 billion by 2023, growing at a CAGR of 5.3% from 2018
to 2023. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Visit Endoscopic Pelvic Surgery Devices Market
by Device Type (Access Devices, Access Site Closure Devices, Ancillary Devices,
Endoscopes, Hand Instruments, Insufflation Products), Procedure Volume by
Geography (Endoscopic Surgical Procedures, Obstetric/Gynecologic Surgical
Procedures, Urologic Surgery Procedures) and Forecast 2015-2023 at </span><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/endoscopic-pelvic-surgery-devices-market/"><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/report/endoscopic-pelvic-surgery-devices-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-size:11.0pt;line-height:107%'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global </span><span lang=EN-US style='font-size:10.0pt;line-height:107%;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>endoscopic pelvic
surgery devices </span><span lang=EN-US style='font-size:10.0pt;line-height:
107%;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>market research report provides market size
(Revenue USD Million 2015 to 2023), market share analysis, growth trends and
forecast (CAGR%, 2018 to 2023). The global </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>endoscopic pelvic surgery devices </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market
research report is further segmented by geography into North America (U.S.,
Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany,
France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of
APAC), and Rest of the World. In addition, the global </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>endoscopic pelvic surgery devices </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market
report provides the detailed market landscape (market drivers, restraints,
opportunities), market attractiveness analysis, and market profitability
analysis by key products and regions or countries.<span
style='mso-spacerun:yes'> </span>The report also tracks the major competitors
operating in the global market by company overview, financial snapshot, major
products, technologies, services offered and recent developments.</span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Major players operating in the global
endoscopic pelvic surgery devices market and profiled in this report include B.
Braun Melsungen AG, Becton, Dickinson and Company, Boston Scientific
Corporation, ConMed, Cook Incorporated, Daiichi (First) Medical Co., Eisai Co.
Ltd., Fujinon (Fujifilm), Geiger Medical Technologies, Hitachi Ltd., Jiangsu
Guanchuang Medical Technology, Johnson &amp; Johnson, KARL STORZ GmbH &amp; Co.
KG, Lexion Medical, Medrobotics, Medtronic, Inc., Nikon Corporation, Olympus
Corporation, Pall Corporation, Richard Wolf GmbH, Smith &amp; Nephew, Stryker
Corporation, Sumitomo Bakelite, Synergy Health, Teleflex, Wisap Medical
Technology GmbH, W. L. Gore &amp; Associates, and Zenith Medical.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l17 level1 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Device Type<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Access Devices <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Access Site
Closure Devices<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Ancillary Devices
<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Endoscopes <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Hand Instruments <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Insufflation
Products<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l17 level1 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Procedure Volume
by Geography <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Endoscopic
Surgical Procedures <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Obstetric/Gynecologic
Surgical Procedures <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Urologic Surgery
Procedures <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l17 level1 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Geography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>North America
(U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Latin America
(Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Asia Pacific
(Japan, China, India, Rest of APAC<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rest of the World<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l17 level1 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>B. Braun
Melsungen AG<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Becton, Dickinson
and Company<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Boston Scientific
Corporation<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>ConMed<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Cook Incorporated<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Daiichi (First)
Medical Co.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Eisai Co. Ltd.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Fujinon
(Fujifilm)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Geiger Medical
Technologies<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.10.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Hitachi Ltd.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.11.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Jiangsu
Guanchuang Medical Technology<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.12.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Johnson &amp; Johnson<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.13.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>KARL STORZ GmbH
&amp; Co. KG<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.14.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Lexion Medical<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.15.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Medrobotics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.16.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Medtronic, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.17.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Nikon Corporation<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.18.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Olympus
Corporation<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.19.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Pall Corporation<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.20.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Richard Wolf GmbH<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.21.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Smith &amp;
Nephew<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.22.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Stryker
Corporation<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.23.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Sumitomo Bakelite<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.24.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Synergy Health<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.25.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Teleflex<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.26.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Wisap Medical
Technology GmbH<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.27.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>W. L. Gore &amp;
Associates<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l17 level2 lfo25'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.28.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Zenith Medical<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'>To request Table of Contents and
Sample Pages of this report visit:</span><span lang=EN-US style='font-size:
10.0pt;line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/endoscopic-pelvic-surgery-devices-market/"><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/report/endoscopic-pelvic-surgery-devices-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-size:11.0pt;line-height:107%'><o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><strong><span
lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>About Us</span></strong><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst,
Inc. is a global healthcare market research and consulting company providing
market analysis, and competitive intelligence services to global clients. The
company publishes syndicate, custom and consulting grade healthcare reports
covering animal healthcare, biotechnology, clinical diagnostics, healthcare
informatics, healthcare services, medical devices, medical equipment, and
pharmaceuticals.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at clients specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>Contact Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><br
clear=all style='mso-special-character:line-break;page-break-before:always'>
</span><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'><o:p></o:p></span></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Diagnostic and Guided Interventional Cardiology Devices Market US$ 6 Billion by
2023 <o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global diagnostic interventional cardiology devices market expected to reach
US$ 6 billion by 2023, growing at CAGR 5.2% over the forecast period, </span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>due to increasing
preference for minimally invasive procedures, growing geriatric population and
higher incidence of cardiovascular diseases worldwide</span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global </span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>diagnostic interventional cardiology devices
</span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market research
report provides market size (Revenue USD Million 2015 to 2023), market share
analysis, growth trends and forecast (CAGR%, 2018 to 2023). The global </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>diagnostic interventional cardiology devices </span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market research
report is further segmented by geography into North America (U.S., Canada),
Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France,
Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC),
and Rest of the World. In addition, the global </span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>diagnostic
interventional cardiology devices </span><span lang=EN-US style='font-size:
10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>market report provides the detailed market
landscape (market drivers, restraints, opportunities), market attractiveness
analysis, and market profitability analysis by key products and regions or
countries.<span style='mso-spacerun:yes'> </span>The report also tracks the
major competitors operating in the global market by company overview, financial
snapshot, major products, technologies, services offered and recent
developments.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Visit Diagnostic Interventional
Cardiology Devices Market by Device Type (Transcatheter Angiography Devices, Intravascular
Ultrasound (IVUS) Devices, Guide Wire-based Intravascular Stenosis Assessment
or Fractional Flow Reserve (FFR) Devices, Intracardiac Echocardiography (ICE)
Devices, Optical Coherence Tomography (OCT) Devices, Robotic-Assisted Surgical
Devices) and Forecast 2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/diagnostic-interventional-cardiology-devices-market/"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/diagnostic-interventional-cardiology-devices-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'> <o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Major
players operating in the global diagnostic interventional cardiology devices market
and profiled in this report include ACIST Medical Systems (Bracco SPA), Auris
Surgical Robotics Inc., B. Braun Medical (B. Braun Melsungen), Biosense Webster
Inc. (Johnson &amp; Johnson), Boston Scientific Corp., Catheter Precision, Cook
Medical, Corindus Vascular Robotics Inc., GE Healthcare, Hansen Medical Inc., Kaiser
Permanente, Medtronic PLC, Merit Medical Systems, Opsens Inc., Philips
Healthcare/ Royal Phillips, Siemens Healthineers, St. Jude Medical Inc. (Abbott
International), Stereotaxis Inc., Shimadzu Medical Systems, Smiths Medical, Terumo
Interventional, and Toshiba America Medical Systems.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l23 level1 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Device Type<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Transcatheter
Angiography Devices<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Intravascular Ultrasound
(IVUS) Devices<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Guide Wire-based
Intravascular Stenosis Assessment or Fractional Flow Reserve (FFR) Devices<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Intracardiac
Echocardiography (ICE) Devices<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Optical Coherence
Tomography (OCT) Devices<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Robotic-Assisted
Surgical Devices<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l23 level1 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Geography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>North America
(U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Latin America
(Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Asia Pacific
(Japan, China, India, Rest of APAC<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rest of the World<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l23 level1 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>ACIST Medical
Systems (Bracco SPA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Auris Surgical
Robotics Inc. <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>B. Braun Medical
(B. Braun Melsungen)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Biosense Webster
Inc. (Johnson &amp; Johnson)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Boston Scientific
Corp.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Catheter
Precision <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Cook Medical<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Corindus Vascular
Robotics Inc. <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>GE Healthcare<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.10.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Hansen Medical
Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.11.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Kaiser Permanente<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.12.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Medtronic PLC<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.13.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Merit Medical
Systems<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.14.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Opsens Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.15.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Philips
Healthcare/ Royal Phillips<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.16.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Siemens
Healthineers<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.17.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>St. Jude Medical
Inc. (Abbott International)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.18.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Stereotaxis Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.19.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Shimadzu Medical
Systems<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.20.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Smiths Medical<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.21.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Terumo
Interventional<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;mso-add-space:auto;
text-indent:-.3in;mso-list:l23 level2 lfo24'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.22.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Toshiba America
Medical Systems<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'>To request Table of Contents and
Sample Pages of this report visit:</span><span lang=EN-US style='font-size:
10.0pt;line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/diagnostic-interventional-cardiology-devices-market/"><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/report/diagnostic-interventional-cardiology-devices-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-size:11.0pt;line-height:107%'><o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><strong><span
lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>About Us</span></strong><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst,
Inc. is a global healthcare market research and consulting company providing
market analysis, and competitive intelligence services to global clients. The
company publishes syndicate, custom and consulting grade healthcare reports
covering animal healthcare, biotechnology, clinical diagnostics, healthcare
informatics, healthcare services, medical devices, medical equipment, and
pharmaceuticals.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at clients specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>Contact Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><br
clear=all style='mso-special-character:line-break;page-break-before:always'>
</span><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'><o:p></o:p></span></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Antibody Drug Conjugates Market US$ 5 Billion by 2023 <o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global antibody drug conjugates market expected to reach US$ 5 billion by 2023,
growing at CAGR 22% over the forecast period, </span><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>owing to increasing drug prices and
rapid approval of new treatments</span><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Antibodydrug conjugates (ADCs), which
consist of a mAb chemically linked to a small-molecule therapeutics, are a
niche class of drugs that offer promise, particularly as oncology drugs. ADCs
are one of the fastest growing classes of oncology therapeutics. In the quest
for more targeted therapies and potentially more clinically efficacious drugs,
bio/pharmaceutical companies are increasing their research and product
development in biologics. Although the majority of this work is focused on
monoclonal antibodies (mAbs) and recombinant proteins, progress is being made
in specialized drug types.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>In 2011, US-FDA approved Seattle
Genetics/Takedas Adcetris (brentuximab vedotin) for treating Hodgkin lymphoma
and anaplastic large cell lymphoma, followed by, Roches Kadcyla (trastuzumab
emtansine) approval in 2013 for the treatment of breast cancer. Advancements
over the past several decades have led to a new generation of ADCs comprising
non-immunogenic mAbs, linkers with balanced stability and highly potent
cytotoxic agents. In the recent years, with the popularity and growth of ADC
pipelines, companies have invested in the required supply chains for raw
materials and services to support the highly specialized skills required for
ADC containment, development, manufacturing, and analysis. With a number of
ADCs in clinical development, the key question is whether ADCs will be able to
fill a role in biopharmaceutical development. The future of ADCs in the
biopharmaceutical market will ultimately depend on their clinical success.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Visit
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/antibody-drug-conjugates-market/"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Antibody
Drug Conjugates Market</span></a></span><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'> by Marketed
Drugs - Adcetris or SGN-35 (Brentuximab vedotin), Kadcyla or T-DM1 (Trastuzumab
emtansine), Pipeline Drugs - Rova-T or SC16LD6.5 (Rovalpituzumab tesirine), CDX</span><span
lang=EN-US style='font-size:10.0pt;font-family:"MS Gothic";mso-bidi-font-family:
"MS Gothic"'>&#8209;</span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>011 (Glembatumumab vedotin), Besponsa
or CMC-544 (Inotuzumab ozogamicin), IMGN853 (Mirvetuximab soravtansine), SGN</span><span
lang=EN-US style='font-size:10.0pt;font-family:"MS Gothic";mso-bidi-font-family:
"MS Gothic"'>&#8209;</span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>CD33A (Vadastuximab talirine) and Forecast
2015-2023. </span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global </span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>antibody drug conjugates </span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market research
report provides market size (Revenue USD Million 2015 to 2023), market share
analysis, growth trends and forecast (CAGR%, 2018 to 2023). The global </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>antibody drug conjugates </span><span lang=EN-US style='font-size:
10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>market research report is further segmented by
geography into North America (U.S., Canada), Latin America (Brazil, Mexico,
Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia
Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In
addition, the global </span><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>antibody drug
conjugates </span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market
report provides the detailed market landscape (market drivers, restraints,
opportunities), market attractiveness analysis, and market profitability
analysis by key products and regions or countries.<span
style='mso-spacerun:yes'> </span><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The report also tracks the major
competitors operating in the global market by company overview, financial
snapshot, major products, technologies, services offered and recent
developments. </span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Major players operating in the global antibody
drug conjugates market and profiled in this report include AbbVie, Agensys,
Inc., Bayer AG, Concortis Biotherapeutics, F. Hoffman-La Roche Ltd., ImmunoGen,
Inc., Immunomedics, Inc., NBE-Therapeutics, Novartis AG, Pfizer, Sanofi, Seattle
Genetics, Inc., and Takeda Pharmaceutical Company Limited.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l24 level1 lfo22'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Marketed Drugs<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l24 level2 lfo22'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Adcetris or
SGN-35 (Brentuximab vedotin)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l24 level2 lfo22'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Kadcyla or T-DM1
(Trastuzumab emtansine)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l24 level1 lfo22'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Pipeline Drugs<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l24 level2 lfo22'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rova-T or
SC16LD6.5 (Rovalpituzumab tesirine)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l24 level2 lfo22'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>CDX</span><span
lang=EN-US style='font-size:10.0pt;font-family:"MS Gothic";mso-bidi-font-family:
"MS Gothic"'>&#8209;</span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>011 (Glembatumumab vedotin)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l24 level2 lfo22'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Besponsa or
CMC-544 (Inotuzumab ozogamicin) <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l24 level2 lfo22'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>IMGN853
(Mirvetuximab soravtansine) <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l24 level2 lfo22'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>SGN</span><span
lang=EN-US style='font-size:10.0pt;font-family:"MS Gothic";mso-bidi-font-family:
"MS Gothic"'>&#8209;</span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>CD33A (Vadastuximab talirine)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l24 level1 lfo22'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Geography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l24 level2 lfo22'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>North America (U.S.,
Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l24 level2 lfo22'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Latin America
(Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l24 level2 lfo22'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l24 level2 lfo22'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Asia Pacific
(Japan, China, India, Rest of APAC<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l24 level2 lfo22'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rest of the World<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l24 level1 lfo22'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l24 level2 lfo22'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>AbbVie<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l24 level2 lfo22'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Agensys, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l24 level2 lfo22'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Bayer AG<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l24 level2 lfo22'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Concortis
Biotherapeutics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l24 level2 lfo22'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>F. Hoffman-La
Roche Ltd.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l24 level2 lfo22'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>ImmunoGen, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l24 level2 lfo22'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Immunomedics,
Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l24 level2 lfo22'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>NBE-Therapeutics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l24 level2 lfo22'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Novartis AG<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l24 level2 lfo22'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.10.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Pfizer<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l24 level2 lfo22'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.11.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Sanofi<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l24 level2 lfo22'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.12.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Seattle Genetics,
Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;mso-add-space:auto;
text-indent:-.3in;mso-list:l24 level2 lfo22'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.13.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Takeda
Pharmaceutical Company Limited<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'>To request Table of Contents and
Sample Pages of this report visit:</span><span lang=EN-US style='font-size:
10.0pt;line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/antibody-drug-conjugates-market/"><span
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/antibody-drug-conjugates-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'> <o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>About Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst,
Inc. is a global healthcare market research and consulting company providing
market analysis, and competitive intelligence services to global clients. The
company publishes syndicate, custom and consulting grade healthcare reports
covering animal healthcare, biotechnology, clinical diagnostics, healthcare
informatics, healthcare services, medical devices, medical equipment, and
pharmaceuticals.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at clients specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>Contact Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><br
clear=all style='mso-special-character:line-break;page-break-before:always'>
</span><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'><o:p></o:p></span></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Idiopathic Pulmonary Fibrosis (IPF) Treatment Market US$ 4.6 Billion by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global idiopathic pulmonary fibrosis treatment market expected to reach US$ 4.
billion by 2023, growing at CAGR 13.1% over the forecast period, </span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>owing to
increasing drug prices and rapid approval of new treatments</span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Idiopathic
pulmonary fibrosis (IPF) is a rare, but serious lung disease. According to the </span><span
lang=EN-US><a
href="https://ghr.nlm.nih.gov/condition/idiopathic-pulmonary-fibrosis#statistics"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>National
Institutes of Health</span></a></span><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>, about 100,000
people in the United States have IPF, and approximately 30,000 to 40,000 new
cases are found each year. Worldwide, IPF affects 13 to 20 out of every 100,000
people. Common comorbid medical conditions found in patients with idiopathic
pulmonary fibrosis include chronic obstructive pulmonary disease, obstructive
sleep apnea, gastroesophageal reflux disease, and coronary artery disease. According
to </span><span lang=EN-US><a
href="http://www.pulmonaryfibrosis.org/life-with-pf/pulmonary-fibrosis-treatment-options"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Pulmonary
Fibrosis Foundation</span></a></span><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>, the mon-pharmacologic
management of pulmonary fibrosis (PF) to manage symptoms and prevent future complications
includes home pulse oximetry, pulmonary rehabilitation, vaccination, weight
management, and lung transplantation. In the United States; in 2013, PF
accounted for nearly half of all lung transplants performed. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Several
different medications have been used for the treatment of PF. Corticosteroids
(prednisone), Cyclophosphamide (Cytoxan), Azathioprine (Imuran), Mycophenolate
mofetil (Cellcept, Myfortic), N-acetylcysteine (NAC), Nintedanib (Ofev),
Pirfenidone (Esbriet, Pirfenex, Pirespa), and Proton pump inhibitors (Prilsec
OTC, Nexium, others). Some of the therapeutic approaches currently being
studied include anti-fibrotic therapies, inhibitors of growth factor
proteins, stem cell therapies, and genetic research. In 2014, </span><span
lang=EN-US><a
href="https://blogs.fda.gov/fdavoice/index.php/2014/10/two-fda-drug-approvals-for-idiopathic-pulmonary-fibrosis-ipf/"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>US-FDA</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'> approved two anti-fibrotic medications are drugs that inhibit or
reduce fibrosis in the lung: Ofev (nintedanib) and Esbriet (pirfenidone) for the
treatment of patients with IPF. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Visit
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/idiopathic-pulmonary-fibrosis-treatment-market/"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Idiopathic
Pulmonary Fibrosis (IPF) Treatment Market</span></a></span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
by Treatment Type - Pharmacological Treatment (Pirfenidone (Esbriet),
Nintedanib (Ofev), Generic Pirfenidone); Non-pharmacological Treatment (Oxygen
Therapy, Pulmonary Rehabilitation, Mechanical Ventilation, Lung
Transplantation, Other Non-Pharmacological Treatment); Patients by Disease
Severity (Mild, Moderate, Severe); Drug Pipeline Analysis (AEOL-10150,
Lebrikizumab, Tipelukast, Tralokinumab, FG-3019, Simtuzumab, BMS-986020,
AF-219, SAR156597, BG00011, PRM-151, PBI-4050)<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>and
Forecast 2015-2023. </span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global </span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>idiopathic pulmonary fibrosis
treatment</span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
market research report provides market size (Revenue USD Million 2015 to 2023),
patient numbers by disease severity and by country (U.S., Japan, U.K. Germany,
France, Italy, Spain, 2015 to 2023), market share analysis, growth trends and
forecast (CAGR%, 2018 to 2023). The global </span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>idiopathic
pulmonary fibrosis treatment</span><span lang=EN-US style='font-size:10.0pt;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'> market research report is further segmented
by geography into North America (U.S., Canada), Latin America (Brazil, Mexico,
Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia
Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In
addition, the global </span><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>idiopathic
pulmonary fibrosis treatment</span><span lang=EN-US style='font-size:10.0pt;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'> market report provides the detailed market
landscape (market drivers, restraints, opportunities), market attractiveness
analysis, and market profitability analysis by key products and regions or
countries.<span style='mso-spacerun:yes'> </span>The report also tracks the
major competitors operating in the global market by company overview, financial
snapshot, major products, technologies, services offered and recent developments.
</span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Major players operating in the global
idiopathic pulmonary fibrosis treatment market and profiled in this report
include Aeolus Pharmaceuticals, Baxter International, Biogen, Inc., Boehringer
Ingelheim, F. Hoffmann-La Roche, FibroGen, Inc., Gilead Sciences, Inventiva
Pharma, MediciNova, Inc., Merck &amp; Co. (Afferent Pharmaceuticals, Inc.),
Promedior, Inc., Prometheus Laboratories, Inc., and Shionogi &amp; Company.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l9 level1 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Treatment Type<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Pharmacological
Treatment - Drug (Brand)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l9 level3 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Pirfenidone
(Esbriet)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l9 level3 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Nintedanib (Ofev)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l9 level3 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Generic
Pirfenidone<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Non-pharmacological
Treatment<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l9 level3 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Oxygen Therapy<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l9 level3 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Pulmonary
Rehabilitation<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l9 level3 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Mechanical
Ventilation<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l9 level3 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Lung
Transplantation<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l9 level3 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Other
Non-Pharmacological Treatment<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l9 level1 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Patients (Disease
Severity) <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Mild<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Moderate<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Severe<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l9 level1 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Pipeline Analysis<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>AEOL-10150<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Lebrikizumab<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Tipelukast<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Tralokinumab<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>FG-3019<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Simtuzumab<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>BMS-986020<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>AF-219<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>SAR156597<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.10.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>BG00011<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.11.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>PRM-151<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.12.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>PBI-4050 <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l9 level1 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Geography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>North America
(U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Latin America
(Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Asia Pacific
(Japan, China, India, Rest of APAC<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rest of the World<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l9 level1 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Aeolus
Pharmaceuticals<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Baxter
International<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Biogen, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Boehringer
Ingelheim<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>F. Hoffmann-La
Roche<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>FibroGen, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Gilead Sciences<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Inventiva Pharma<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>MediciNova, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.10.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Merck &amp; Co.
(Afferent Pharmaceuticals, Inc.)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.11.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Promedior, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.12.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Prometheus
Laboratories, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l9 level2 lfo21'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.13.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Shionogi &amp;
Company<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'>To request Table of Contents and
Sample Pages of this report visit:</span><span lang=EN-US style='font-size:
10.0pt;line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/idiopathic-pulmonary-fibrosis-treatment-market/"><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi'>https://www.ihealthcareanalyst.com/report/idiopathic-pulmonary-fibrosis-treatment-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-size:11.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>About Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst,
Inc. is a global healthcare market research and consulting company providing
market analysis, and competitive intelligence services to global clients. The
company publishes syndicate, custom and consulting grade healthcare reports
covering animal healthcare, biotechnology, clinical diagnostics, healthcare
informatics, healthcare services, medical devices, medical equipment, and
pharmaceuticals.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at clients specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>Contact Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><br
clear=all style='mso-special-character:line-break;page-break-before:always'>
</span><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'><o:p></o:p></span></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Acute Myeloid Leukemia (AML) Treatment Market US$ 1.55 Billion 2021<o:p></o:p></span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global acute myeloid leukemia treatment market expected to reach US$ 1.55
billion by 2023, growing at CAGR 14.8% over the forecast period, </span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>owing to
introduction of high-priced products and strong pipeline of upcoming
drugs.<span style='mso-spacerun:yes'> </span>During the forecast period, the
marketed drugs, pipeline drugs and others are predicted to contribute 55%, 35%,
and 10% market share of the global </span><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>acute
myeloid leukemia drugs market, respectively.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Acute myeloid leukemia (AML) is the
second most common type of leukemia diagnosed in adults and children. In 2017,
in the </span><span lang=EN-US><a
href="http://www.cancer.net/cancer-types/leukemia-acute-myeloid-aml/statistics"><span
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>United States</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>, an estimated
21,380 people will be diagnosed with AML. Most patients with newly diagnosed
AML are offered the combination of standard-dose cytarabine with an
anthracycline (daunorubicin or idarubicin) regimen, whereas those with
adverse-risk disease are offered allogeneic stem-cell transplant (SCT) in first
remission. The treatment of AML is divided into categories based on their
mechanisms of action: cytotoxic agents, small-molecule inhibitors, and targeted
therapies. These drug candidates range from cytotoxic chemotherapies, targeted
small-molecule inhibitors, and monoclonal antibodies. Currently available
hypomethylating agents azacitidine and decitabine are FDA-approved for use in
the United States. Tyrosine kinase inhibitors (TKIs) or FLT3 inhibitors, such
as midostaurin (Rydapt) were developed as targeted therapies that interferes
with aberrant tyrosine kinase activation in malignant cells. <o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Chemotherapy is the major form of
remission induction therapy for acute myeloid leukemia. Some of the other chemo
drugs that may be used to treat AML include: Cladribine (Leustatin),
Fludarabine (Fludara), Topotecan, Etoposide (VP-16), 6-thioguanine (6-TG),
Hydroxyurea (Hydrea), Corticosteroid drugs, such as prednisone or dexamethasone
(Decadron), Methotrexate (MTX), 6-mercaptopurine (6-MP), Azacitidine (Vidaza),
and Decitabine (Dacogen). Arsenic trioxide (Trisenox) and all-trans retinoic
acid (ATRA) are anti-cancer drugs that can be used alone or in combination with
chemotherapy for remission induction of a certain subtype of AML called
promyelocytic leukemia. A stem cell transplant or bone marrow transplant, may
be used for consolidation therapy. In 2017, the U.S. Food and Drug
Administration approved </span><span lang=EN-US><a
href="https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm555778.htm"><span
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Rydapt (midostaurin</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>) as a target
therapy for the treatment of adult patients with newly diagnosed acute myeloid
leukemia. There are several promising drug currently in the phase III pipeline include
</span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>chemotherapy drugs such as </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-size:11.0pt'>CC-486,
Guadecitabine (SGI-110), Liposomal cytarabine daunorubicin (Vyxeos),
Sapacitabine, Vosaroxin (Qinprezo), </span><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>fixed-combination
drugs such as </span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-size:
11.0pt'>AG-221, Ganetespib, Idasanutlin, Vadastuximab talirine (SGN-CD33A), </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>and kinase inhibitor</span><span lang=EN-US style='font-size:10.0pt;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'> candidates such as </span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'>Gedatolisib, Gilteritinib, Midostaurin,
Quizartinib, and Volasertib</span><span lang=EN-US style='font-size:10.0pt;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>. </span><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-size:11.0pt'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Visit
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/acute-myeloid-leukemia-drugs-market/"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Acute
Myeloid Leukemia Treatment Market</span></a></span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
by Drug Type - Hypomethylating Agents - Vidaza (Azacitidine), Dacogen
(Decitabine), Cytarabine-based Chemotherapy Drugs, Others; by Pipeline Analysis
(Phase III Drugs) - Chemotherapy Drugs, Vyxeos (Fixed-combination Drugs:
Daunorubicin and Cytarabine); Kinase Inhibitors (Midostaurin, Quizartinib) and Forecast
2015-2023. </span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global </span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>acute myeloid leukemia treatment </span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market research
report provides market size (Revenue USD Million 2015 to 2023), market share
analysis, growth trends and forecast (CAGR%, 2018 to 2023). The global </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>acute myeloid leukemia treatment </span><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>market research report is further
segmented by geography into North America (U.S., Canada), Latin America
(Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest
of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the
World. In addition, the global </span><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>acute myeloid
leukemia treatment </span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market
report provides the detailed market landscape (market drivers, restraints,
opportunities), market attractiveness analysis, and market profitability
analysis by key products and regions or countries.<span
style='mso-spacerun:yes'> </span>The report also tracks the major competitors
operating in the global market by company overview, financial snapshot, major
products, technologies, services offered and recent developments. </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>Major players operating in the global acute myeloid leukemia treatment
market and profiled in this report include Astellas Pharma, Astex
Pharmaceuticals, Bayer, Boehringer Ingelheim, Celgene (AgiosCelgene), Cyclacel
Pharmaceuticals, Daiichi Sankyo, Jazz Pharmaceuticals, Novartis, Onyx Pharma,
Otsuka Pharmaceuticals, Pfizer, Roche, Seattle Genetics, Sunesis
Pharmaceuticals, and Synta Pharmaceuticals.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l6 level1 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Drug Type<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l6 level2 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Hypomethylating
Agents<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l6 level3 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Vidaza
(Azacitidine)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l6 level3 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Dacogen
(Decitabine)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l6 level2 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Cytarabine-based
Chemotherapy Drugs<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l6 level2 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Others<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l6 level1 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Pipeline Analysis
(Phase III Drugs)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l6 level2 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Chemotherapy
Drugs<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l6 level2 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Vyxeos
(Fixed-combination Drugs: Daunorubicin and Cytarabine)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l6 level2 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Kinase Inhibitors<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l6 level3 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Midostaurin<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l6 level3 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Quizartinib<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l6 level1 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Geography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l6 level2 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>North America
(U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l6 level2 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Latin America
(Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l6 level2 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l6 level2 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Asia Pacific
(Japan, China, India, Rest of APAC<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l6 level2 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rest of the World<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l6 level1 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l6 level2 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Astellas Pharma <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l6 level2 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Astex
Pharmaceuticals <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l6 level2 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Bayer<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l6 level2 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Boehringer
Ingelheim <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l6 level2 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Celgene
(AgiosCelgene)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l6 level2 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Cyclacel
Pharmaceuticals <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l6 level2 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Daiichi Sankyo <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l6 level2 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Jazz
Pharmaceuticals<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l6 level2 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Novartis <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l6 level2 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.10.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Onyx Pharma<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l6 level2 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.11.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Otsuka
Pharmaceuticals<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l6 level2 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.12.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Pfizer <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l6 level2 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.13.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Roche<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l6 level2 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.14.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Seattle Genetics <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l6 level2 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.15.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Sunesis
Pharmaceuticals <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;mso-add-space:auto;
text-indent:-.3in;mso-list:l6 level2 lfo20'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.16.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Synta
Pharmaceuticals <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'>To request Table of Contents and
Sample Pages of this report visit:</span><span lang=EN-US style='font-size:
10.0pt;line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/acute-myeloid-leukemia-drugs-market/"><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/report/acute-myeloid-leukemia-drugs-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-size:11.0pt;line-height:107%'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>About Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst,
Inc. is a global healthcare market research and consulting company providing
market analysis, and competitive intelligence services to global clients. The
company publishes syndicate, custom and consulting grade healthcare reports
covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at clients specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>Contact Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com<o:p></o:p></span></p>

<b style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=all style='mso-special-character:line-break;
page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>U.S.
Therapeutic Interventional Cardiology Devices Market US$ 2.64 Billion by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
U.S. therapeutic interventional cardiology devices market expected to reach US$
2.64 billion by 2023, growing at CAGR 0.2% over the forecast period. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>For more details on U.S. </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>Therapeutic Interventional Cardiology Devices Market by Devices
Type (Coronary Stent Systems, Percutaneous Transluminal Coronary Angioplasty
Devices, Coronary Atherectomy Systems - Laser Atherectomy Systems, Mechanical
Atherectomy Systems, Transcatheter Septal Defect Repair Devices, Coronary
Thrombectomy Systems) and Forecast 2015-2023, contact us at </span><span
lang=EN-US><a href="https://www.ihealthcareanalyst.com/contact/"><span
style='font-size:10.0pt'>https://www.ihealthcareanalyst.com/contact/</span></a></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><br>
The global </span><span lang=EN-US style='font-size:10.0pt;line-height:107%;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>U.S. therapeutic
interventional cardiology devices </span><span lang=EN-US style='font-size:
10.0pt;line-height:107%;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>market research report provides market
size (Revenue USD Million 2015 to 2023), procedure volumes, market share
analysis, growth trends and forecast (CAGR%, 2018 to 2023). In addition, the </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>U.S. therapeutic interventional cardiology
devices </span><span lang=EN-US style='font-size:10.0pt;line-height:107%;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>market report provides the detailed market
landscape (market drivers, restraints, opportunities), market attractiveness
analysis, and market profitability analysis by key products and regions or
countries.<span style='mso-spacerun:yes'> </span>The report also tracks the
major competitors operating in the global market by company overview, financial
snapshot, major products, technologies, services offered and recent
developments.</span><span lang=EN-US style='font-size:10.0pt;line-height:107%;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Major
players operating in the global therapeutic interventional cardiology devices market
and profiled in this report include Abbott Laboratories, Inc., B. Braun
Melsungen AG, Bayer AG, Boston Scientific Corporation, BVM Medical Ltd.,
Cardiovascular Systems Inc., Cook Medical, Inc., C.R. Bard, Inc., Edwards
Lifesciences, Getinge Group, iVascular, Johnson &amp; Johnson (Cordis
Corporation/ Cardinal Health, Inc.), Kyoto Medical Planning Corporation Ltd.,
Lepu Medical Technology, Medtronic, Inc., Merit Medical Systems, Inc., Siemens
AG, Smiths Medical, Spectranetics Corp., Terumo Corporation, Vascular
Solutions, Inc., and W. L. Gore &amp; Associates.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l2 level1 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Device Type<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Coronary Stent
Systems<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Percutaneous
Transluminal Coronary Angioplasty (PTCA) Devices<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Coronary
Atherectomy Systems<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l2 level3 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Laser Atherectomy
Systems<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l2 level3 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Mechanical
Atherectomy Systems<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Transcatheter
Septal Defect Repair Devices<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Coronary
Thrombectomy Systems<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l2 level1 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Abbott
Laboratories, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>B. Braun
Melsungen AG<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Bayer AG<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Boston Scientific
Corporation<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>BVM Medical Ltd.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Cardiovascular
Systems Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Cook Medical,
Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>C.R. Bard, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Edwards
Lifesciences<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.10.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Getinge Group<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.11.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>iVascular<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.12.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Johnson &amp;
Johnson (Cordis Corporation/ Cardinal Health, Inc.)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.13.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Kyoto Medical
Planning Corporation Ltd.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.14.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Lepu Medical
Technology<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.15.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Medtronic, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.16.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Merit Medical
Systems, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.17.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Siemens AG<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.18.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Smiths Medical<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.19.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Spectranetics
Corp.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.20.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Terumo
Corporation<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.21.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Vascular
Solutions, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.55in;mso-add-space:auto;text-indent:-.3in;
line-height:107%;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>2.22.<span
style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>W. L. Gore &amp; Associates<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'>To request Table of Contents and
Sample Pages of this report, contact us:</span><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'> <span style='mso-spacerun:yes'></span></span><span
lang=EN-US><a href="https://www.ihealthcareanalyst.com/contact/"><span
style='font-size:10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/contact/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>About Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst,
Inc. is a global healthcare market research and consulting company providing
market analysis, and competitive intelligence services to global clients. The
company publishes syndicate, custom and consulting grade healthcare reports
covering animal healthcare, biotechnology, clinical diagnostics, healthcare
informatics, healthcare services, medical devices, medical equipment, and
pharmaceuticals.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at clients specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>Contact Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com<o:p></o:p></span></p>

<b style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=all style='mso-special-character:line-break;
page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Inhalation Drug Delivery Devices Market US$ 15.39 Billion by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global inhalation drug delivery devices market expected to reach US$ 15.3
billion by 2023, growing at CAGR 1.2% over the forecast period, </span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>owing to rising
prevalence of asthma, cystic fibrosis, and chronic obstructive pulmonary
disease worldwide</span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>. North America accounted for the
highest 54.8% share, followed by Europe 12.8% share of the global market. The key
driving factors for growth include generic erosion, increasing incidence of
pulmonary diseases and an increasing awareness of the inherent benefits offered
by introduction of novel products.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Respiratory conditions such as asthma,
chronic obstructive pulmonary, and emphysema disease are classical therapeutic
areas of the pulmonary sector. Asthma and chronic obstructive pulmonary disease
(COPD) represent the leading chronic respiratory diseases in the world, owing
to their high prevalence and high burden on the health system. Asthma
prevalence is still increasing in both developed and developing countries, for
different reasons. While in developed countries the increase in asthma
prevalence is mainly related to their lifestyle (exposure to indoor allergens,
low levels of exercise, diets that are poor in antioxidants and obesity), in
developing countries the increased prevalence is mainly related to the air
pollution and high rates of smoking. According to </span><span lang=EN-US><a
href="http://www.globalasthmareport.org/burden/burden.php"><span
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>global asthma report</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'> as many as 334
million people have asthma, and that the burden of disability is high. According
to </span><span lang=EN-US><a
href="http://www.who.int/respiratory/copd/burden/en/"><span style='font-size:
10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>WHO</span></a></span><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'> estimates, 65 million people have
moderate to severe chronic obstructive pulmonary disease (COPD). Currently, an
estimated 300 million people worldwide have asthma and up to 10% of adults
older than 40 years of age may have COPD, with perhaps millions remaining
undiagnosed.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global asthma and chronic obstructive pulmonary disease (COPD) drugs market
expected to reach US$ 57.5 billion by 2023, growing at CAGR 5.1% over the forecast
period, whereas the global </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/inhalation-nasal-spray-generic-drugs-market/"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>inhalation
and nasal spray generic drugs market</span></a></span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
expected to reach US$ 39 billion by 2023, growing at CAGR 6.6% over the forecast
period. </span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Inhalation drug delivery covers many
different types of devices: nebulizers, pressurized metered dose inhalers
(MDIs), breath-activated inhalers (including dry powder inhalers), and emerging
novel delivery systems. The number of inhaler devices available in the market
for inhaled therapies has increased significantly in the past decade. There are
two types of nebulizers, jet and ultrasonic, that differ in the force used to
generate the aerosol from the respective liquid. Some of the newest nebulizer
models in the market include breath-enhanced jet nebulizers such as the Pari LC</span><span
lang=EN-US> </span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>or
Respironics SideStream; breath-actuated nebulizers such as the AeroEclipse; vibrating
mesh nebulizers such as Pari eFlow rapid, Omron U22, AKITA2, APIXNEB. Pressurized
metered-dose inhalers (pMDIs) can be classified as breath-actuated or
coordination devices. Breath-actuated pMDIs, such as the Easibreathe, are
designed to address the problem of poor coordination between inhaler actuation
and patients breathe. Spacers and valved holding chambers (VHCs) are used with
pMDIs to increase the efficiency of aerosol delivery. Multi-dose liquid
inhalers (Respimat Soft Mist inhaler) combines the advantages of pMDIs and
nebulizers. Dry powder inhalers (DPIs) are portable devices that require
minimum patient coordination between breathing and actuation of the device to
deliver powder medications. Thermal vaporization aerosol devices such as
STACCATO uses heat to vaporize a thin film of the drug, which later condenses
in the lungs into droplets or particles depending on the nature of the drug. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Visit
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/inhalation-drug-delivery-devices-market/"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Inhalation
Drug Delivery Devices Market</span></a></span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
by Device Type (Asthma Devices, COPD Devices), and Technology (Dry Powder
Inhalers; Metered Dose Inhalers - Breath-actuated MDIs, Spacers for MDIs; Nebulizers)
and Forecast 2015-2023.<span style='mso-spacerun:yes'> </span></span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The global </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>inhalation drug delivery devices </span><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>market research report provides market
size (Revenue USD Million 2015 to 2023), market share analysis, growth trends
and forecast (CAGR%, 2018 to 2023). The global </span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>inhalation
drug delivery devices </span><span lang=EN-US style='font-size:10.0pt;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>market research report is further segmented by
geography into North America (U.S., Canada), Latin America (Brazil, Mexico,
Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia
Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In
addition, the global </span><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>inhalation drug
delivery devices </span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market
report provides the detailed market landscape (market drivers, restraints,
opportunities), market attractiveness analysis, and market profitability
analysis by key products and regions or countries.<span
style='mso-spacerun:yes'> </span>The report also tracks the major competitors
operating in the global market by company overview, financial snapshot, major
products, technologies, services offered and recent developments. </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>Major players operating in the global inhalation drug delivery
devices market and profiled in this report include Activaero GmbH, AstraZeneca
Plc, Boehringer Ingelheim GmbH, Chiesi Farmaceutici SpA, GlaxoSmithKline Plc, Koninklijke
Philips NV, Merck &amp; Co, Inc., Monaghan Medical Corporation, Novartis AG, OMRON
Healthcare Europe BV, PARI international, Pfizer, Inc., Roche Pharmaceuticals/F.
Hoffman-La Roche Ltd., SkyePharma PLC/Vectura Group Plc, Sunovion
Pharmaceuticals, Inc., and Teva Pharmaceutical Industries Ltd.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US><span style='mso-spacerun:yes'></span></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l5 level1 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Device Type<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l5 level2 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Asthma Devices<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l5 level2 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>COPD Devices<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l5 level1 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Technology<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l5 level2 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Dry Powder
Inhalers (DPIs)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l5 level3 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Metered Dose
Inhalers (MDIs)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l5 level3 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Breath-actuated
MDIs <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l5 level2 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Spacers for MDIs <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l5 level2 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Nebulizers<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l5 level1 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Geography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l5 level2 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>North America
(U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l5 level2 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Latin America
(Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l5 level2 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l5 level2 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Asia Pacific
(Japan, China, India, Rest of APAC<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l5 level2 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rest of the World<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l5 level1 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l5 level2 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Activaero GmbH<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l5 level2 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>AstraZeneca Plc<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l5 level2 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Boehringer
Ingelheim GmbH<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l5 level2 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Chiesi
Farmaceutici SpA<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l5 level2 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>GlaxoSmithKline
Plc<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l5 level2 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Koninklijke
Philips NV<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l5 level2 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Merck &amp; Co,
Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l5 level2 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Monaghan Medical
Corporation<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l5 level2 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Novartis AG<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l5 level2 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.10.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>OMRON Healthcare
Europe BV<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l5 level2 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.11.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>PARI
international<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l5 level2 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.12.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Pfizer, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l5 level2 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.13.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Roche Pharmaceuticals/F.
Hoffman-La Roche Ltd.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l5 level2 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.14.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>SkyePharma
PLC/Vectura Group Plc<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l5 level2 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.15.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Sunovion
Pharmaceuticals, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l5 level2 lfo17'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.16.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Teva
Pharmaceutical Industries Ltd. <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.25in;mso-add-space:auto;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'>To request Table of Contents and
Sample Pages of this report visit:</span><span lang=EN-US style='font-size:
10.0pt;line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/inhalation-drug-delivery-devices-market/"><span
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/inhalation-drug-delivery-devices-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'> <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>About Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst,
Inc. is a global healthcare market research and consulting company providing
market analysis, and competitive intelligence services to global clients. The
company publishes syndicate, custom and consulting grade healthcare reports
covering animal healthcare, biotechnology, clinical diagnostics, healthcare
informatics, healthcare services, medical devices, medical equipment, and
pharmaceuticals.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at clients specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>Contact Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com<o:p></o:p></span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
8.0pt;margin-left:0in;mso-add-space:auto;line-height:107%'><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br
clear=all style='mso-special-character:line-break;page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Biopsy Devices Market US$ 2.5 billion by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global </span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>biopsy
devices </span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>market expected to reach US$ 2.5
billion by 2023, growing at CAGR 5.6% over the forecast period, </span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>owing to increased
rates of cancer, higher preference for minimal invasive technologies and rising
geriatric population worldwide</span><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>According
to </span><span lang=EN-US><a
href="https://www.cancer.gov/about-cancer/understanding/statistics"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>National
Cancer Institute</span></a></span><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>, in 2016, an
estimated 1,685,210 new cases of cancer are diagnosed in the United States
alone. The most common cancers in 2016 are projected to be breast cancer, lung
and bronchus cancer, prostate cancer, colon and rectum cancer, bladder cancer,
melanoma of the skin, non-Hodgkin lymphoma, thyroid cancer, kidney and renal
pelvis cancer, leukemia, endometrial cancer, and pancreatic cancer. The US currently
holds the largest market share, but sales in the Asia Pacific and rest of the
world is expected to experience the largest amount of growth over the forecast
period. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Biopsies are performed in several
different ways. Some biopsies involve removing a small amount of tissue with a
needle while others involve surgically removing an entire lump, or nodule, that
is suspicious. </span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>For the majority of cancers, the only
way to make a definitive diagnosis is to perform a biopsy to collect cells for
closer examination. Biopsies are usually performed to identify and diagnose
cancerous tumor and to design a suitable treatment plan for the patients.
Biopsies are performed using image-guidance modalities such as X-ray imaging,
magnetic resonance imaging (MRI), computed tomography (CT) and ultrasound
imaging. Bone marrow biopsy is commonly used to diagnose both noncancerous and
cancerous diseases including blood cancers, such as leukemia, lymphoma and
multiple myeloma. Through the use of imaging methods such as X-ray or
ultrasound, a breast abnormality or breast lump can be detected, even in its
earliest stages. Breast biopsy devices can also be used for fibroadenomas (non-cancerous
breast lumps). Skin biopsies are for some basal cell or squamous cell skin
cancers. Examples of endoscopic biopsy procedures include cystoscopy,
bronchoscopy and colonoscopy. Needle biopsy procedures include fine-needle
aspiration, core needle biopsy, vacuum-assisted biopsy, and image-guided biopsy.
These procedures can be performed using manually guided systems as well as
robotic systems.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Browse </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/biopsy-devices-market/"><span
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Biopsy Devices Market</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'> by Product Types
(Needle-Based Guns -Vacuum-Assisted, Core Needle, Fine Needle Aspiration;
Biopsy Needles  Disposable, Reusable; Biopsy Forceps  Cold and Hot; Guidance
Systems  Manual and Robotic) and Forecast 2015-2023. The global biopsy devices
market report provides market size estimates (Revenue USD million - 2015 to
2023) for key market segments based on product type (needle-based guns
-vacuum-assisted, core needle, fine needle aspiration; biopsy needles 
disposable, reusable; biopsy forceps  cold and hot; guidance systems  manual
and robotic), and forecasts growth trends (CAGR% - 2018 to 2023). The global
biopsy devices market report also provides the detailed market landscape
(market drivers, restraints, opportunities), market attractiveness analysis and
profiles of major competitors in the global market including company overview,
financial snapshot, key products, technologies and services offered, and recent
developments. The global biopsy devices market research report is further
segmented by geography into North America (U.S., Canada), Latin America
(Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest
of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the
World. Major players operating in the global biopsy devices market and included
in this report are Angiotech, C R Bard Inc., CareFusion Corporation, Devicor
Medical Products Inc. and Hologic Inc. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l27 level1 lfo16'><![if !supportLists]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><span
style='mso-list:Ignore'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span></b><![endif]><b style='mso-bidi-font-weight:normal'><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>Device Type<o:p></o:p></span></b></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l27 level2 lfo16'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Needle-based
Biopsy Guns<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l27 level3 lfo16'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Vacuum-assisted
Biopsy (VA) Devices<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l27 level3 lfo16'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Core Needle
Biopsy (CN) Devices<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l27 level3 lfo16'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Fine Needle
Aspiration Biopsy (FNA) Devices<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l27 level2 lfo16'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Biopsy Needles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l27 level3 lfo16'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Disposable<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l27 level3 lfo16'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Reusable<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l27 level2 lfo16'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Biopsy Forceps<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l27 level3 lfo16'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Cold (General)
Biopsy Forceps<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l27 level3 lfo16'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Hot Biopsy
Forceps<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l27 level2 lfo16'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Biopsy Guidance
Systems<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l27 level3 lfo16'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Manual Systems<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l27 level3 lfo16'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Robotic Systems<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l27 level2 lfo16'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Others (Brushes,
Curettes, Punches)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l27 level1 lfo16'><![if !supportLists]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><span
style='mso-list:Ignore'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span></b><![endif]><b style='mso-bidi-font-weight:normal'><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>Geography (Region, Country)<o:p></o:p></span></b></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l27 level2 lfo16'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>North America
(U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l27 level2 lfo16'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Latin America
(Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l27 level2 lfo16'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l27 level2 lfo16'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Asia Pacific
(Japan, China, India, Rest of APAC)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l27 level2 lfo16'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rest of the World
<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l27 level1 lfo16'><![if !supportLists]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><span
style='mso-list:Ignore'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span></b><![endif]><b style='mso-bidi-font-weight:normal'><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>Company Profiles<o:p></o:p></span></b></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l27 level2 lfo16'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Angiotech<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l27 level2 lfo16'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>C. R. Bard, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l27 level2 lfo16'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Cardinal Health
Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l27 level2 lfo16'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Carefusion
Corporation<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l27 level2 lfo16'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Devicor Medical
Products, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l27 level2 lfo16'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>DTR Medical<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l27 level2 lfo16'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Hologic, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l27 level2 lfo16'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>INRAD, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l27 level2 lfo16'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>UK Biopsy<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'>To request Table of Contents and
Sample Pages of this report visit:</span><span lang=EN-US style='font-size:
10.0pt;line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/biopsy-devices-market/"><span
style='font-size:10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/report/biopsy-devices-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'> <o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>About Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst,
Inc. is a global healthcare market research and consulting company providing
market analysis, and competitive intelligence services to global clients. The
company publishes syndicate, custom and consulting grade healthcare reports
covering animal healthcare, biotechnology, clinical diagnostics, healthcare
informatics, healthcare services, medical devices, medical equipment, and
pharmaceuticals.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at clients specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>Contact Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'><o:p>&nbsp;</o:p></span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:#00B050;mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='mso-special-character:line-break;page-break-before:
always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:#00B050'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Stem Cell Therapy Market US$ 9.4 billion by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global stem cell therapy market expected to reach US$ 9.4 billion by 2023,
growing at CAGR 10.6% over the forecast period, </span><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>owing to advancement in human
development, genetic and chromosomal disorders, human reproduction, and new
disease therapies</span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Stem cells are being studied for a
number of medical applications such as neurodegeneration, brain and spinal cord
injury, generation of heart muscle cells, blood-cell formation, re-growing
teeth, cochlear hair cell regrowth, blindness and vision impairment, pancreatic
beta cells, transplantation, orthopedics, wound healing, Infertility, and
HIV/AIDS. Ancillary materials (AMs) are components or reagents used during the
manufacture of cell therapy products but are not intended to be part of the
final products. AMs for cell- and tissue-based therapies include serum
derivatives, antibiotics, cytokines, growth factors, culture media, antibodies,
and enzymes. Continued growth in the cell therapy industry and
commercialization of cell therapies through clinical trials has led to
increased awareness around the need for specialized and complex materials
utilized for stem cell therapies.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Although, bone marrow transplant is
the most widely used stem cell therapy, some therapies derived from umbilical
cord blood are in development for treating neurodegenerative diseases and
conditions such as diabetes, heart disease, and other conditions. Most of the stem
cell therapies involving osteobiologic products on the market and in
development utilize multipotent mesenchymal SCs (MSCs), such as Osteocel (NuVasive),
Trinity (Orthofix) and LiquidGen (Skye Orthbiologics). Several stem cell
therapy products are in the late-stage (phase III) pipeline including Ixmyelocel</span><span
lang=EN-US style='font-size:10.0pt;font-family:"MS Gothic";mso-bidi-font-family:
"MS Gothic"'>&#8209;</span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>T
(patient-specific autologous multicellular therapy) for treatment of critical
limb ischaemia, Off-the-shelf mesenchymal precursors for HSCT in
haematological malignancies, Prochymal (adult human mesenchymal stem cells) for
treating Crohns disease and graft versus host disease, Auto-CD34+ cells (adult
autologous CD34+ cells) for chronic myocardial ischaemia, Cx601
(adipose-derived allogeneic stem cell suspension) for complex perianal fistula
, and C</span><span lang=EN-US style='font-size:10.0pt;font-family:"MS Gothic";
mso-bidi-font-family:"MS Gothic"'>&#8209;</span><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Cure (BM-derived stem cells treated
with cardiopoietic cocktail) for treatment of congestive heart failure. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/stem-cells-market/"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>stem
cells market</span></a></span><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'> was
approximately 13 billion dollars in 2016, and from 2017, the expected annual
growth rate is 14.7%, which would expand the market to 29.6 billion dollars by
2023. The global stem cells market is segmented by type of stem cells (adult
stem cells, human embryonic stem cells, induced pluripotent stem cells, rat
neural stem cells), by stem cell technologies (stem cells isolation, culture,
cryopreservation, IVF), and by therapeutic applications (cardiology, diabetes,
hematology, neurology, oncology, and orthopedics diseases and disorders).<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Visit
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/stem-cell-therapy-market/"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Stem
Cell Therapy Market</span></a></span><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'> by Geography 
North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA),
Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan,
China, India, Rest of APAC), Rest of the World and Forecast 2015-2023. </span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The global </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>stem cell therapy </span><span lang=EN-US style='font-size:10.0pt;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>market research report provides market size
(Revenue USD Million 2015 to 2023), market share analysis, growth trends and
forecast (CAGR%, 2018 to 2023). In addition, the global </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>stem cell therapy </span><span lang=EN-US style='font-size:10.0pt;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>market report provides the detailed market
landscape (market drivers, restraints, opportunities), market attractiveness
analysis, and market profitability analysis by key products and regions or
countries.<span style='mso-spacerun:yes'> </span>The report also tracks the
major competitors operating in the global market by company overview, financial
snapshot, major products, technologies, services offered and recent
developments. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Major
players operating in the global stem cell therapy market and profiled in this
report include Aastrom Biosciences, Alliancells Bioscience Co. Ltd., AlloCure,
Inc., Anterogen Co. Ltd., Astellas Pharma (Ocata Therapeutics/Advanced Cell
Technology), Baxter Healthcare, Bioheart, BrainStorm Therapeutics, Caladrius
Biosciences, Cardio3 Sciences, Cellonis Biotechnology, Cytori Therapeutics,
FCB-Pharmicell Co. Ltd., Gamida Cell, Geron Corporation, LifeCell, Ixion
Biotechnology, Medipost Co. Ltd., Mesoblast, Neuralstem, Inc., NeuroGeneration,
Inc., NuVasive, Inc., Orthofix, Osiris Therapeutics, Pfizer, ReNeuron, Skye
Orthbiologics, LLC, Stem Cell Therapeutics, STEMCELL Technologies, StemCells,
Inc., Stemedica Cell Technologies, Inc., Stempeutics Research, TiGenix, and
ViaCyte.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l10 level1 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Geography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>North America
(U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Latin America
(Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Asia Pacific
(Japan, China, India, Rest of APAC)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rest of the World<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level1 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Aastrom Biosciences<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Alliancells
Bioscience Co. Ltd.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>AlloCure, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Anterogen Co.
Ltd.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Astellas Pharma
(Ocata Therapeutics/Advanced Cell Technology)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Baxter Healthcare<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Bioheart<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>BrainStorm
Therapeutics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Caladrius
Biosciences<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.10.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Cardio3 Sciences<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.11.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Cellonis
Biotechnology<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.12.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Cytori Therapeutics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.13.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>FCB-Pharmicell
Co. Ltd.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.14.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Gamida Cell<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.15.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Geron Corporation<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.16.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>LifeCell <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.17.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Ixion
Biotechnology <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.18.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Medipost Co. Ltd.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.19.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Mesoblast<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.20.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Neuralstem, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.21.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>NeuroGeneration,
Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.22.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>NuVasive, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.23.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Orthofix<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.24.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Osiris
Therapeutics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.25.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Pfizer<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.26.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>ReNeuron<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.27.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Skye
Orthbiologics, LLC<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.28.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Stem Cell Therapeutics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.29.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>STEMCELL
Technologies<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.30.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>StemCells, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.31.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Stemedica Cell
Technologies, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.32.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Stempeutics
Research<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.33.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>TiGenix<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;mso-add-space:auto;
text-indent:-.3in;mso-list:l10 level2 lfo14'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.34.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>ViaCyte<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.25in'><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'>To request Table of Contents and
Sample Pages of this report visit:</span><span lang=EN-US style='font-size:
10.0pt;line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/stem-cell-therapy-market/"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/stem-cell-therapy-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'> <o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>About Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst,
Inc. is a global healthcare market research and consulting company providing
market analysis, and competitive intelligence services to global clients. The
company publishes syndicate, custom and consulting grade healthcare reports
covering animal healthcare, biotechnology, clinical diagnostics, healthcare
informatics, healthcare services, medical devices, medical equipment, and
pharmaceuticals.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at clients specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>Contact Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br
clear=all style='mso-special-character:line-break;page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Head and Neck Squamous Cell Carcinoma Drugs Market US$ 2.3 Billion by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global head and neck squamous cell carcinoma drugs market expected to reach US$
2.3 billion by 2023, growing at CAGR 23.6% over the forecast period, </span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>mainly due to
rising epidemic of oropharynx cancer associated with the human papillomavirus</span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US><a
href="http://www.cancer.net/cancer-types/head-and-neck-cancer/statistics"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Head
and neck cancer</span></a></span><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'> is common in
several regions of the world. The annual incidence of head and neck cancers
worldwide is more than 550,000 cases each year. About 90% of all head and neck
cancers are squamous cell carcinomas. HNSCC is the sixth leading cancer by
incidence worldwide. The primary risk factors associated with head and neck
cancer include tobacco use, alcohol consumption, human papillomavirus (HPV)
infection (for oropharyngeal cancer), and Epstein-Barr virus (EBV) infection
(for nasopharyngeal cancer). Head and neck cancer accounts for about 3% of all
cancers in the United States. In 2016, an estimated 63,030 people (46,290 men
and 16,740 women) have developed head and neck cancer, whereas in 2017, an
estimated 129,800 patients will be diagnosed with SCCHN in the United States,
five major European markets and Japan.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Treatment
options include single-agent therapy and combination regimens using either
conventional cytotoxic chemotherapy and/or molecularly targeted agents combined
with best supportive care. Checkpoint inhibitor immunotherapy is an option for
patients with progressive disease after their initial chemotherapy regimen.
Historically, the most widely used agents include platinum compounds
(cisplatin, carboplatin), taxanes (docetaxel, paclitaxel, abraxane),
methotrexate, fluorouracil, and cetuximab. Pembrolizumab and nivolumab, checkpoint
inhibitors of programmed cell death protein 1 (PD-1) have also been approved.
Keytruda (pembrolizumab); Merck; For the treatment of head and neck squamous
cell cancer, Approved August 2016. On November 10, 2016, the U. S. Food and
Drug Administration approved nivolumab (OPDIVO Injection, Bristol-Myers Squibb
Company), for the treatment of patients with recurrent or metastatic squamous
cell carcinoma of the head and neck (SCCHN) with disease progression on or
after a platinum-based therapy.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The management of advanced head and
neck squamous cell carcinoma (HNSCC) consists of multiple-modality therapy with
surgery, radiation, and chemotherapy. Palliative radiation therapy is
beneficial for treating symptomatic metastatic sites. Selective drugs have been
developed that target either the extracellular ligand-binding region of the
EGFR (including a number of monoclonal antibodies, immunotoxins, and
ligand-binding cytotoxic agents) or the intracellular tyrosine kinase region
(including various small-molecule inhibitors). Targeted therapies such as
cetuximab, panitumumab, zalutumumab, nimotuzumab, erlotinib, gefitinib and
lapatinib against the epidermal growth factor receptor (EGFR) are the most
promising molecular therapeutics for head and neck squamous cell carcinoma.
Drugs commonly used as single agents in the treatment include docetaxel,
paclitaxel, cetuximab, capecitabine, pemetrexed, and methotrexate. Two
checkpoint inhibitors or programmed cell death protein 1 (PD1) inhibitors,
Pembrolizumab (Keytruda), manufactured by Merck &amp; Co. and Nivolumab
(Opdivo), manufactured by Bristol-Myers Squibb received FDA accelerated
approval in 2016. New therapies include mTOR inhibitors, anti-angiogenic
agents, and IGF1R inhibitors.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Drugs
approved for head and neck cancer include Abitrexate (Methotrexate), Blenoxane
(Bleomycin), Bleomycin, Cetuximab, Docetaxel, Erbitux (Cetuximab), Folex
(Methotrexate), Folex PFS (Methotrexate), Hydrea (Hydroxyurea), Hydroxyurea,
Keytruda (Pembrolizumab), Methotrexate, Methotrexate LPF (Methotrexate), Mexate
(Methotrexate), Mexate-AQ (Methotrexate), Nivolumab, Opdivo (Nivolumab),
Pembrolizumab, Taxotere (Docetaxel). Drug combinations used in head and neck
cancer include TPF - Docetaxel (Taxotere), Cisplatin (Platinol), and
Fluorouracil. <span style='color:#221E1F;mso-bidi-font-weight:bold'>Drugs in
the phase III clinical pipeline for SCCHN include Avelumab, Durvalumab,
Gilotrif/Giotrif (afatinib), Multikine (leukocyte interleukin), Tremelimumab,
and Yervoy (ipilimumab). The immune checkpoint inhibitors (durvalumab,
tremelimumab, ipilimumab and avelumab) are expected to obtain approval by 2023.<o:p></o:p></span></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Browse Head and Neck Squamous Cell
Carcinoma Drugs Market by Drug Class - Cytotoxic Agents, Epidermal Growth
Factor Receptor (EGFR) Inhibitors, Programmed Cell Death Protein 1 (PD1)
Inhibitors, PD1 Ligand 1 (PDL1) Inhibitors, Cytotoxic T Lymphocyte Antigen 4
(CTLA4) Inhibitors and Forecast 2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/head-neck-squamous-cell-carcinoma-drugs-market/"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/head-neck-squamous-cell-carcinoma-drugs-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'> <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global </span><span lang=EN-US style='font-size:10.0pt;line-height:107%;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>head and neck
squamous cell carcinoma drugs </span><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>market research report provides market
size (Revenue USD Million 2015 to 2023), market share analysis, growth trends
and forecast (CAGR%, 2018 to 2023). The global </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>head and neck squamous cell carcinoma drugs </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market
research report is further segmented by geography into North America (U.S.,
Canada), Europe (U.K., Germany, France, Italy, Spain), Latin America (Brazil,
Mexico, Rest of LA), Asia Pacific (Japan, China, India, Rest of APAC), and Rest
of the World. In addition, the global </span><span lang=EN-US style='font-size:
10.0pt;line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>head
and neck squamous cell carcinoma drugs </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market report
provides the detailed market landscape (market drivers, restraints,
opportunities), market attractiveness analysis, and market profitability
analysis by key products and regions or countries.<span
style='mso-spacerun:yes'> </span>The report also tracks the major competitors
operating in the global market by company overview, financial snapshot, major
products, technologies, services offered and recent developments. </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Major players operating in the global head and
neck squamous cell carcinoma drugs market and profiled in this report include
Advaxis, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, CEL-SCI, Five
Prime Therapeutics, Incyte, IRX Therapeutics, MacroGenics, Merck KGaA,
Novartis, Ono Pharmaceuticals (BMS), and Pfizer.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-align:justify;text-indent:-.25in;mso-list:l29 level1 lfo13'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Drug Class<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l29 level2 lfo13'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Cytotoxic Agents<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l29 level2 lfo13'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Epidermal Growth
Factor Receptor (EGFR) Inhibitors<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l29 level2 lfo13'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Programmed Cell
Death Protein 1 (PD1) Inhibitors<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l29 level2 lfo13'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>PD1 Ligand 1
(PDL1) Inhibitors<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l29 level2 lfo13'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Cytotoxic T
Lymphocyte Antigen 4 (CTLA4) Inhibitors<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l29 level1 lfo13'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Geography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l29 level2 lfo13'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>North America (U.S.,
Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l29 level2 lfo13'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l29 level2 lfo13'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Latin America
(Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l29 level2 lfo13'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Asia Pacific
(Japan, China, India, Rest of APAC)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l29 level2 lfo13'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rest of the World<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l29 level1 lfo13'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l29 level2 lfo13'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Advaxis<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l29 level2 lfo13'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>AstraZeneca<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l29 level2 lfo13'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Boehringer
Ingelheim<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l29 level2 lfo13'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Bristol-Myers Squibb<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l29 level2 lfo13'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>CEL-SCI<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l29 level2 lfo13'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Five Prime
Therapeutics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l29 level2 lfo13'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Incyte<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l29 level2 lfo13'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>IRX Therapeutics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l29 level2 lfo13'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>MacroGenics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l29 level2 lfo13'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.10.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Merck KGaA<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l29 level2 lfo13'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.11.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Novartis<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l29 level2 lfo13'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.12.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Ono
Pharmaceuticals (BMS)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;mso-add-space:auto;
text-indent:-.3in;mso-list:l29 level2 lfo13'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.13.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Pfizer<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'>To request Table of Contents and
Sample Pages of this report visit:</span><span lang=EN-US style='font-size:
10.0pt;line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/head-neck-squamous-cell-carcinoma-drugs-market/"><span
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/head-neck-squamous-cell-carcinoma-drugs-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'> <o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>About Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst,
Inc. is a global healthcare market research and consulting company providing
market analysis, and competitive intelligence services to global clients. The
company publishes syndicate, custom and consulting grade healthcare reports covering
animal healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>In addition to
multi-client studies, we offer creative consulting services and conduct proprietary
single-client assignments targeted at clients specific business objectives,
information needs, time frame and budget. Please contact us to receive a
proposal for a proprietary single-client study.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>Contact Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com<o:p></o:p></span></p>

<b style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:#00B050;mso-ansi-language:
EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br clear=all
style='mso-special-character:line-break;page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;
color:#00B050'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Rheumatoid Arthritis Drugs Market US$ 42.8 billion by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global rheumatoid arthritis drugs</span><span lang=EN-US style='font-size:10.0pt;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'> </span><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market
expected to reach US$ 42.8 billion by 2023, growing at CAGR 8.6% over the forecast
period, </span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>mainly
due to number of promising RA therapies are in development and drug approvals</span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Rheumatoid arthritis (RA) is a chronic
autoimmune condition of the connective tissue in synovial joints characterized
by inflammation that can lead to impaired movement and disability.
Small-molecule disease-modifying anti-rheumatic drugs (DMARDs) include methotrexate
(Trexall, Otrexup, Rasuvo), leflunomide (Arava), hydroxychloroquine (Plaquenil)
and sulfasalazine (Azulfidine). Biological drugs such as inhibitors of tumor
necrosis factor (TNF) blocks the activity of key inflammatory mediators that
give rise to the main characteristics of RA. These include infliximab
(Remicade), adalimumab (Humira), etanercept (Enbrel), golimumab (Simponi) and
certolizumab pegol (Cimzia). Several other biological response modifiers such
as checkpoint inhibitor, cytotoxic T lymphocyte-associated protein 4 (CTLA4)
inhibits the production of inflammatory cytokines such as TNF,
interferon-&#947; and interleukin-2 (IL-2). These include abatacept (Orencia),
Rituximab (MabThera), and Tocilizumab (Actemra/RoActemra). Janus Kinase (JAK)
inhibitors such as Tofacitinib (Xeljanz), Filgotinib and baricitinib are
recently approved by the US FDA, while a number of promising RA therapies are
in development. The RA therapies by category in clinical pipeline (phase II and
III) include JAK inhibitors (ABT-494, Baricitinib, Filgotinib), IL-6 inhibitors
or IL-6R antagonists (ALX 0061, Clazakizumab, Sarilumab, Sirukumab), and Others
(Denosumab, Mavrilimumab). <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Browse
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/rheumatoid-arthritis-drugs-market/"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rheumatoid
Arthritis Drugs Market</span></a></span><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'> by Drug Class -
Disease-Modifying Anti-Rheumatic Drugs (DMARDs), </span><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Tumor Necrosis Factor</span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'> (TNF) Inhibitors, </span><span lang=EN-US style='font-size:10.0pt;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Janus Kinase (JAK)</span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
Inhibitors, Other Biologics and Forecast 2015-2023. </span><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The global </span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>rheumatoid
arthritis drugs</span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
market research report provides market size (Revenue USD Million 2015 to 2023),
market share analysis, growth trends and forecast (CAGR%, 2018 to 2023). The
global </span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>rheumatoid arthritis drugs</span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'> market research
report is further segmented by geography into North America (U.S., Canada),
Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France,
Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC),
and Rest of the World. In addition, the global </span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>rheumatoid
arthritis drugs</span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
market report provides the detailed market landscape (market drivers,
restraints, opportunities), market attractiveness analysis, and market
profitability analysis by key products and regions or countries.<span
style='mso-spacerun:yes'> </span>The report also tracks the major competitors
operating in the global market by company overview, financial snapshot, major
products, technologies, services offered and recent developments. </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>Major players operating in the global rheumatoid arthritis drugs
market and profiled in this report include AbbVie, Ablynx, Alder
Biopharmaceuticals, Amgen, Bristol-Myers Squibb, Centocor, Daiichi Sankyo, Eli
Lilly, Galapagos NV, Genentech (Roche), Gilead, GlaxoSmithKline, Incyte Corp.,
Janssen Biotech, Johnson &amp; Johnson, MedImmune, Merck &amp; Co., Pfizer,
Regeneron, Sanofi, and UCB.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l25 level1 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Drug Class<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l25 level2 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Disease-Modifying
Anti-Rheumatic Drugs (DMARDs)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l25 level2 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Tumor Necrosis Factor</span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
(TNF) Inhibitors<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l25 level2 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Janus Kinase
(JAK) Inhibitors<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l25 level2 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Other Biologics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l25 level1 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Geography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l25 level2 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>North America
(U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l25 level2 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Latin America
(Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l25 level2 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Europe (U.K., Germany,
France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l25 level2 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Asia Pacific
(Japan, China, India, Rest of APAC)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l25 level2 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rest of the World<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l25 level1 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l25 level2 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>AbbVie <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l25 level2 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Ablynx <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l25 level2 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Alder
Biopharmaceuticals<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l25 level2 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Amgen<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l25 level2 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Bristol-Myers
Squibb<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l25 level2 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Centocor<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l25 level2 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Daiichi Sankyo<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l25 level2 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Eli Lilly<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l25 level2 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Galapagos NV<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l25 level2 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.10.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Genentech (Roche)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l25 level2 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.11.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Gilead<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l25 level2 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.12.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>GlaxoSmithKline<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l25 level2 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.13.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Incyte Corp. <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l25 level2 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.14.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Janssen Biotech<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l25 level2 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.15.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Johnson &amp;
Johnson<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l25 level2 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.16.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>MedImmune<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l25 level2 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.17.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Merck &amp; Co.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l25 level2 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.18.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Pfizer<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l25 level2 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.19.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Regeneron<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l25 level2 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.20.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Sanofi <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;mso-add-space:auto;
text-indent:-.3in;mso-list:l25 level2 lfo12'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.21.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>UCB<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.25in'><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'>To request Table of Contents and
Sample Pages of this report visit:</span><span lang=EN-US style='font-size:
10.0pt;line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/rheumatoid-arthritis-drugs-market/"><span
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/rheumatoid-arthritis-drugs-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:#00B050'> <o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>About Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst,
Inc. is a global healthcare market research and consulting company providing
market analysis, and competitive intelligence services to global clients. The
company publishes syndicate, custom and consulting grade healthcare reports
covering animal healthcare, biotechnology, clinical diagnostics, healthcare
informatics, healthcare services, medical devices, medical equipment, and
pharmaceuticals.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at clients specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>Contact Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com<o:p></o:p></span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:#00B050;mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='mso-special-character:line-break;page-break-before:
always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:#00B050'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Genomic Sequencing Technologies Market US$ 9.4 Billion by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global genomic sequencing technologies market expected to reach US$ 9.4 billion
by 2023, growing at CAGR 14% over the forecast period, </span><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>mainly due to high-throughput - next
generation sequencing technologies, and advances in personalized medicine</span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>In recent years, there has been an
increasing fragmentation of the genomic sequencing (GS) technologies market as
several competing manufacturers launched NGS platforms. The high-throughput -
next generation sequencing (HT-NGS) technologies are currently the hottest
topic in the field of human and animal genomics researches, which can produce
over 100 times more data compared to the most sophisticated capillary
sequencers based on the Sanger method. These technologies are revolutionizing
the analysis of chromatin immunoprecipitation coupled to DNA microarray
(ChIP-chip) or sequencing (ChIP-seq), RNA sequencing (RNA-seq), whole genome
genotyping, genome wide structural variation, de novo assembling and
re-assembling of genome, mutation detection and carrier screening, detection of
inherited disorders and complex human diseases. The transition of GS technologies
requires a radical overhaul of the existing pharmaceutical research and
development (R&amp;D) model, involving a more collaborative approach with shared
resources between drug developers during the early stages of target validation.
Over the years, innovations in sequencing protocols, molecular biology and
automation increased the technological capabilities of sequencing while
decreasing the cost. Today, newer pyrosequencing methods have drastically cut
the cost of sequencing and allowed the possibility of personalized genome
information. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The second generation HT-NGS platforms
can generate about five hundred million bases of raw sequence (Roche) to
billions of bases in a single run (Illumina, SOLiD). Third-generation
long-range DNA sequencing and mapping technologies are creating a renaissance
in high-quality genome sequencing. Third-generation technologies have been used
to produce highly accurate de novo assemblies of hundreds of microbial genomes,
and highly contiguous reconstructions of many dozens of plant and animal
genomes, enabling new insights into evolution and sequence diversity. They have
also been applied to resequencing analyses, to create detailed maps of
structural variations8 and phasing variants across large regions of human
chromosomes. The three commercially available third-generation DNA sequencing
technologies are Pacific Biosciences (PacBio) Single Molecule Real Time (SMRT)
sequencing, the Illumina Tru-seq Synthetic Long-Read technology and the Oxford
Nanopore Technologies sequencing platform. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Browse
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/genomic-sequencing-technologies-market/"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Genomic
Sequencing Technologies Market</span></a></span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
by Product Type (Sequencing Instruments, Reagents &amp; Consumables, Sequencing
Services), Application (Commercial, Healthcare, Research) and Forecast
2015-2023. </span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global </span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>genomic sequencing technologies </span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market research
report provides market size (Revenue USD Million 2015 to 2023), market share
analysis, growth trends and forecast (CAGR%, 2018 to 2023). The global </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>genomic sequencing technologies </span><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>market research report is further
segmented by geography into North America (U.S., Canada), Latin America
(Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest
of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the
World. In addition, the global </span><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>genomic
sequencing technologies </span><span lang=EN-US style='font-size:10.0pt;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>market report provides the detailed market
landscape (market drivers, restraints, opportunities), market attractiveness
analysis, and market profitability analysis by key products and regions or
countries.<span style='mso-spacerun:yes'> </span>The report also tracks the
major competitors operating in the global market by company overview, financial
snapshot, major products, technologies, services offered and recent
developments. </span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Major players operating in the global
genomic sequencing technologies market and profiled in this report include
Agilent Technologies, Genia, Illumina (BlueGnome/ Verinata), International
Business Machines Corp., Knome, Inc., Oxford Nanopore Technologies, Pacific
Biosciences, Raindance Technologies, Inc., Roche, Thermo Fisher Scientific
(Life Technologies/Navigenics), and Torrent Systems.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l16 level1 lfo11'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Product Type<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l16 level2 lfo11'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Sequencing
Instruments, reagents and consumables<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l16 level2 lfo11'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Sequencing
Services <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l16 level1 lfo11'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Application<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l16 level2 lfo11'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Commercial <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l16 level2 lfo11'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Healthcare <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l16 level2 lfo11'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Research <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l16 level1 lfo11'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Geography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l16 level2 lfo11'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>North America
(U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l16 level2 lfo11'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Latin America
(Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l16 level2 lfo11'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l16 level2 lfo11'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Asia Pacific
(Japan, China, India, Rest of APAC)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l16 level2 lfo11'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rest of the World<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l16 level1 lfo11'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l16 level2 lfo11'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Agilent
Technologies <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l16 level2 lfo11'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Genia<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l16 level2 lfo11'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Illumina
(BlueGnome/ Verinata)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l16 level2 lfo11'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>International
Business Machines Corp.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l16 level2 lfo11'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Knome, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l16 level2 lfo11'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Oxford Nanopore
Technologies<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l16 level2 lfo11'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Pacific
Biosciences<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l16 level2 lfo11'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Raindance
Technologies, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l16 level2 lfo11'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Roche<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l16 level2 lfo11'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.10.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Thermo Fisher
Scientific (Life Technologies/Navigenics)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l16 level2 lfo11'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.11.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Torrent Systems<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.25in;mso-add-space:auto;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'>To request Table of Contents and
Sample Pages of this report visit:</span><span lang=EN-US style='font-size:
10.0pt;line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/genomic-sequencing-technologies-market/"><span
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/genomic-sequencing-technologies-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'> <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>References:<o:p></o:p></span></b></p>

<p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.25in;mso-add-space:auto;text-align:justify;
text-indent:-.25in;line-height:107%;mso-list:l11 level1 lfo15'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/next-generation-sequencing-market/"><span
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Next-Generation Sequencing Market</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'> by NGS Platforms (Illumina  HiSeq Series,
HiSeq X Ten &amp; HiSeq X Five, MiSeq Series, NextSeq 500, Thermo Fisher 
SOLiD Series, Ion PGM, Ion Proton, Ion S5 &amp; Ion S5 XL, Pacific Biosciences
 PacBio RS II, Sequel System), NGS Data Analysis (ChIP Sequencing, De Novo
Sequencing, Exome Sequencing, Methyl Sequencing, RNA Sequencing, Targeted
Resequencing, Whole Genome Sequencing), Technology (Ion Semiconductor
Sequencing, Pyrosequencing, Sequencing by Ligation, Sequencing by Synthesis,
Single-Molecule Real-time Sequencing), Applications (Agriculture and Animal
Research, Biomarker Discovery, Diagnostics, Drug Discovery, Personalized Medicine),
and End Users (Academic and Research Institutes, Hospitals &amp; Clinics,
Pharmaceutical and Biotechnology Companies) and Forecast 2015-2023<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.25in;mso-add-space:auto;text-align:justify;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.25in;mso-add-space:auto;text-align:justify;
text-indent:-.25in;line-height:107%;mso-list:l11 level1 lfo15'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/cancer-genome-sequencing-market/"><span
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Cancer Genome Sequencing Market</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'> by Technology Types (Second and Third
Generation Sequencing), and Cancer Types (Breast Cancer, Prostate Cancer,
Colorectal Cancer) and Forecast 2015-2023<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>About Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst,
Inc. is a global healthcare market research and consulting company providing
market analysis, and competitive intelligence services to global clients. The
company publishes syndicate, custom and consulting grade healthcare reports
covering animal healthcare, biotechnology, clinical diagnostics, healthcare
informatics, healthcare services, medical devices, medical equipment, and
pharmaceuticals.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at clients specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>Contact Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com<o:p></o:p></span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
8.0pt;margin-left:.25in;mso-add-space:auto;text-align:justify;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:#92D050;mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='mso-special-character:line-break;page-break-before:
always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:#92D050'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Heart Valve Repair and Replacement Devices Market US$ 9.8 Billion by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global heart valve repair and replacement devices market expected to reach US$ 9.8
billion by 2023, growing at CAGR 9.9% over the forecast period, </span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>mainly due to new
device approvals, technological advancements, and rising geriatric population</span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>In the United States, about 106,000
heart valve operations are performed each year. Nearly all of these operations
are done to repair or replace the mitral or aortic valves. Heart valve repair
is a surgical technique used to fix defects in heart valves in valvular heart
diseases, and provides an alternative to valve replacement. Minimally invasive
heart valve surgery technique uses smaller incisions to repair or replace heart
valves, which also reduces the length of the hospital stay and the recovery
time. Transcatheter aortic valve implantation (TAVI) or transcatheter aortic
valve replacement (TAVR) is a minimally invasive procedure to repair a damaged
or diseased aortic valve. Percutaneous aortic valve replacement (PAVR), or TAVI
or TAVR involves replacement of the aortic valve of the heart through the blood
vessels. The most common valve surgical procedure is aortic valve replacement
for aortic stenosis, or narrowing of the aortic valve. More recently,
transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve
regurgitation therapy (TMVrep) has become a reality. In the recent years,
transcatheter heart-valve management procedures with TAVR and TMVrep systems
are gaining significant boost in terms of number of procedures performed
worldwide. Compared to invasive or surgical systems, the emerging
transcatheter-based, minimally invasive TAVR and TMVrep systems are accounted
for higher market share over the forecast period. The heart valve repair and
replacement devices market is driven by the growing numbers of valvular disease
resulting from rising obesity rates and growing prevalence of diabetes
worldwide. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Browse
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/heart-valve-repair-replacement-devices-market/"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Heart
Valve Repair and Replacement Devices Market</span></a></span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
by Device Type - Percutaneous Balloon Valvuloplasty (PBV), Heart Valve Surgery,
Transcatheter Devices - Transcatheter Aortic Valve Replacement (TAVR),
Transcatheter Mitral Valve Regurgitation Therapy (TMVrep) and Forecast
2015-2023. </span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global </span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>heart valve repair and replacement
devices </span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market
research report provides market size (Revenue USD Million 2015 to 2023), market
share analysis, growth trends and forecast (CAGR%, 2018 to 2023). The global </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>heart valve repair and replacement devices </span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market research
report is further segmented by geography into North America (U.S., Canada),
Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France,
Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC),
and Rest of the World. In addition, the global </span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>heart
valve repair and replacement devices </span><span lang=EN-US style='font-size:
10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>market report provides the detailed market
landscape (market drivers, restraints, opportunities), market attractiveness
analysis, and market profitability analysis by key products and regions or
countries.<span style='mso-spacerun:yes'> </span>The report also tracks the
major competitors operating in the global market by company overview, financial
snapshot, major products, technologies, services offered and recent
developments. </span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Major players operating in the global
heart valve repair and replacement devices market and profiled in this report
include Abbott Laboratories, B. Braun Melsungen, Boston Scientific Corporation,
Braile Biomedica, C.R. Bard, CarboMedics/LivaNova, Cardiac Dimension, CardiaMed,
Cardiosolutions, Cook Medical, CryoLife, Edwards Lifesciences, FOC Medical,
InterValve, JenaValve Technology, Labcor, Lanzhou Lanfei Medical Instrument,
Lepu Medical, Medtronic, NeoChord, ON-X Life Technologies, Osypka Medical,
Siemens Healthcare, Symetis, Toray Medical, TTK Healthcare, Valtech Cardio, and
Vascutek/Terumo Corporation.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l4 level1 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Device Type<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Percutaneous
Balloon Valvuloplasty (PBV)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Heart Valve
Surgery<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Transcatheter
Devices<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l4 level3 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Transcatheter
Aortic Valve Replacement (TAVR) <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l4 level3 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Transcatheter
Mitral Valve Regurgitation Therapy (TMVrep)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l4 level1 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Geography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>North America
(U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Latin America
(Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Asia Pacific
(Japan, China, India, Rest of APAC<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rest of the World<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l4 level1 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Abbott
Laboratories<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>B. Braun
Melsungen<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Boston Scientific
Corporation<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Braile Biomedica<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>C.R. Bard<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>CarboMedics
(LivaNova)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Cardiac Dimension<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>CardiaMed<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Cardiosolutions<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.10.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Cook Medical<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.11.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>CryoLife<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.12.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Edwards
Lifesciences<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.13.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>FOC Medical<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.14.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>InterValve<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.15.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>JenaValve
Technology<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.16.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Labcor<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.17.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Lanzhou Lanfei
Medical Instrument<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.18.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Lepu Medical<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.19.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Medtronic<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.20.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>NeoChord<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.21.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>ON-X Life
Technologies<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.22.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Osypka Medical<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.23.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Siemens
Healthcare<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.24.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Symetis<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.25.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Toray Medical<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.26.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>TTK Healthcare<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.27.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Valtech Cardio<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;mso-add-space:auto;
text-indent:-.3in;mso-list:l4 level2 lfo10'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.28.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Terumo
Corporation (Vascutek)<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.25in'><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'>To request Table of Contents and
Sample Pages of this report visit:</span><span lang=EN-US style='font-size:
10.0pt;line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/heart-valve-repair-replacement-devices-market/"><span
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/heart-valve-repair-replacement-devices-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'> <o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>About Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst,
Inc. is a global healthcare market research and consulting company providing
market analysis, and competitive intelligence services to global clients. The
company publishes syndicate, custom and consulting grade healthcare reports
covering animal healthcare, biotechnology, clinical diagnostics, healthcare
informatics, healthcare services, medical devices, medical equipment, and
pharmaceuticals.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at clients specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>Contact Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:#92D050;mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='mso-special-character:line-break;page-break-before:
always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:#92D050'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Interventional Cardiology Diagnostic and Therapeutic Devices Market Analysis
and Forecast 2015-2023<o:p></o:p></span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Diagnostic interventional cardiology
includes coronary angiogram to determine any blockage to arteries and
intravascular ultrasound (IVUS) to evaluate a hearts arteries.
Minimally-invasive heart surgery and treatment consists of cardiac
catheterization to diagnose or treat certain heart conditions, angioplasty and
stent placement (percutaneous coronary intervention or PCI) to restore healthy
blood flow to the heart, carotid angioplasty and stenting (CAS) to open
narrowed or blocked carotid arteries, angioplasty and stent placement to open
narrowed or blocked peripheral arteries, rotational atherectomy to remove
calcified lesions from arteries, percutaneous balloon valvuloplasty to open a
narrowed or blocked heart valve, transcatheter aortic valve replacement
(TAVR/TAVI)<span style='mso-spacerun:yes'> </span>to replace an aortic valve,
also as an alternative to open-heart surgery for high-risk patients, and adult
heart structural procedures to treat congenital heart defects such as aortic
valve stenosis, atrial septal defect, ventricular septal defect, or pulmonary
valve stenosis and other adult congenital heart defects. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Browse </span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Interventional
Cardiology Diagnostic and Therapeutic Devices Market by Diagnostic Devices
(Coronary Angiography, Intravascular Ultrasound, Guidewire-Based Physiologic, Intravascular
Stenosis Assessment, Optical Coherence Tomography, Intracardiac
Echocardiography), Therapeutic Devices Type (Coronary Stent Systems,
Percutaneous Transluminal Coronary Angioplasty Devices, Coronary Atherectomy
Systems - Laser Atherectomy Systems, Mechanical Atherectomy Systems, Transcatheter
Septal Defect Repair Devices, Coronary Thrombectomy Systems) and Forecast
2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/interventional-cardiology-diagnostic-therapeutic-devices-market/"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/interventional-cardiology-diagnostic-therapeutic-devices-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'> <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global </span><span lang=EN-US style='font-size:10.0pt;line-height:107%;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>interventional
cardiology diagnostic and therapeutic devices </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market research
report provides market size (Revenue USD Million 2015 to 2023), procedure
volumes, market share analysis, growth trends and forecast (CAGR%, 2018 to 2023).
The global </span><span lang=EN-US style='font-size:10.0pt;line-height:107%;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>interventional
cardiology diagnostic and therapeutic devices </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market research
report is further segmented by geography into North America (U.S., Canada),
Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France,
Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC),
and Rest of the World. In addition, the global </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>interventional cardiology diagnostic and therapeutic
devices </span><span lang=EN-US style='font-size:10.0pt;line-height:107%;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>market report provides the detailed market
landscape (market drivers, restraints, opportunities), market attractiveness
analysis, and market profitability analysis by key products and regions or
countries.<span style='mso-spacerun:yes'> </span>The report also tracks the
major competitors operating in the global market by company overview, financial
snapshot, major products, technologies, services offered and recent
developments.</span><span lang=EN-US style='font-size:10.0pt;line-height:107%;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Major
players operating in the global interventional cardiology diagnostic and
therapeutic devices market and profiled in this report include Abbott
Laboratories, Inc., B. Braun Melsungen AG, Bayer AG, Boston Scientific
Corporation, BVM Medical Ltd., Cardiovascular Systems Inc., Cook Medical, Inc.,
C.R. Bard, Inc., Edwards Lifesciences, Getinge Group, iVascular, Johnson &amp;
Johnson (Cordis Corporation/ Cardinal Health, Inc.), Kyoto Medical Planning
Corporation Ltd., Lepu Medical Technology, Medtronic, Inc., Merit Medical
Systems, Inc., Siemens AG, Smiths Medical, Spectranetics Corp., Terumo
Corporation, Vascular Solutions, Inc., and W. L. Gore &amp; Associates.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l2 level1 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Diagnostic
Devices<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Coronary
Angiography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Intravascular
Ultrasound<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Guidewire-Based
Physiologic<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Intravascular
Stenosis Assessment<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Optical Coherence
Tomography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Intracardiac
Echocardiography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l2 level1 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Therapeutic Devices<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Coronary Stent
Systems<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Percutaneous
Transluminal Coronary Angioplasty (PTCA) Devices<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Coronary
Atherectomy Systems<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l2 level3 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Laser Atherectomy
Systems<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l2 level3 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Mechanical
Atherectomy Systems<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Transcatheter
Septal Defect Repair Devices<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Coronary
Thrombectomy Systems<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l2 level1 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Geography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>North America
(U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Latin America
(Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Asia Pacific
(Japan, China, India, Rest of APAC<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rest of the World<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l2 level1 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Abbott
Laboratories, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>B. Braun
Melsungen AG<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Bayer AG<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Boston Scientific
Corporation<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>BVM Medical Ltd.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Cardiovascular
Systems Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Cook Medical,
Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>C.R. Bard, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Edwards
Lifesciences<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.10.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Getinge Group<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.11.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>iVascular<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.12.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Johnson &amp;
Johnson (Cordis Corporation/ Cardinal Health, Inc.)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.13.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Kyoto Medical Planning
Corporation Ltd.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.14.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Lepu Medical
Technology<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.15.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Medtronic, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.16.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Merit Medical
Systems, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.17.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Siemens AG<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.18.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Smiths Medical<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.19.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Spectranetics
Corp.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.20.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Terumo
Corporation<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.21.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Vascular
Solutions, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.55in;mso-add-space:auto;text-indent:-.3in;
line-height:107%;mso-list:l2 level2 lfo9'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-list:Ignore'>6.22.<span
style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>W. L. Gore &amp; Associates<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'>To request Table of Contents and
Sample Pages of this report visit:</span><span lang=EN-US style='font-size:
10.0pt;line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/interventional-cardiology-diagnostic-therapeutic-devices-market/"><span
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/interventional-cardiology-diagnostic-therapeutic-devices-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'> <o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>About Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst,
Inc. is a global healthcare market research and consulting company providing
market analysis, and competitive intelligence services to global clients. The
company publishes syndicate, custom and consulting grade healthcare reports covering
animal healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>In addition to
multi-client studies, we offer creative consulting services and conduct proprietary
single-client assignments targeted at clients specific business objectives,
information needs, time frame and budget. Please contact us to receive a
proposal for a proprietary single-client study.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>Contact Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br
clear=all style='mso-special-character:line-break;page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Colorectal Cancer Drugs Market US$ 7.2 Billion by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global colorectal cancer drugs market expected to reach US$ 7.2 billion by 2023,
growing at CAGR 2.3% over the forecast period, </span><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>mainly due to colorectal polyps
screening and improved treatment over the last few decades</span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Colorectal cancer (CRC) is a significant
challenge to the healthcare system as one of the leading forms of cancer around
the world the third most frequently diagnosed malignancy, after lung and breast
cancer. According to </span><span lang=EN-US><a
href="https://www.cancer.org/research/cancer-facts-statistics/colorectal-cancer-facts-figures.html"><span
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>American Cancer Society</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'> (2017), in the
US, an estimated 135,430 people will be diagnosed with colorectal cancer. The
American Cancer Societys estimates number of 95,520 new cases of colon cancer
and 39,910 new cases of rectal cancer in the United States for 2017. Several
lifestyle-related factors have been linked to colorectal cancer such as age, family
history of colorectal cancer or adenomatous polyps, being overweight or obese, physical
inactivity, certain types of diets, smoking, and heavy alcohol use. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The early stages of non-metastatic CRC
(stages I-III) can be treated with surgical resection followed by radiotherapy
and/or chemotherapy, whereas patients with mCRC generally receive systemic chemotherapy.
</span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>The drugs approved by USFDA for colon cancer
include Avastin (Bevacizumab), Bevacizumab, Camptosar (Irinotecan
Hydrochloride), Capecitabine, Cetuximab, Cyramza (Ramucirumab), Eloxatin
(Oxaliplatin), Erbitux (Cetuximab), 5-FU (Fluorouracil Injection), Fluorouracil
Injection, Irinotecan Hydrochloride, Leucovorin Calcium, Lonsurf (Trifluridine
and Tipiracil Hydrochloride), Nivolumab, Opdivo (Nivolumab), Oxaliplatin, Panitumumab,
Ramucirumab, Regorafenib, Stivarga (Regorafenib), Trifluridine and Tipiracil Hydrochloride,
Vectibix (Panitumumab), Wellcovorin (Leucovorin Calcium), Xeloda (Capecitabine),
Zaltrap (Ziv-Aflibercept), Ziv-Aflibercept. Drug combinations used and approved
by USFDA in colon cancer include Capox, Folfiri, Folfiri-Bevacizumab, Folfiri-Cetuximab,
Folfox, Fu-Lv, Xeliri, Xelox.<span style='mso-spacerun:yes'> </span><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Some
common chemotherapy drugs used for colorectal cancer include: 5-Fluorouracil
(5-FU), Capecitabine (Xeloda), Irinotecan (Camptosar), Oxaliplatin (Eloxatin),
Trifluridine and tipiracil (Lonsurf). </span><span lang=EN-US style='font-size:
10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Targeted therapy drugs for colorectal cancer
include anti- vascular endothelial growth factor (VEGF) therapies that stops
VEGF from forming new blood vessels and pass nutrients to tumor cells (also
known as, anti-angiogenesis therapy). These include</span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
</span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>monoclonal antibody
therapy such as, Bevacizumab (Avastin), Ramucirumab (Cyramza), Ziv-aflibercept
(Zaltrap), and Ramucirumab (Cyramza). Anti- epidermal growth factor receptor
(EGFR) therapies target EGFR protein that often appears in high amounts on the
surface of cancer cells and helps them grow. These include: Cetuximab
(Erbitux), and Panitumumab (Vectibix). </span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Regorafenib
(Stivarga) is a type of targeted therapy known as a kinase inhibitor, used to
treat advanced colorectal cancer. It blocks several kinase proteins that either
help tumor cells grow or help form new blood vessels to feed the tumor. Immune
checkpoint inhibitors such as Pembrolizumab (Keytruda) targets PD-1, a protein
on immune system cells that normally prevents cells from attacking other cells
in the body. Dabrafenib and trametinib, the first BRAF and MEK inhibitor
combination drugs are in clinical development. Similarly, Atezolizumab,
Binimetinib, Cobimetinib, Encorafenib, Fruquintinib, Lefitolimod, Masitinib,
Napabucasin, Nintedanib, Nivolumab, OncoVax, and Pembrolizumab are some of the
drugs that are in active phase II and phase III clinical development for
colorectal cancer. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Browse
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/colorectal-cancer-drugs-market/"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Colorectal
Cancer Drugs Market</span></a></span><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'> by Drug Class -
Vascular Endothelial Growth Factor (VEGF) Inhibitors, Epidermal Growth Factor
Receptor (EGFR) Inhibitors, Programmed Cell Death Protein 1/PD1 Ligand 1
(PD1/PDL1) Inhibitors, B-Raf Kinase (BRAF) or MEK Inhibitors -
Mitogen-activated Protein Kinase (MAPK) / Extracellular Signal-Regulated Kinase
(ERK), Tyrosine Kinase (TKI) Inhibitors, Immunomodulators, Chemotherapies and Forecast
2015-2023. </span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global </span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>colorectal cancer drugs </span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market research
report provides market size (Revenue USD Million 2015 to 2023), market share
analysis, growth trends and forecast (CAGR%, 2018 to 2023). The global </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>colorectal cancer drugs </span><span lang=EN-US style='font-size:
10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>market research report is further segmented by
geography into North America (U.S., Canada), Latin America (Brazil, Mexico,
Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia
Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In
addition, the global </span><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>colorectal cancer
drugs </span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market
report provides the detailed market landscape (market drivers, restraints,
opportunities), market attractiveness analysis, and market profitability
analysis by key products and regions or countries.<span
style='mso-spacerun:yes'> </span>The report also tracks the major competitors
operating in the global market by company overview, financial snapshot, major
products, technologies, services offered and recent developments. </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>Major players operating in the global colorectal cancer drugs
market and profiled in this report include AB Science, Amgen, Array BioPharma,
Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Elli Lilly, Genentech
(Roche), Hutchison MediPharma, Merck &amp; Co., Mologen, Regeneron, Sanofi,
Sumitomo Dainippon, Taiho Pharmaceutical, and Vaccinogen.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l13 level1 lfo8'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Drug Class<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l13 level2 lfo8'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Vascular
Endothelial Growth Factor (VEGF) Inhibitors<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l13 level2 lfo8'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Epidermal Growth
Factor Receptor (EGFR) Inhibitors<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l13 level2 lfo8'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Programmed Cell
Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l13 level2 lfo8'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>BRAF or MEK
Inhibitors (MAPK/ERK kinase)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l13 level2 lfo8'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Tyrosine Kinase
(TKI) Inhibitors <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l13 level2 lfo8'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Immunomodulators<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l13 level2 lfo8'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Chemotherapies<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l13 level1 lfo8'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Geography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l13 level2 lfo8'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>North America
(U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l13 level2 lfo8'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Latin America
(Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l13 level2 lfo8'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l13 level2 lfo8'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Asia Pacific
(Japan, China, India, Rest of APAC<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l13 level2 lfo8'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rest of the World<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l13 level1 lfo8'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l13 level2 lfo8'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>AB Science<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l13 level2 lfo8'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Amgen<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l13 level2 lfo8'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Array BioPharma<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l13 level2 lfo8'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Bayer<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l13 level2 lfo8'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Boehringer
Ingelheim<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l13 level2 lfo8'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Bristol-Myers
Squibb<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l13 level2 lfo8'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Elli Lilly<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l13 level2 lfo8'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Genentech (Roche)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l13 level2 lfo8'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Hutchison
MediPharma <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l13 level2 lfo8'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.10.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Merck &amp; Co.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l13 level2 lfo8'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.11.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Mologen<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l13 level2 lfo8'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.12.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Regeneron <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l13 level2 lfo8'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.13.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Sanofi<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l13 level2 lfo8'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.14.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Sumitomo
Dainippon<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l13 level2 lfo8'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.15.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Taiho
Pharmaceutical<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;mso-add-space:auto;
text-indent:-.3in;mso-list:l13 level2 lfo8'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.16.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Vaccinogen<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:#70AD47;mso-themecolor:accent6'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'>To request Table of Contents and
Sample Pages of this report visit:</span><span lang=EN-US style='font-size:
10.0pt;line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/colorectal-cancer-drugs-market/"><span
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/colorectal-cancer-drugs-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:#70AD47;mso-themecolor:accent6'> <o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>About Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst,
Inc. is a global healthcare market research and consulting company providing
market analysis, and competitive intelligence services to global clients. The
company publishes syndicate, custom and consulting grade healthcare reports
covering animal healthcare, biotechnology, clinical diagnostics, healthcare
informatics, healthcare services, medical devices, medical equipment, and
pharmaceuticals.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at clients specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>Contact Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com<o:p></o:p></span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:#70AD47;mso-themecolor:accent6;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=all style='mso-special-character:line-break;
page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:#70AD47;mso-themecolor:accent6'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Endocrine Disorders Testing Market US$ 12.2 Billion by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global endocrine disorders testing</span><span lang=EN-US style='font-size:
10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'> </span><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market
expected to reach US$ 12.2 billion by 2023, growing at CAGR 7.7% over the forecast
period, due to increasing incidences of endocrine disorders and rising
geriatric population worldwide. The major driving factors of endocrine
laboratory testing market includes increasing health care awareness rise of
endocrine disorders such as diabetes, thyroid disorders, and infertility, and
advancement of the technology. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
endocrine system uses a variety of hormones to regulate many different
functions in the body such as growth, metabolism, and reproduction. Endocrine disorders
can result in hormone overproduction (hyperfunction) or underproduction
(hypofunction) or dysfunction</span><span lang=EN-US> </span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>because
of the feedback mechanisms involved in the endocrine system. Every gland of the
endocrine system such as pineal, pituitary, and thyroid and secretory organs
such as hypothalamus and pancreas, releases specific hormones into bloodstream
to regulate the body functioning. Some hormones (cortisol, follicle-stimulating
hormone, luteinizing hormone) have a daily or monthly pattern of release. Other
hormones are generally present in very small quantities in the blood and are
released in specific situations, such as the release of epinephrine
(adrenaline) from the adrenal glands in response to stress. The endocrine disorder
tests help in detecting the deviations in the secretion of the hormones to
understand the disorders like infertility, menopause, thyroid dysfunction. Although,
there are many different types of endocrine disorders, diabetes is the most
common endocrine disorder diagnosed in the U.S. There are many diagnostic tests
including radiologic evaluations and biochemical procedures for measuring
circulating hormones to determine problems in the endocrine system. Maximum
number of diagnostic tests are performed in commercial laboratories followed by
hospital settings. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Browse
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/endocrine-laboratory-testing-market/"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Endocrine
Disorders Testing Market</span></a></span><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'> by Test
Type (Cortisol Test, Dehydroepiandrosterone Sulfate Test, Estradiol Test,
Follicle Stimulating Hormone Test, Human Chorionic Gonadotropin Test, Insulin
Test, Luteinizing Hormone Test, Progesterone Test, Prolactin Test, Testosterone
Test, Thyroid Stimulating Hormone Test, Others - Gastrin, Thymosin, Secretin),
Technology (Tandem Mass Spectrometry, Immunoassay Technologies, Monoclonal and
Polyclonal Antibody Technologies, Sensor Technologies, Clinical Chemistry
Technologies, Other Technologies), End Users (Hospitals, Commercial
Laboratories, Ambulatory Care Centers, Home-based Tests, Physician Offices,
Others) and Forecast 2015-2023. </span><span lang=EN-US style='font-size:10.0pt;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>The global </span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>endocrine
disorders testing</span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
market report provides market size (Revenue USD Million 2015 to 2023), market
share, trends and forecasts growth trends (CAGR%, 2018 to 2023). The global </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>endocrine disorders testing</span><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'> market research report is further
segmented by geography into North America (U.S., Canada), Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India,
Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the
World. The global </span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>endocrine disorders testing</span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'> market report
also provides the detailed market landscape (market drivers, restraints,
opportunities), market attractiveness analysis and also tracks the major
competitors operating in the market by company overview, financial snapshot,
key products, technologies and services offered, market share analysis and
recent trends in the global market. </span><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Major
players operating in the global endocrine disorders testing market and profiled
in this report include Abbott Laboratories, AB Sciex Pte. Ltd., Agilent
Technologies, Biomedical Diagnostics, bioMerieux SA, Bio-Rad Laboratories,
DiaSorin S.p.A., F. Hoffmann-La Roche Ltd., Laboratory Corporation of America
Holdings (LabCorp), Ortho-Clinical Diagnostics, Quest Diagnostics, Siemens
Healthcare GmbH (Siemens AG), Sysmex Corporation., and Thermo Fisher
Scientific, Inc. <o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l28 level1 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Test Type<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Cortisol Test<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Dehydroepiandrosterone
Sulfate (DHEAS) Test<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Estradiol (E2)
Test<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Follicle
Stimulating Hormone (FSH) Test<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Human Chorionic Gonadotropin
(hCG) Test<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Insulin Test<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Luteinizing
Hormone (LH) Test<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Progesterone (P4)
Test<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Prolactin Test<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.10.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Testosterone Test<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.11.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Thyroid
Stimulating Hormone (TSH) Test<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.12.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Others (Gastrin,
Thymosin, Secretin, etc.)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l28 level1 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Technology<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Clinical
Chemistry Technologies<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Immunoassay
Technologies<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Monoclonal and
Polyclonal Antibody Technologies<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Sensor
Technologies<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Tandem Mass
Spectrometry<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Other
Technologies<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l28 level1 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>End Users<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Ambulatory Care
Centers<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Commercial
Laboratories<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Home-based Tests<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Hospitals<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Physician Offices<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Others<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l28 level1 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Geography (Region,
Country)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>North America
(U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Latin America
(Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Asia Pacific
(Japan, China, India, Rest of APAC)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rest of the World
(Middle East &amp; Africa)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l28 level1 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Abbott
Laboratories<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>AB Sciex Pte.
Ltd.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Agilent
Technologies<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Biomedical
Diagnostics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>bioMerieux SA<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Bio-Rad
Laboratories<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>DiaSorin S.p.A.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>F. Hoffmann-La
Roche Ltd.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Laboratory
Corporation of America Holdings (LabCorp)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.10.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Ortho-Clinical
Diagnostics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.11.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Quest Diagnostics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.12.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Siemens
Healthcare GmbH (Siemens AG)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.13.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Sysmex
Corporation.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l28 level2 lfo7'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.14.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Thermo Fisher
Scientific, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'>To request Table of Contents and
Sample Pages of this report visit:</span><span lang=EN-US style='font-size:
10.0pt;line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/endocrine-laboratory-testing-market/"><span
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/endocrine-laboratory-testing-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'> <o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>About Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst,
Inc. is a global healthcare market research and consulting company providing
market analysis, and competitive intelligence services to global clients. The
company publishes syndicate, custom and consulting grade healthcare reports
covering animal healthcare, biotechnology, clinical diagnostics, healthcare
informatics, healthcare services, medical devices, medical equipment, and
pharmaceuticals.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at clients specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>Contact Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com<o:p></o:p></span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:#70AD47;mso-themecolor:accent6;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=all style='mso-special-character:line-break;
page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:#70AD47;mso-themecolor:accent6'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Antihypertensive Drugs Market US$ 23.1 Billion 2023<o:p></o:p></span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global antihypertensive drugs market expected to reach US$ 24.3 billion by 2023,
steadily declining at CAGR 2.5% over the forecast period, mainly due to patent
expiration of blockbuster drugs and increasing generic competition worldwide.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Hypertension is the leading
preventable cause of premature death worldwide. It is an important public
health challenge in both economically developing and developed countries. The
worldwide prevalence of hypertension is estimated to be about 40% in all
adults. This represented a 5.2% increase in the global prevalence between 2000
and 2010, where the prevalence of hypertension decreased by 2.6% in high-income
countries, but increased by 7.7% in low/middleincome countries due to numerous
and varied obstacles in healthcare delivery and limited resources. Measures are
required to prevent the development of hypertension and to improve awareness,
treatment and control of hypertension globally. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Antihypertensive drugs are used to
treat high blood pressure and its complications, such as stroke and myocardial
infarction. The most important and most widely used drugs include thiazide
diuretics, calcium channel blockers, ACE inhibitors, angiotensin II receptor
antagonists (ARBs), and beta blockers. These drugs can prevent heart failure,
kidney failure and acute stroke induced by hypertension and delay the
development of atherosclerosis by controlling the blood pressure. Although
clinical evidence shows calcium channel blockers and thiazide-type diuretics
are preferred first-line treatments, an ACE inhibitor is recommended by NICE in
the UK for those under 55 years old. Angiotensin II receptor blockers (ARBs)
comprises several leading brands such as Benicar (olmesartan medoxomil), Diovan
(valsartan) and Micardis (telmisartan). The others category includes
endothelin receptor antagonists such as Tracleer, Opsumit (bosentan and
macitentan) and Letairis (ambrisentan). All drug classes, except </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:#221E1F'>fixed-dose combinations (FDCs),</span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'> represent sales
of monotherapies. The antihypertensive drugs currently in the phase III
clinical development includes Amlodipine/celecoxib, Azilsartan/amlodipine/
hydrochlorothiazide, Bardoxolone methyl, Candesartan cilexetil/nifedipine,
Candesartan cilexetil/rosuvastatin, CS 3150, Esuberaprost,
Fimasartan/amlodipine, Fimasartan/hydrochlorothiazide, HCP 1401 and HCP1305,
Nitric oxide inhalation (INOpulse), Telmisartan/amlodipine/ chlorthalidone,
Telmisartan/chlorthalidone, alsartan/amlodipine/rosuvastatin, and
Valsartan/pitavastatin.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Browse
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/antihypertensive-drugs-market/"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Antihypertensive
Drugs Market</span></a></span><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'> by Drug Class -
Angiotensin II Receptor Blockers (ARBs), Angiotensin-converting Enzyme (ACE)
Inhibitors, &#946;-blockers, Calcium Channel Blockers (CCBs), Diuretics,
Fixed-dose Combinations (FDCs), Others and Forecast 2015-2023. </span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The global </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>antihypertensive drugs </span><span lang=EN-US style='font-size:
10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>market research report provides market size
(Revenue USD Million 2015 to 2023), market share analysis, growth trends and
forecast (CAGR%, 2018 to 2023). The global </span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>antihypertensive
drugs </span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market
research report is further segmented by geography into North America (U.S.,
Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany,
France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of
APAC), and Rest of the World. In addition, the global </span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>antihypertensive
drugs </span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market
report provides the detailed market landscape (market drivers, restraints,
opportunities), market attractiveness analysis, and market profitability
analysis by key products and regions or countries.<span
style='mso-spacerun:yes'> </span>The report also tracks the major competitors
operating in the global market by company overview, financial snapshot, major
products, technologies, services offered and recent developments. </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>Major players operating in the global antihypertensive drugs
market and profiled in this report include </span><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Actelion (Nippon Shinyaku), </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>Alvogen, Bayer, Bellerophon Therapeutics, </span><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Boehringer Ingelheim, </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>Boryung Pharmaceutical (Stendhal), CJ Healthcare, </span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Daiichi Sankyo,
Gilead, Eli Lilly</span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>, HanAll Biopharma (Yuhan), Hanmi
Pharmaceutical, JW Pharmaceutical, Kitov Pharmaceuticals, Kyowa Hakko Kirin,
Lung Biotechnology, Nippon Shinyaku, </span><span lang=EN-US style='font-size:
10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Novartis, </span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Pfizer,
Stendhal, Reata Pharmaceuticals (Kyowa Hakko Kirin), Takeda, </span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>United
Therapeutics, and </span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Yuhan.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l21 level1 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Drug Class<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Angiotensin II
Receptor Blockers (ARBs) <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Angiotensin-converting
Enzyme (ACE) Inhibitors <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>&#946;-blockers<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Calcium Channel
Blockers (CCBs)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Diuretics <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Fixed-dose
Combinations (FDCs)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Others <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l21 level1 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Geography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>North America
(U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Latin America
(Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Asia Pacific
(Japan, China, India, Rest of APAC<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>5.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rest of the World<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l21 level1 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Company Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Actelion <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Alvogen<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Bayer<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Bellerophon
Therapeutics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Boehringer Ingelheim<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Boryung
Pharmaceutical <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>CJ Healthcare<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Daiichi Sankyo<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Gilead<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.10.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Eli Lilly<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.11.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>HanAll Biopharma <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.12.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Hanmi
Pharmaceutical<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.13.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>JW Pharmaceutical<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.14.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Kitov
Pharmaceuticals<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.15.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Kyowa Hakko Kirin<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.16.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Lung
Biotechnology<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.17.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Nippon Shinyaku<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.18.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Novartis<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.19.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Pfizer<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.20.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Stendhal<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.21.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Reata
Pharmaceuticals <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.22.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Takeda<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.23.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>United Therapeutics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;mso-add-space:auto;
text-indent:-.3in;mso-list:l21 level2 lfo6'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>6.24.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Yuhan<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'>To request Table of Contents and
Sample Pages of this report visit:</span><span lang=EN-US style='font-size:
10.0pt;line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>
<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/antihypertensive-drugs-market/"><span
style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/antihypertensive-drugs-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'> <o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>About Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst,
Inc. is a global healthcare market research and consulting company providing
market analysis, and competitive intelligence services to global clients. The
company publishes syndicate, custom and consulting grade healthcare reports
covering animal healthcare, biotechnology, clinical diagnostics, healthcare
informatics, healthcare services, medical devices, medical equipment, and
pharmaceuticals.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>In addition to multi-client
studies, we offer creative consulting services and conduct proprietary
single-client assignments targeted at clients specific business objectives,
information needs, time frame and budget. Please contact us to receive a
proposal for a proprietary single-client study.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>Contact Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com<o:p></o:p></span></p>

<b style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=all style='mso-special-character:line-break;
page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify'><b style='mso-bidi-font-weight:
normal'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Global Transcatheter Arterial
Chemoembolization (TACE) Market USD 17.7 Billion by 2023 <o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;
color:#5B9BD5;mso-themecolor:accent1'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global transcatheter arterial chemoembolization (TACE) market to reach US$ 17.7
Billion by 2023, growing at 5.1% CAGR over the forecast period. Increase in
adoption of minimally invasive surgeries due to technological innovations and
worldwide increasing cancer prevalence is projected to drive the transcatheter
arterial chemoembolization market. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Hepatocellular
carcinomas (HCC) and renal cell carcinomas are one of the commonest
malignancies world-wide, largely due to the high prevalence of hepatitis B
infection in the developing world. Transcatheter arterial chemoembolization or
transarterial chemoembolization (TACE) is a minimally invasive procedure
performed in interventional radiology to restrict a tumors blood supply. Small
embolic particles coated with chemotherapeutic drugs are injected selectively
through a catheter into an artery directly supplying the tumor. These particles
both block the blood supply and induce cytotoxicity, attacking the tumor in
several ways. Transarterial chemoembolization is also increasingly being used
for patients on the transplant waiting list to prevent further tumor growth. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>North
America accounted for a major share of the market in 2016 due to gradually
increasing cases of HCC, increasing investment, novel drug delivery systems
development and presence of major market players in the region. Most of the
major players operating in the region have made a series of strategic
acquisitions leading to the increase in their market share. Increasing cancer
prevalence in the region is the one of the key factors contributing to the
growth of TACE market. The TACE market has been estimated based on HCC
prevalence and incidence in each country/region using the Barcelona Clinic
Liver cancer (BCLC) staging system and treatment strategy and Clinical Practice
Guidelines for the Management of Hepatocellular Carcinoma, proposed by the Japan
Society of Hepatology (JSH), 2012. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>To
request Table of Contents and Sample Pages of this report, contact us:<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/contact/"><span style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/contact/</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'> <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global transcatheter arterial chemoembolization (TACE) market provides market
size (revenue US$ million) and number of procedures for TACE, market size
(revenue US$ million) and volume (number of units) for micro catheter, micro
guidewire used in TACE procedures, market share analysis by key players, growth
trends and forecast (CAGR%, 2018 to 2023). The global transcatheter arterial
chemoembolization market research report is further segmented by geography into
North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest
of EU), Asia Pacific (Japan, China, South Korea, Rest of APAC), Latin America
(Brazil, Mexico, Rest of LA), and Rest of the World. The global transcatheter
arterial chemoembolization market report also provides the detailed market
landscape (market drivers, restraints, opportunities), market attractiveness
analysis and also tracks the major competitors operating in the market by
company overview, financial snapshot, key products, technologies and services
offered. Major players operating in the global embolization in interventional
oncology market and included in this report are Boston Scientific, BTG International,
Cook Medical, Covidien, Depuy Synthes, Merit Medical Systems, Inc., Sequent
Medical, Stryker, Surefire Medical, Inc., and Terumo Medical Corporation.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-align:justify;text-indent:-.25in;mso-list:l20 level1 lfo5'><![if !supportLists]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><span
style='mso-list:Ignore'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span></b><![endif]><b style='mso-bidi-font-weight:normal'><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>Transcatheter Arterial Chemoembolization<o:p></o:p></span></b></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Market size by
Geography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Number of
Procedures by Geography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-align:justify;text-indent:-.25in;mso-list:l20 level1 lfo5'><![if !supportLists]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><span
style='mso-list:Ignore'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span></b><![endif]><b style='mso-bidi-font-weight:normal'><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>Device Type<o:p></o:p></span></b></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Micro Catheter<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-align:justify;text-indent:-.35in;mso-list:l20 level3 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Market size by
Geography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-align:justify;text-indent:-.35in;mso-list:l20 level3 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Number of Units
Sold by Geography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Micro Guidewire<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-align:justify;text-indent:-.35in;mso-list:l20 level3 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Market size by
Geography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-align:justify;text-indent:-.35in;mso-list:l20 level3 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Number of Units
Sold by Geography<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-align:justify;text-indent:-.25in;mso-list:l20 level1 lfo5'><![if !supportLists]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><span
style='mso-list:Ignore'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span></b><![endif]><b style='mso-bidi-font-weight:normal'><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>Geography (Region, Country)<o:p></o:p></span></b></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>North America
(U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Latin America
(Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Asia Pacific
(Japan, China, South Korea, Rest of APAC)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Middle East &amp;
Africa<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-align:justify;text-indent:-.25in;mso-list:l20 level1 lfo5'><![if !supportLists]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><span
style='mso-list:Ignore'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span></b><![endif]><b style='mso-bidi-font-weight:normal'><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>Company Profiles<o:p></o:p></span></b></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Abbott
Laboratories, Inc., USA <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>ABK Biomedical,
Inc., Canada <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Asahi Intecc Co.,
Ltd., Japan <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>BioSphere
Medical, Inc., USA (Merit Medical Systems, Inc.) <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Blockade Medical,
USA (BALT International) <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Boston Scientific
Corporation <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Braile Biomedica,
Brazil <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>BTG International
<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Cook Medical,
Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.10.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Covidien plc
(Medtronic plc)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.11.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Depuy Synthes
(JnJ) <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.12.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Guerbet Group,
France <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.13.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Magle Life
Science, Sweden <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.14.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Medtronic, Inc.
(Covidien), USA <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.15.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Merit Medical
Systems, Inc. <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.16.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Penumbra, Inc.,
USA <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.17.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Pfizer, Inc., USA
<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.18.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>PharmaCept,
Germany <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.19.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Piolax Medical
Devices, Inc. (Piolax, Inc.)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.20.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Sequent Medical
(Terumo Corporation) <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.21.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Sirtex Medical
Limited, Australia<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.22.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>St. Jude Medical,
Inc., USA <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.23.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Stryker
Corporation<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.24.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Surefire Medical,
Inc. <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.25.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Terumo Medical
Corporation <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;mso-add-space:auto;
text-align:justify;text-indent:-.3in;mso-list:l20 level2 lfo5'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.26.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Vascular
Solutions, Inc., USA <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>To
request Table of Contents and Sample Pages of this report, contact us:<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/contact/"><span style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/contact/</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'> <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b style='mso-bidi-font-weight:
normal'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>About Us<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst,
Inc. is a global healthcare market research and consulting company providing
market analysis, and competitive intelligence services to global clients. The
company publishes syndicate, custom and consulting grade healthcare reports
covering animal healthcare, biotechnology, clinical diagnostics, healthcare
informatics, healthcare services, medical devices, medical equipment, and
pharmaceuticals.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>In
addition to multi-client studies, we offer creative consulting services and
conduct proprietary single-client assignments targeted at clients specific
business objectives, information needs, time frame and budget. Please contact
us to receive a proposal for a proprietary single-client study.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b style='mso-bidi-font-weight:
normal'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>Contact Us<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>iHealthcareAnalyst,
Inc.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>2109,
Mckelvey Hill Drive,<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Maryland
Heights, MO 63043<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>United
States<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Email:
sales@ihealthcareanalyst.com<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Website:
https://www.ihealthcareanalyst.com<o:p></o:p></span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:#5B9BD5;mso-themecolor:accent1;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=all style='mso-special-character:line-break;
page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:#5B9BD5;mso-themecolor:accent1'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Ovarian Cancer Drugs Market US$ 5.6 Billion by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global </span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>ovarian
cancer drugs </span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>market expected to reach US$ 5.6
billion by 2023, steadily growing at CAGR 19.1% over the forecast period,
mainly due to <span style='color:#211D1E'>continued uptake and expected launces
of the approved PARP inhibitors, owing to their impressive efficacy, long
treatment duration and the large number of treatment opportunities in the
first-line advanced setting. Although angiogenesis inhibitors accounted for the
majority of the 2016 market, this drug class is expected to capture a minority
market share in 2021.</span><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>In 2017, according to </span><span
lang=EN-US><a
href="https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html"><span
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>American Cancer Society</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'> estimates about 22,280
new cases of ovarian cancer will be diagnosed, whereas in 2016, an estimated
~20,000 patients were diagnosed with ovarian cancer in the United States alone.
In 2015, it was present in 1.2 million women and resulted in 161,100 deaths
worldwide. The risk of ovarian cancer increases in women with aged 55-64 years.
Ovarian cancer is the 8th most common cancer among women and ranks 5th in
cancer deaths among women, accounting for more deaths than any other cancer of
the female reproductive system. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The most common preliminary tests
include blood test (CA-125, OVA-1, Inhibin B and Inhibin A), transvaginal
ultrasound, CT scan or computerized tomography and biopsy. A diagnosis of
ovarian cancer is confirmed through a biopsy of tissue, usually removed during
surgery. The Pap test does not test for ovarian cancer; it screens for cervical
cancer. Treatment usually includes some combination of surgery, radiation
therapy, and chemotherapy. Chemotherapy in ovarian cancer typically consists of
platins, a group of platinum-based drugs, combined with non-platins. Common
therapies can include paclitaxel, cisplatin, topotecan, doxorubicin,
epirubicin, and gemcitabine. The vascular endothelial growth factor (VEGF)
inhibitor, bevacizumab (Avastin; Roche/ Genentech), is approved (excluding the
United States) as a first-line treatment in combination with standard
chemotherapy. In Europe and the United States, bevacizumab is also approved for
recurrent ovarian cancer. Currently, ovarian cancer drugs in active development
(clinical phase II and III pipeline) includes Acalabrutinib, Atezolizumab,
Avelumab, AZD1775, Cediranib, Epacadostat, Fosbretabulin, Gemogenovatucel-T,
Lurbinectedin, Micellular paclitaxel, Mirvetuximab soravtansine, Trametinib,
and Veliparib. <span style='mso-spacerun:yes'></span><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Browse
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/ovarian-cancer-drugs-market/"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Ovarian
Cancer Drugs Market</span></a></span><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'> by Drug Class
(Angiogenesis inhibitors, Poly (ADP Ribose) Polymerase Inhibitors, Programmed
Cell Death Protein 1 Ligand 1 Inhibitors), Pipeline Analysis by Target and
Development Stage and Forecast 2015-2023. </span><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The global ovarian cancer drugs market
segmentation is based on drug class (angiogenesis inhibitors, poly (ADP ribose)
polymerase inhibitors, programmed cell death protein 1 ligand 1 inhibitors),
and pipeline analysis by target and development stage. The global ovarian
cancer drugs market report provides market size (Revenue USD Million 2015 to
2023), market share, trends and forecasts growth trends (CAGR%, 2018 to 2023).
The global ovarian cancer drugs market research report is further segmented by
geography into North America (U.S., Canada), Latin America (Brazil, Mexico,
Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia
Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global
ovarian cancer drugs market report also provides the detailed market landscape
(market drivers, restraints, opportunities), market attractiveness analysis and
also tracks the major competitors operating in the market by company overview,
financial snapshot, key products, technologies and services offered, market
share analysis and recent trends in the global market. Major players operating
in the global ovarian cancer drugs market and profiled in this report include
AbbVie, AstraZeneca (Acerta Pharma), Boehringer Ingelheim GmbH, Five Prime
Therapeutics, Gradalis, Incyte Corporation, MacroGenics, Mateon Therapeutics,
Merck KGaA, Novartis, Novogen, Inc., Oasmia Pharmaceuticals, Pfizer, Inc.,
PharmaMar (Chugai), and Roche (Genentech).</span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.25in;
margin-bottom:.0001pt;text-indent:-.25in;mso-list:l15 level1 lfo4'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>Drug Class<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l15 level2 lfo4'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>Angiogenesis inhibitors<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l15 level2 lfo4'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>Poly (ADP Ribose)
Polymerase (PARP) Inhibitors<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l15 level2 lfo4'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>Programmed Cell Death
Protein 1 Ligand 1 (PDL1) Inhibitors<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l15 level2 lfo4'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>Pipeline Analysis by
Target and Development Stage<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'><o:p>&nbsp;</o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.25in;
margin-bottom:.0001pt;text-indent:-.25in;mso-list:l15 level1 lfo4'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>Geography (Region,
Country)<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l15 level2 lfo4'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>North America (U.S.,
Canada)<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l15 level2 lfo4'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>Europe (U.K., Germany,
France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l15 level2 lfo4'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>Asia Pacific (Japan,
China, India, Rest of APAC)<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l15 level2 lfo4'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>Latin America (Brazil,
Mexico, Rest of LA)<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l15 level2 lfo4'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>Rest of the World<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'><o:p>&nbsp;</o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.25in;
margin-bottom:.0001pt;text-indent:-.25in;mso-list:l15 level1 lfo4'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>Company Profiles<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l15 level2 lfo4'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>AbbVie<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l15 level2 lfo4'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>AstraZeneca (Acerta
Pharma)<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l15 level2 lfo4'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>Boehringer Ingelheim
GmbH<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l15 level2 lfo4'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>Five Prime
Therapeutics<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l15 level2 lfo4'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>Gradalis<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l15 level2 lfo4'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>3.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>Incyte Corporation<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l15 level2 lfo4'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>3.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>MacroGenics<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l15 level2 lfo4'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>3.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>Mateon Therapeutics<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l15 level2 lfo4'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>3.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>Merck KGaA<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l15 level2 lfo4'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>3.10.<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'>Novartis<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l15 level2 lfo4'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>3.11.<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'>Oasmia Pharmaceuticals<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l15 level2 lfo4'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>3.12.<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'>Pfizer, Inc.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l15 level2 lfo4'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>3.13.<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'>PharmaMar (Chugai)<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l15 level2 lfo4'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>3.14.<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'>Roche (Genentech)<o:p></o:p></span></p>

<p style='margin:0in;margin-bottom:.0001pt'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><o:p>&nbsp;</o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>To request Table of Contents and Sample Pages of this
report visit:</span><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin'> </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/ovarian-cancer-drugs-market/"><span
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/ovarian-cancer-drugs-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'> <span
style='color:black'><span style='mso-spacerun:yes'></span><o:p></o:p></span></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>About Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst,
Inc. is a global healthcare market research and consulting company providing
market analysis, and competitive intelligence services to global clients. The
company publishes syndicate, custom and consulting grade healthcare reports
covering animal healthcare, biotechnology, clinical diagnostics, healthcare
informatics, healthcare services, medical devices, medical equipment, and
pharmaceuticals.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at clients specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>Contact Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com<o:p></o:p></span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br
clear=all style='mso-special-character:line-break;page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Global
Infectious Disease Vaccines Market US$ 27.4 Billion by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global infectious disease vaccines market expected to reach US$ 27.4 billion by
2023, steadily growing at CAGR 3.4% over the forecast period, mainly due to
successful launch of new products and highest-selling vaccines. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Vaccines are known to be the safest,
most effective way to prevent infectious diseases. DTP combination vaccines
include vaccines against diphtheria, tetanus and pertussis (DTP) that also
contain one or more components to provide protection against other infections,
including hepatitis B, Haemophilus influenzae type B and/or polio.
Meningococcal vaccines include meningococcal group A, C, W-135 and Y vaccines,
meningococcal group B vaccines and meningococcal group C vaccines. Pentacel is
a DTP, Haemophilus influenzae type B and polio vaccine. Pediarix is a DTP,
hepatitis B and polio vaccine. Menactra and Menveo are meningococcal type A, C,
W-135 and Y vaccines. Bexsero and Trumenba are meningococcal type B vaccines. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Overall,
pneumococcal vaccines widely used in childhood vaccination programs are the
highest-selling vaccines within all the categories. The herpes zoster (shingles)
vaccines market is predicted to have the highest growth rate during the
forecast period. Prevnar 13 (pneumococcal vaccine), Gardasil (HPV vaccine), Pentacel
(DTaP, Hib &amp; polio vaccine), Fluzone (influenza vaccine), and Bexsero (meningococcal
b vaccine) are the highest-selling vaccines in 2016. Other promising vaccines
that are in the active clinical development include Shingrix (herpes zoster
vaccine), RSV F Vaccine (respiratory syncytial virus vaccine), Combination Respiratory
Vaccine (influenza and RSV vaccine), and GEN-003 (herpes simplex virus vaccine).
<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Browse
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/infectious-disease-vaccines-market/"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Infectious
Disease Vaccines Market</span></a></span><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'> by Type
(Brand) - Diphtheria, Tetanus and Pertussis (DTP) Combination Vaccines
(Boostrix, Pediarix, Pentacel, Other, Herpes Zoster Vaccines (Zostavax,
Shingrix, Other); Human Papilloma Virus Vaccines (Gardasil, Other); Influenza
Vaccines (FluLaval, Fluzone, Other); Meningococcal Vaccines (Menveo, Bexsero,
Menactra, Trumenba, Other); Pneumococcal Vaccines (Pneumovax, Synflorix,
Prevnar/Prevnar 13, Other); Rotavirus Vaccines (Rotarix, RotaTeq, Other) and Forecast
2015-2023. </span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global </span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>infectious disease vaccines </span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market report
provides market size (Revenue USD Million 2015 to 2023), market share, trends
and forecasts growth trends (CAGR%, 2018 to 2023). The global </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>infectious disease vaccines </span><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>market research report is further
segmented by geography into North America (U.S., Canada), Latin America
(Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest
of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the
World. The global </span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>infectious disease vaccines </span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>market report
also provides the detailed market landscape (market drivers, restraints,
opportunities), market attractiveness analysis and also tracks the major
competitors operating in the market by company overview, financial snapshot,
key products, technologies and services offered, market share analysis and
recent selected vaccine product licensing deals in the last two years in the
global market. </span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Major players operating in the global
infectious disease vaccines market and profiled in this report include Astellas
Pharma, CSL Behring, Dynavax Technologies, Emergent BioSolutions,
GlaxoSmithKline, Merck, Mitsubishi Tanabe Pharma, Novavax, Pfizer, and Sanofi.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l7 level1 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Type (Brand)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l7 level2 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>DTP Combination
Vaccines<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l7 level3 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Boostrix<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l7 level3 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Pediarix<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l7 level3 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Pentacel<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l7 level3 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Other<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l7 level2 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Herpes Zoster
Vaccines<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l7 level3 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Zostavax<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l7 level3 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Shingrix<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l7 level3 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Other<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l7 level2 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Human Papilloma
Virus Vaccines<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l7 level3 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Gardasil<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l7 level3 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Other<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l7 level2 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Influenza
Vaccines<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l7 level3 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>FluLaval<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l7 level3 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Fluzone<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l7 level3 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.4.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Other<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l7 level2 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Meningococcal
Vaccines<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l7 level3 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.5.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Menveo<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l7 level3 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.5.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Bexsero<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l7 level3 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.5.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Menactra<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l7 level3 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.5.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Trumenba<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l7 level3 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.5.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Other<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l7 level2 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Pneumococcal
Vaccines<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l7 level3 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.6.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Pneumovax<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l7 level3 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.6.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Synflorix<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l7 level3 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.6.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Prevnar/Prevnar
13<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l7 level3 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.6.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Other<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l7 level2 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rotavirus
Vaccines<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l7 level3 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.7.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rotarix<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l7 level3 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.7.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>RotaTeq<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l7 level3 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.7.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Other<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.85in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><o:p>&nbsp;</o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.25in;
margin-bottom:.0001pt;text-indent:-.25in;mso-list:l7 level1 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>Geography (Region,
Country)<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l7 level2 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>North America (U.S.,
Canada)<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l7 level2 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>Europe (U.K., Germany,
France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l7 level2 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>Asia Pacific (Japan,
China, India, Rest of APAC)<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l7 level2 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>Latin America (Brazil,
Mexico, Rest of LA)<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l7 level2 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>Rest of the World<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l7 level1 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Company Profiles <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l7 level2 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Astellas Pharma<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l7 level2 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>CSL Behring<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l7 level2 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Dynavax
Technologies<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l7 level2 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Emergent
BioSolutions<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l7 level2 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>GlaxoSmithKline<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l7 level2 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Merck<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l7 level2 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Mitsubishi Tanabe
Pharma<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l7 level2 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Novavax<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l7 level2 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Pfizer<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;mso-add-space:auto;
text-indent:-.3in;mso-list:l7 level2 lfo3'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>3.10.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Sanofi<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black;background:white'><o:p>&nbsp;</o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>To request Table of Contents and Sample Pages of this
report visit:</span><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin'> </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/infectious-disease-vaccines-market/"><span
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/infectious-disease-vaccines-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><span style='mso-spacerun:yes'> </span><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>About Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst,
Inc. is a global healthcare market research and consulting company providing
market analysis, and competitive intelligence services to global clients. The
company publishes syndicate, custom and consulting grade healthcare reports
covering animal healthcare, biotechnology, clinical diagnostics, healthcare
informatics, healthcare services, medical devices, medical equipment, and
pharmaceuticals.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at clients specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>Contact Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com<o:p></o:p></span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black;background:white;mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA'><br clear=all style='mso-special-character:line-break;
page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black;background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b style='mso-bidi-font-weight:
normal'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;background:white'>Global Multiple Sclerosis
Treatment Market </span></b><b style='mso-bidi-font-weight:normal'><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>US$ 23.2 Billion by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin;color:black;background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global multiple sclerosis drugs market to reach US$ 23.2 billion by 2023,
steadily growing at CAGR 0.7% during forecast period, mainly due to large
number of&nbsp;both existing therapeutics and<br>
new entrants.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;
color:black;background:white'>Multiple sclerosis (MS) is the most widespread
disabling neurological condition of young adults around the world. MS is more
common among people in Europe, the United States, Canada, New Zealand, and
sections of Australia and less common among people in Asia and the tropics. The
</span><span lang=EN-US><a href="https://msfocus.org/"><span style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;background:
white'>Multiple Sclerosis Foundation</span></a></span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;
color:black;background:white'> estimates that more than 400,000 people in the
United States and about 2.5 million people around the world have MS. Although, an
increasing number of people are being diagnosed with MS, there is increased
awareness of MS and better diagnostic tools, such as magnetic resonance imaging
(MRI), for diagnosing the disease. MS is also an expensive disease to treat. direct
and indirect healthcare costs range from $8,528 to $54,244 per patient per year
in the United States.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;
color:black;background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;
color:black;background:white'>Treatment for MS depends on the specific symptoms
and may include: treating relapses of MS symptoms (with steroid medication),
treating specific MS symptoms, and treatment to reduce the number of relapses
(disease-modifying therapies). Treatment options for relapsing-remitting MS
include: Beta interferons are among the most commonly prescribed medications to
treat MS and can reduce the frequency and severity of relapses. Glatiramer
acetate (Copaxone) may help block your immune system's attack on myelin.
Dimethyl fumarate (Tecfidera) can reduce relapses. Fingolimod (Gilenya) and
Teriflunomide (Aubagio) oral medications reduces relapse rate. Natalizumab
(Tysabri) blocks the movement of potentially damaging immune cells from your
bloodstream to your brain and spinal cord. Alemtuzumab (Lemtrada) drug helps
reduce relapses of MS by targeting a protein on the surface of immune cells and
depleting white blood cells. In the past few years considerable improvements
to slow MS disease progression has been made, as drugs such as fingolimod,
dimethyl fumarate (Tecfidera), alemtuzumab (Lemtrada) and ocrelizumab have been
launched. Currently, multiple sclerosis drugs in active development (clinical
phase II and III pipeline) includes ARGX-113, GNbAC1, IB-MS, Imilecleucel-T,
M2951, MIS416, Ofatumumab, Opicinumab, Ozanimod, Ponesimod, Siponimod, and
Ublituximab. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;
color:black;background:white'>Browse </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/multiple-sclerosis-treatment-market/"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;
background:white'>Multiple Sclerosis Treatment Market</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black;background:white'> by </span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Drug
Class (Brand) - Alemtuzumab (Lemtrada), Dimethyl Fumarate (Tecifidera), Gilneya
(Fingolimod), Glatiramer Acetate (Copaxone), Interferon-&#946;1a (Avonex),
Interferon-&#946;1a (Rebif), Interferon-&#946;1b (Betaseron/Extavia),
Natalizumab (Tysabri), Peginterferon-&#946;1a (Plegridy), Teriflunomide (Aubagio),
Clinical Pipeline (Phase III) - Daclizumab (Zinbryta), Ocrelizumab (Ocrevus),
Ozanimod (RPC-1063) and Forecast 2015-2023. </span><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>The global </span><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;
color:black;background:white'>multiple sclerosis treatment</span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'> market report
provides market size (Revenue USD Million 2015 to 2023), market share, trends
and forecasts growth trends (CAGR%, 2018 to 2023). The global </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black;background:white'>multiple sclerosis treatment</span><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'> market research
report is further segmented by geography into North America (U.S., Canada),
Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France,
Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC),
and Rest of the World. The global </span><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black;
background:white'>multiple sclerosis treatment</span><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'> market report also provides the
detailed market landscape (market drivers, restraints, opportunities), market
attractiveness analysis and also tracks the major competitors operating in the
market by company overview, financial snapshot, key products, technologies and
services offered, market share analysis and recent trends in the global market.
Major players operating in the global </span><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black;
background:white'>multiple sclerosis drugs</span><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'> market and included in this report
are </span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black;background:white'>Actelion, arGEN-x,
Bayer Healthcare, Biogen Idec, Celgene, GeNeuro, Innate Immunotherapeutics,
InnoBioscience, Merck, Novartis, Opexa Therapeutics, Pfizer, Sanofi-Aventis,
Teva Pharmaceuticals, and TG Therapeutics.</span><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin;color:black;background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l0 level1 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black;background:white'>Drug Class (Brand)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;background:white'>Alemtuzumab
(Lemtrada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;background:white'>Dimethyl
Fumarate (Tecifidera)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;background:white'>Gilneya
(Fingolimod)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;background:white'>Glatiramer
Acetate (Copaxone)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;background:white'>Interferon-&#946;1a
(Avonex)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;background:white'>Interferon-&#946;1a
(Rebif)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;background:white'>Interferon-&#946;1b
(Betaseron/Extavia)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;background:white'>Natalizumab
(Tysabri)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;background:white'>Peginterferon-&#946;1a
(Plegridy)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>1.10.<span style='font:7.0pt "Times New Roman"'>
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;background:white'>Teriflunomide
(Aubagio)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:#92D050;background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l0 level1 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;background:white'>Clinical
Pipeline (Phase III)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;background:white'>Daclizumab
(Zinbryta)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;background:white'>Ocrelizumab
(Ocrevus)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;background:white'>Ozanimod
(RPC-1063)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.85in;mso-add-space:auto'><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black;background:white'><o:p>&nbsp;</o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.25in;
margin-bottom:.0001pt;text-indent:-.25in;mso-list:l0 level1 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>Geography (Region,
Country)<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>North America (U.S.,
Canada)<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>Europe (U.K., Germany,
France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>Asia Pacific (Japan,
China, India, Rest of APAC)<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>Latin America (Brazil,
Mexico, Rest of LA)<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>Rest of the World<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l0 level1 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>4.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black;background:white'>Company Profiles <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>4.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black;background:white'>Actelion<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>4.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black;background:white'>arGEN-x<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>4.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black;background:white'>Bayer Healthcare<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>4.4.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black;background:white'>Biogen Idec<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>4.5.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black;background:white'>Celgene<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>4.6.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black;background:white'>GeNeuro<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>4.7.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black;background:white'>Innate Immunotherapeutics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>4.8.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black;background:white'>InnoBioscience<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>4.9.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black;background:white'>Merck<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>4.10.<span
style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black;background:white'>Novartis<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>4.11.<span
style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black;background:white'>Opexa Therapeutics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>4.12.<span
style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black;background:white'>Pfizer<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>4.13.<span
style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black;background:white'>Sanofi-Aventis<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>4.14.<span
style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black;background:white'>Teva Pharmaceuticals<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;mso-add-space:auto;
text-indent:-.3in;mso-list:l0 level2 lfo1'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>4.15.<span
style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black;background:white'>TG Therapeutics<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'><o:p>&nbsp;</o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>To request Table of Contents and Sample Pages of this
report visit:</span><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin'> </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/multiple-sclerosis-treatment-market/"><span
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/multiple-sclerosis-treatment-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'> <o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>About Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst,
Inc. is a global healthcare market research and consulting company providing
market analysis, and competitive intelligence services to global clients. The
company publishes syndicate, custom and consulting grade healthcare reports
covering animal healthcare, biotechnology, clinical diagnostics, healthcare
informatics, healthcare services, medical devices, medical equipment, and
pharmaceuticals.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at clients specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>Contact Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com<o:p></o:p></span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black;mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='mso-special-character:line-break;page-break-before:
always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;
color:black'><o:p>&nbsp;</o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><b style='mso-bidi-font-weight:normal'><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'>Global
Psoriasis Drugs Market US$ 10.5 Billion by 2023<o:p></o:p></span></b></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>The global psoriasis
drugs market largely driven by high-priced biologics is expected to reach US$ 10.5
billion, with a CAGR of 3.8% during forecast period. With a number of branded
specialty biologics set to lose their exclusivity status in many of the larger
markets, growth is likely to be affected by biosimilar erosion.<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>Psoriasis is a chronic
immune-mediated skin disorder that affects about 23% of the population
worldwide. Psoriasis is the most prevalent autoimmune disease in the United
States. According to the </span><span lang=EN-US><a href="https://ifpa-pso.com/"><span
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'>International
Federation of Psoriasis Associations</span></a></span><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'> (IFPA), about 3 percent of the worlds population has some form
of psoriasis. In the United States, there are about 150,000 new cases every
year.<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>A range of agents are
available for the symptomatic treatment of psoriasis.&nbsp;Topical treatments
such as form of lotions, foams, creams, ointments, gels, and shampoos
containing steroids, tar preparations, and calcium- modulating drugs are very
useful because they are relatively safe, fairly effective, and can be applied
directly to the affected skin. Most oral medications act by targeting portions
of the immune system. Phototherapy or light therapy, involves exposing the skin
to ultraviolet light on a regular basis and under medical supervision. Biologic
drugs are usually prescribed for moderate to severe psoriasis and psoriatic
arthritis that has not responded to other treatments. The first biologic agent
for psoriasis, the tumour necrosis factor (TNF) antagonist etanercept (Enbrel;
Amgen), was approved in 2004. Biosimilar infliximab (Remsima; Celltrion, or
Inflectra; Hospira) is already available in several markets, including the
European Union and Japan, and is under review by the FDA. Biosimilars of
etanercept and biosimilar adalimumab are also likely to be launched during the
forecast period. Currently, psoriasis drugs in active development (clinical
phase II and III pipeline) includes topical antipsoriatics (Benvitimod, DFD-01,
M8010, Pefcalcitol, Ulobetasol lotion), oral antipsoriatics (LAS-41008,
FP-187), and antipsoriatic biologics for systemic use (Brodalumab, Ixekizumab,
Guselkumab, Tildrakizumab).<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>Browse </span><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/psoriasis-treatment-market/"><span
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'>Psoriasis
Drugs Market</span></a></span><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'> by Drug Class
(Interleukin Blockers, TNF Inhibitors, Vitamin D Analogues or Combinations,
Others), Therapy Type (Systemic Therapeutic Drugs, Topical Therapeutic Drugs,
Combinations, Others), Distribution Channel (Hospital Pharmacy, Online Sales,
Retail Pharmacy, Others) and Forecast 2015-2023. The global psoriasis drugs
market segmentation is based on drug class (interleukin blockers, TNF
inhibitors, vitamin d analogues or combinations, others), therapy type
(systemic therapeutic drugs, topical therapeutic drugs, combinations, others),
distribution channel (hospital pharmacy, online sales, retail pharmacy,
others). <o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>The global psoriasis
drugs market report provides market size (US$ million 2015-2023), market share,
trends and forecasts growth trends (CAGR%, 2018-2023). The global psoriasis
drugs market research report is further segmented by geography into North
America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe
(U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China,
India, Rest of APAC), and Rest of the World. The global psoriasis treatment
market report also provides the detailed market landscape (market drivers,
restraints, opportunities), market attractiveness analysis and also tracks the
major competitors operating in the market by company overview, financial
snapshot, key products, technologies and services offered, market share
analysis and recent trends in the global market. Major players operating in the
global psoriasis drugs market and profiled in this report include AbbVie, Inc.,
Almirall, Amgen, Inc., AstraZeneca, Biogen, Eli Lilly &amp; Company, Forward
Pharma, GlaxoSmithKline, Johnson &amp; Johnson (Janssen Biotech), LEO Pharma
A/S, Maruho, Merck &amp; Co., Inc., Novartis AG, Pfizer, Inc., Promius Pharma,
and Therapeutics, Inc.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.25in;text-indent:-.25in;mso-list:l30 level1 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Drug Class<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>1.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Interleukin Blockers<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>1.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>TNF Inhibitors<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>1.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Vitamin D Analogues or Combinations<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>1.4.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Others<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.25in;text-indent:-.25in;mso-list:l30 level1 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Therapy Type<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>2.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Systemic Therapeutic Drugs<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>2.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Topical Therapeutic Drugs<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>2.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Combinations<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>2.4.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Others<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.25in;text-indent:-.25in;mso-list:l30 level1 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Distribution Channel<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>3.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Hospital Pharmacy<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>3.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Online Sales<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>3.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Retail Pharmacy<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>3.4.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Others<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.25in;text-indent:-.25in;mso-list:l30 level1 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>4.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Geography (Region, Country)<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>4.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>North America (U.S., Canada)<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>4.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Latin America (Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>4.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Europe (U.K., Germany, France, Italy, Spain, Rest of
EU)<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>4.4.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Asia Pacific (Japan, China, India, Rest of APAC)<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>4.5.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Rest of the World<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.25in;text-indent:-.25in;mso-list:l30 level1 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>5.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Company Profiles<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>5.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>AbbVie, Inc.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>5.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Almirall<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>5.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Amgen, Inc.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>5.4.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>AstraZeneca<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>5.5.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Biogen<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>5.6.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Eli Lilly &amp; Company<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>5.7.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Forward Pharma<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>5.8.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>GlaxoSmithKline<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>5.9.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Johnson &amp; Johnson (Janssen Biotech)<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>5.10.<span
style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>LEO Pharma A/S<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>5.11.<span
style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Maruho<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>5.12.<span
style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Merck &amp; Co., Inc.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>5.13.<span
style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Novartis AG<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>5.14.<span
style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Pfizer, Inc.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>5.15.<span
style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Promius Pharma<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:.55in;text-indent:-.3in;mso-list:l30 level2 lfo2'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>5.16.<span
style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'>Therapeutics, Inc.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>To request Table of Contents and Sample Pages of this
report visit:&nbsp;</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/psoriasis-treatment-market/"><span
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:#0131BF'>https://www.ihealthcareanalyst.com/report/psoriasis-treatment-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>About Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst,
Inc. is a global healthcare market research and consulting company providing
market analysis, and competitive intelligence services to global clients. The
company publishes syndicate, custom and consulting grade healthcare reports
covering animal healthcare, biotechnology, clinical diagnostics, healthcare
informatics, healthcare services, medical devices, medical equipment, and
pharmaceuticals.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at clients specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>Contact Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com<o:p></o:p></span></p>

<b style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:minor-latin;
mso-bidi-theme-font:minor-latin;color:black;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=all style='mso-special-character:line-break;
page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin;color:black'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:15.0pt;background:white'><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'>Global Novel Drug Delivery Systems
for Cancer Therapy Market US$ 21.2 Billion by 2023<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>The
global </span><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;
color:black'>novel drug delivery systems for cancer therapy </span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>market expected to reach US$ 21.2 billion by 2023, growing at CAGR
16.6% over the forecast period, due to increasing incidences of various types
of cancer such as bile duct, colorectal, liver, pancreatic cancers, and its
significant benefits over other conventional therapies.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'><br>
According to the online cancer database </span><span lang=EN-US><a
href="http://globocan.iarc.fr/Default.aspx"><span style='font-size:10.0pt;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'>GLOBOCAN</span></a></span><span lang=EN-US
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin;color:black'> by the International
Agency for Research on Cancer (IARC), globally 14.1 million people were
diagnosed with cancers (excluding non-melanoma skin cancer) during 2012 as compared
to 12.7 million in 2008. The incidence rate is expected to reach 15.2 million
and 17.1 million in 2015 and 2020, respectively. In terms of geographic
distribution, the novel drug delivery systems for cancer therapy market has
been segmented into five major regions: North America, Europe, Latin America,
Asia Pacific, and Rest of the World. Additionally, each region has been
segmented into respective major countries such as the U.S. and Canada (North
America); Germany, the U.K., (Europe); Brazil, Mexico (Latin America); Japan,
China, India (Asia Pacific), and Rest of the World. North America accounted for
the largest share of global market in 2016 followed by Europe region.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Novel
drug delivery systems (NDDS) are capable of controlling the rate of drug
delivery, sustaining the duration of therapeutic activity and targeting the
drug to the disease tissue leading to better therapeutic effect with minimum
side effects. Novel Drug Delivery Systems (NDDS) have numerous points of
interest, which comprise better therapy by increasing the efficacy and duration
of drug activity, improved patient compliance through reduced dosing frequency.
It provides appropriate routes of administration and enhanced targeting for a
particular site to anticipate hurtful reactions. The Different types of
advanced drug delivery approach like polymeric Nano capsules, nanoparticles,
liposomes, nanoemulsion, microsphere, microcapsules, hydrogels have been
expressed utilizing bioactive and plant extracts. NDDS have significant
advantages over conventional therapy for cancer treatment, which include
improved solubility and bioavailability, low toxicity, maximum therapeutic
effect, sustained and controlled drug delivery, improvement of stability and
batter security from physical and biochemical degradation. Lipoproteins,
nanoparticles, Microspheres etc. as advanced drug delivery systems have become
an attractive field of new research and measured excellent candidates with
great potential in the area of novel drug delivery systems.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Visit
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/novel-drug-delivery-systems-cancer-therapy-market/"><span
style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'>Novel Drug Delivery Systems for Cancer
Therapy Market</span></a></span><span lang=EN-US style='font-size:10.0pt;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'> by Technology (Embolization
Particles  Drug Eluting Beads, Polyvinyl Alcohol Particles, Microspheres,
Gelatin-Based Embolization Devices, Selective Internal Radiation Therapy,
Holmium-Based Microspheres; Liquid Embolics  Onyx (LES and HD-500), TRUFILL
nBCA LES; Nanoparticles, and Forecast 2015-2023. The global novel drug delivery
systems for cancer therapy market report provides market size (Revenue USD
Million 2015 to 2023), market share and forecasts growth trends (CAGR%, 2018 to
2023). The global novel drug delivery systems for cancer therapy market report
also provides the detailed market landscape (market drivers, restraints,
opportunities), market attractiveness analysis and profiles of major
competitors in the global market including company overview, financial
snapshot, key products, technologies and services offered, and recent
developments. Major players operating in the global novel drug delivery systems
for cancer therapy market and included in this report are Advanced Medical
Isotope Corporation, Bind Therapeutics, Boston Scientific Corporation, BTG plc,
CeloNova BioSciences, Inc., Cook Medical, Inc., Cospheric LLC, Covidien, plc,
Eckert &amp; Ziegler BEBIG, EmboMedics, Inc., Kobo Products, Inc., Merit
Medical Systems, Inc., Mo-Sci Corporation, Nanobiotix, Polysciences, Inc.,
Sirtex Medical, Inc. and Terumo Medical Corporation.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l12 level1 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Technology<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l12 level2 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>1.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Embolization
Particles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l12 level3 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>1.1.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Drug
Eluting Beads<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l12 level3 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>1.1.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Polyvinyl
Alcohol (PVA) Particles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l12 level3 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>1.1.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Microspheres<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l12 level3 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>1.1.4.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Gelatin-Based
Embolization Devices<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l12 level3 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>1.1.5.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Selective
Internal Radiation Therapy (SIRT)/ Radioembolization<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l12 level3 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>1.1.6.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Holmium-based
Microspheres<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l12 level2 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>1.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Liquid
Embolics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l12 level3 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>1.2.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Onyx
(LES and HD-500)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l12 level3 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>1.2.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>TRUFILL
nBCA LES<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l12 level2 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>1.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Nanoparticles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l12 level1 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Geography
(Region, Country)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l12 level2 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>2.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>North
America (U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l12 level2 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>2.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Latin
America (Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l12 level2 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>2.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Europe
(U.K., Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l12 level2 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>2.4.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Asia
Pacific (Japan, China, India, Rest of APAC)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l12 level2 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>2.5.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Rest
of the World<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l12 level1 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Company
Profiles<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l12 level2 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>3.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Advanced
Medical Isotope Corporation<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l12 level2 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>3.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Bind
Therapeutics<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l12 level2 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>3.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Boston
Scientific Corporation<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l12 level2 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>3.4.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>BTG
plc<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l12 level2 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>3.5.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>CeloNova
BioSciences, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l12 level2 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>3.6.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Cook
Medical, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l12 level2 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>3.7.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Cospheric
LLC<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l12 level2 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>3.8.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Covidien,
plc<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l12 level2 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>3.9.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Eckert
&amp; Ziegler BEBIG<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l12 level2 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>3.10.<span
style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>EmboMedics,
Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l12 level2 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>3.11.<span
style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Kobo
Products, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l12 level2 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>3.12.<span
style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Merit
Medical Systems, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l12 level2 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>3.13.<span
style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Mo-Sci
Corporation<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l12 level2 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>3.14.<span
style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Nanobiotix<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l12 level2 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>3.15.<span
style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Polysciences,
Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l12 level2 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>3.16.<span
style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Sirtex
Medical, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;mso-add-space:auto;
text-indent:-.3in;mso-list:l12 level2 lfo19;background:white'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>3.17.<span
style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
lang=EN-US style='font-size:10.0pt;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Terumo
Medical Corporation<o:p></o:p></span></p>

<p class=MsoNormal style='background:white'><span lang=EN-US style='font-size:
10.0pt;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin;color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;
mso-bidi-font-weight:bold'>To request Table of Contents and Sample Pages of
this report visit: <o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/novel-drug-delivery-systems-cancer-therapy-market/"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/novel-drug-delivery-systems-cancer-therapy-market/</span></a></span><span
class=MsoHyperlink><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p></o:p></span></span></p>

<p class=MsoNormal><span class=MsoHyperlink><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p><span
 style='text-decoration:none'>&nbsp;</span></o:p></span></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>About Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst,
Inc. is a global healthcare market research and consulting company providing
market analysis, and competitive intelligence services to global clients. The
company publishes syndicate, custom and consulting grade healthcare reports
covering animal healthcare, biotechnology, clinical diagnostics, healthcare
informatics, healthcare services, medical devices, medical equipment, and
pharmaceuticals.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at clients specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>Contact Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com<o:p></o:p></span></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;
color:#333333'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;
color:#333333'>Global Primary Immunodeficiency Diseases Market US$ 7 Billion by
2023<o:p></o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;
color:#333333'><span style='mso-spacerun:yes'></span><o:p></o:p></span></b></p>

<p style='margin:0in;margin-bottom:.0001pt;text-align:justify'><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'>The
global primary immunodeficiency diseases market expected to reach US$ 7 billion
by 2023, growing at CAGR 6.4% over the forecast period, due to higher incidence
of&nbsp;primary immunodeficiency disorders worldwide. <o:p></o:p></span></p>

<p style='margin:0in;margin-bottom:.0001pt;text-align:justify'><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p style='margin:0in;margin-bottom:.0001pt;text-align:justify'><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'>Primary
immunodeficiency diseases or disorders (PIDD or PI) are caused as part of the
body's immune system is missing or does not function normally, such that it is
an inherited flaw in the immune system that increases the susceptibility to
infections. Besides susceptibility to infections, PIDD may cause other health
problems as well, including allergies, asthma, swollen joints, digestive tract
problems, growth problems or an enlarged liver and spleen. <o:p></o:p></span></p>

<p style='margin:0in;margin-bottom:.0001pt;text-align:justify'><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p style='margin:0in;margin-bottom:.0001pt;text-align:justify'><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'>The
global primary immunodeficiency diseases market report estimates the market
size in US$ million for 2015-2023, and forecasts growth trends over a period of
2018-2023. The market for key market segments has been estimated based on
epidemiology approach considering patient diagnosis rates, patient treatment
rate (IVIG/SCIG), average cost of treatment by regions. The highlights of the
report include global number of PID patients, by disease (including
subclasses), global number of patient population for treatment or therapy,
global number of PID patients, by 15 most commonly identified PIDs by region,
and by country, and PID patients gender and age by global comparative
analysis. The global primary immunodeficiency disease (PIDD or PID or PI)
market is dominated by North America and Europe, collectively accounting for
major share of the market in 2016. National PID registries worldwide,
increasing healthcare expenditure and government support are the major factors
driving the global primary immunodeficiency diseases market during the forecast
period.<o:p></o:p></span></p>

<p style='margin:0in;margin-bottom:.0001pt'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p style='margin:0in;margin-bottom:.0001pt;text-align:justify'><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'>Browse
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/primary-immunodeficiency-diseases-market/"><span
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'>Primary
Immunodeficiency Diseases Market</span></a></span><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:#333333'> by Disease Type (Antibody Deficiency  Agammaglobulinaemia,
Common Variable Immune Deficiency, IgG Subclass Deficiency, SIgAD; Cellular
Immunodeficiency  Ataxia Telangiectasia, DiGeorge Syndrome, Hyper IgM
Syndromes, Wiskott-Aldrich Syndrome; Innate Immune Disorders  Complement
Deficiencies, and Hyper IgE Syndrome) and Test Type (Blood and Prenatal
Testing), and Treatment Type (Immunoglobulin Replacement Therapy, Antibiotics
Therapy, Stem Cell and Gene Therapy) and Forecast 2015-2023. </span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'>The
report also provides the detailed market landscape and profiles of major
competitors in the global market including company overview, financial
snapshot, major products and services offered, and recent trends in strategic
management.<span style='mso-spacerun:yes'> </span>The major companies profiled
in the report include <span style='color:black'>Baxter nternational, Inc., Bio
Products Laboratory, Biotest AG, CSL Behring LLC, Grifols S.A., Kedrion S.p.A.,
LFB S.A., Octapharma AG, and others.<o:p></o:p></span></span></p>

<p style='margin:0in;margin-bottom:.0001pt;text-align:justify'><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l8 level1 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><b style='mso-bidi-font-weight:normal'><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span></b><![endif]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Disease
Type<o:p></o:p></span></b></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l8 level2 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Antibody
Deficiency<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l8 level3 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>1.1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Agammaglobulinaemia
<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l8 level3 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>1.1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Common
Variable Immune Deficiency <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l8 level3 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>1.1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>IgG
Subclass Deficiency <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l8 level3 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>1.1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Selective
IgA Deficiency (SIgAD) <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l8 level3 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>1.1.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Others
<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l8 level2 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Cellular
Immunodeficiency<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l8 level3 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>1.2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Ataxia
Telangiectasia <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l8 level3 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>1.2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>DiGeorge
Syndrome <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l8 level3 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>1.2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Hyper
IgM Syndromes <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l8 level3 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>1.2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Wiskott-Aldrich
Syndrome <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l8 level3 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>1.2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Others
<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l8 level2 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Innate
Immune Disorder<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l8 level3 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>1.3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Complement
Deficiencies <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l8 level3 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>1.3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Hyper
IgE Syndrome <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;text-indent:-.35in;mso-list:l8 level3 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>1.3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Others
<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;mso-add-space:
auto;mso-layout-grid-align:none;text-autospace:none'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;
color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l8 level1 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><b style='mso-bidi-font-weight:normal'><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span></b><![endif]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Test
Type<o:p></o:p></span></b></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l8 level2 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Blood
Testing<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l8 level2 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Prenatal
Testing<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;mso-layout-grid-align:none;text-autospace:none'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;
color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l8 level1 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><b style='mso-bidi-font-weight:normal'><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span></b><![endif]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Treatment
Type<o:p></o:p></span></b></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l8 level2 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Immunoglobulin
Replacement Therapy <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l8 level2 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Antibiotics
Therapy <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l8 level2 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Stem
cell and Gene Therapy <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l8 level2 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Others<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;mso-layout-grid-align:none;text-autospace:none'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;
color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l8 level1 lfo18'><![if !supportLists]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><span
style='mso-list:Ignore'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span></b><![endif]><b style='mso-bidi-font-weight:normal'><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'>Geography (Region, Country)<o:p></o:p></span></b></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l8 level2 lfo18'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>North America
(U.S., Canada)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l8 level2 lfo18'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l8 level2 lfo18'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Asia Pacific
(Japan, China, India, Rest of APAC)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l8 level2 lfo18'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Latin America
(Brazil, Mexico, Rest of LA)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l8 level2 lfo18'><![if !supportLists]><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><span style='mso-list:Ignore'>4.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Rest of the World<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto'><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l8 level1 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><b style='mso-bidi-font-weight:normal'><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin;color:black'><span style='mso-list:Ignore'>5.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span></b><![endif]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Company
Profiles<o:p></o:p></span></b></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l8 level2 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>5.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Baxter
International, Inc.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l8 level2 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><span
style='mso-list:Ignore'>5.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Bio
Products Laboratory</span><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l8 level2 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>5.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Biotest
AG<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l8 level2 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>5.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>CSL Behring
LLC<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l8 level2 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>5.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Grifols
S.A.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l8 level2 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>5.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Kedrion
S.p.A.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;mso-add-space:
auto;text-indent:-.3in;mso-list:l8 level2 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>5.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>LFB
S.A.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;mso-add-space:auto;
text-indent:-.3in;mso-list:l8 level2 lfo18;mso-layout-grid-align:none;
text-autospace:none'><![if !supportLists]><span lang=EN-US style='font-size:
10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'><span
style='mso-list:Ignore'>5.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN-US style='font-size:10.0pt;
mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:black'>Octapharma
AG<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;
mso-bidi-font-weight:bold'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;
mso-bidi-font-weight:bold'>To request Table of Contents and Sample Pages of
this report visit: <o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/primary-immunodeficiency-diseases-market/"><span
style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>https://www.ihealthcareanalyst.com/report/primary-immunodeficiency-diseases-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:
minor-latin'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>About Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>iHealthcareAnalyst,
Inc. is a global healthcare market research and consulting company providing
market analysis, and competitive intelligence services to global clients. The
company publishes syndicate, custom and consulting grade healthcare reports
covering animal healthcare, biotechnology, clinical diagnostics, healthcare
informatics, healthcare services, medical devices, medical equipment, and
pharmaceuticals.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-latin;color:black'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at clients specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.<o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>Contact Us</span></strong><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;
color:black'><o:p></o:p></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:
minor-latin;color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-US><o:p>&nbsp;</o:p></span></p>

</div>

</body>

</html>
